



CASE
COMPREHENSIVE
CANCER CENTER



**American Society of Hematology (ASH) Annual Meeting
Dec 7-10, 2019**

<http://www.hematology.org/Annual-Meeting/Program/>

****Case CCC Members in BOLD; Presenter UNDERLINED****

PRESENTATIONS/AWARDS/SESSION CHAIRS/MODERATORS

Hetty E. Carraway, MD, MBA

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, [Training Program Directors' Workshop](#)

Friday, Dec 6, 2019, 9 AM-12 PM; Bayhill 21-22 (Hyatt Regency Orlando)

Betty K. Hamilton, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, [Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies](#)

Friday, Dec 6, 2019, 12:30-4:30 PM; W308, Level 3 (Orange County Convention Center)

Moderator, [Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials](#)

Sunday, Dec 8, 2019, 7:30-9 AM; W230, Level 2 (Orange County Convention Center)

Cameron Beau Hilton, BA

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

ASH-a-Palooza Program: [Blood Drop: HONORS Award](#)

Friday, Dec 6, 2019, 2:30-3 PM; Bays 102-107 (Topgolf Orlando)

Evi Stavrou, MD

Louis Stokes Cleveland VA Medical Center, Case Western Reserve University

Speaker, [Host and Tumor Factor XII Drive Ovarian Cancer Maintenance and Progression](#)

Friday, Dec 6, 2019, 2:40-3:55 PM; W312, Level 3 (Orange County Convention Center)

Sudipto Mukherjee, MD, PhD, MPH

Case Comprehensive Cancer Center, Cleveland Clinic

Moderator, [Chronic Myeloid Leukemia: Therapy: Predictors of TKI Discontinuation and TFR Outcomes](#)

Saturday, Dec 7, 2019, 7:30-9 AM; Valencia D (W415D), Level 4 (Orange County Convention Center)

Aaron T. Gerds, MD, MS

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [Beyond JAK-STAT: Novel Therapeutic Targets in Ph-negative MPN](#)

Saturday, Dec 7, 2019, 9:30-11 AM; Chapin Theater, Level 3 (Orange County Convention Center)

Saturday, Dec 7, 2019, 4-5:30 PM; Chapin Theater, Level 3 (Orange County Convention Center)

Speaker, [Defining Treatment Strategies for MDS/MPN Overlap Syndromes](#)

Sunday, Dec 8, 2019, 11:15-12:15 AM; Bayhill 17 (Hyatt Regency Orlando)

Anirban Sen Gupta, PhD

Case Comprehensive Cancer Center

Speaker, [*SCI-37 Synthetic Platelets for Treatment of Traumatic Hemmorage and Thrombocytopenia*](#)

Saturday, Dec 7, 2019, 4-5:30 PM; W315 Level 3 (Orange County Convention Center)

Sunday, Dec 8, 2019, 4:30-6 PM; W315 Level 3 (Orange County Convention Center)

Seth J. Corey, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, [*My Metabolism and Myelopoiesis*](#)

Sunday, Dec 8, 2019, 7:30-9 AM; Valencia D (W415D), Level 4 (Orange County Convention Center)

Sunday, Dec 8, 2019, 4:30-6 PM; Valencia D (W415D), Level 4 (Orange County Convention Center)

Brian T. Hill, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Moderator, [*Aggressive Lymphoma \(Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas\)—Results from Retrospective/Observational Studies: Prognostic Markers*](#)

Sunday, Dec 8, 2019, 4:30-6 PM; Valencia A (W415A) (Orange County Convention Center)

Yogenthiran Sauntharajah, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [*The Case For: Curative Therapies for SCD - Does it Make More Sense to Target the Root Cause Than All the Downstream Events*](#)

Sunday, Dec 8, 2019, 4:30-6 PM; W312, Level 3 (Orange County Convention Center)

Mikkael A. Sekeres, MD, MS

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia

Speaker, [*Lowering the Boom on Lower-Risk MDS*](#)

Sunday, Dec 8, 2019, 4:30-6 PM; Hall E1, Level 2 (Orange County Convention Center)

Monday, Dec 9, 2019, 2:45-4:15 PM; Hall E2, Level 2 (Orange County Convention Center)

Speaker, [*Meeting Tips: Giving a Scientific Presentation, Being a Good Discussant and Asking a Question in the Aisle*](#)

Sunday, Dec 8, 2019, 11:15-12:15 AM; W314, Level 3 (Orange County Convention Center)

Chair, [*Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults*](#)

Monday, Dec 9, 2019, 7-8:30 AM; Tangerine 2 (WF2), Level 2 (Orange County Convention Center)

Anjali S. Advani, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Chair, [*Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative*](#)

Speaker, [*Navigating the Nexus of MRD and Novel Agents in ALL*](#)

Monday, Dec 9, 2019, 7-8:30 AM; Chapin Theater (W320), Level 3 (Orange County Convention Center)

Monday, Dec 9, 2019, 4:30-6 PM; Valencia BC (W415BC), Level 4 (Orange County Convention Center)

Jaroslav P. Maciejewski, MD, PhD

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [*Diagnosis of Bone Marrow Failure Versus Hypocellular MDS in Older Adults*](#)

Monday, Dec 9, 2019, 7-8:30 AM; W331, Level 3 (Orange County Convention Center)

Monday, Dec 9, 2019, 2:34-4:15 PM; W331, Level 3 (Orange County Convention Center)

Eric D. Hsi, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Moderator, [Lymphoma Biology—Non-Genetic Studies: Tumor Microenvironment](#)

Monday, Dec 9, 2019, 10:30 AM-12 PM; Tangerine 2 (WF2), Level 2 (Orange County Convention Center)

Navneet S. Majhail, MD, MS

Case Comprehensive Cancer Center, Cleveland Clinic

Speaker, [How to Set up a Health Services and Outcomes Research Program](#)

Monday, Dec 9, 2019, 12:15-1:15 PM; W314, Level 3 (Orange County Convention Center)

Dana E. Angelini, MD

Cleveland Clinic

Moderator, [Health Services Research—Non-Malignant Conditions: Improving Quality in Hematology](#)

Monday, Dec 9, 2019, 2:45-4:15 PM; Valencia BC (W415BC), Level 4 (Orange County Convention Center)

Aziz Nazha, MD

Case Comprehensive Cancer Center, Cleveland Clinic

Moderator, [Emerging Diagnostic Tools and Techniques: New Prognostic and Predictive Methods in Leukemia and Lymphoma](#)

Monday, Dec 9, 2019, 4:30-6 PM; W414AB, Level 4 (Orange County Convention Center)

ORAL ABSTRACTS – CASE CCC PRESENTER

[16 The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia \(AML\) Patients Receiving Induction Chemotherapy](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes
Hematology Disease Topics & Pathways: Adult, AML, Diseases, Study Population, Myeloid Malignancies
Saturday, Dec 7, 2019, 8:15 AM; W304, Level 3 (Orange County Convention Center)

Abby Statler, PhD, MPH^{1*}, Brian P. Hobbs, PhD^{2*}, Tomas Radivoyevitch, PhD^{3*}, Caitlin Siebenaller, PharmD^{4*}, **Sudipto Mukherjee, MD, PhD, MPH⁵**, **Anjali S. Advani, MD⁵**, **Aaron T. Gerds, MD, MS⁶**, **Aziz Nazha, MD⁷**, **Bhumika J. Patel, MD⁵**, **Hetty E. Carraway, MD, MBA⁵** and **Mikhael A. Sekeres, MD, MS⁶**

¹Cancer Biostatistics, Cleveland Clinic, Shaker Heights, OH

²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

⁴Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

[177 A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies
Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies

Saturday, Dec 7, 2019, 12:30 PM; Chapin Theater (W320), Level 3 (Orange County Convention Center)

Mikael A. Sekeres, MD, MS¹, Michael W. Schuster, MD², Magalie Joris, MD^{3*}, Jürgen Krauter, MD^{4*}, Johan A. Maertens, MD, PhD^{5*}, Emmanuel Gyan, MD, PhD⁶, Tibor Kovacsovics, MD⁷, Amit Verma, MBBS⁸, Pares Vyas, MD, PhD⁹, Eunice S. Wang, MD¹⁰, Weidong Wendy Ma^{11*}, Mirjana Zeremski, MD^{11*}, Arthur Kudla^{11*}, Geoffrey Chan, MD¹¹ and Amer M. Zeidan, MBBS, MHS¹²

¹Leukemia Program, Cleveland Clinic, Cleveland, OH

²Stony Brook University Hospital Cancer Center, Stony Brook, NY

³CHU Amiens-Picardie, Amiens, France

⁴Department of Internal Medicine III, Medizinische Klinik Braunschweig GmbH, Braunschweig, Germany

⁵UZ Leuven, Leuven, Belgium

⁶CHU de Tours - Hôpital Bretonneau, Tours, France

⁷Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

⁸Department of Hematology and Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

⁹MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

¹⁰Roswell Park Cancer Institute, Buffalo, NY

¹¹Pfizer Oncology, New York, NY

¹²Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT

227 SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Program: Oral and Poster Abstracts

Type: Oral

Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR T Cells--Refining the Approach

Hematology Disease Topics & Pathways: antibodies, Biological, ALL, Leukemia, Diseases, Therapies, Lymphoid Malignancies

Saturday, Dec 7, 2019, 3 PM; Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)

Anjali S. Advani, MD¹, Anna Moseley, M.S.^{2*}, Michaela Liedtke, MD³, Margaret R O'Donnell, MD⁴, Ibrahim Aldoss, MD⁴, Martha P. Mims, MD, PhD⁵, Kristen Marie O'Dwyer, MD⁶, Megan Othus, PhD⁷ and Harry P. Erba, MD, PhD⁸

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²SWOG Statistical Center, Fred Hutch, Seattle, WA

³Stanford University Cancer Center, Stanford, CA

⁴Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA

⁵Departments of Hematology and Oncology, Baylor College of Medicine, Houston, TX

⁶University of Rochester Medical Center, Rochester, NY

⁷SWOG Statistics and Data Management Center, Seattle, WA

⁸University of Alabama At Birmingham, Durham, NC

381 Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?

Program: Oral and Poster Abstracts

Type: Oral

Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies

Hematology Disease Topics & Pathways: Diseases, AML, Clinically relevant, Quality Improvement

Sunday, Dec 8, 2019, 8 AM; W307, Level 3 (Orange County Convention Center)

Abby Statler, PhD, MPH^{1*}, Brian P. Hobbs, PhD^{2*}, Tomas Radivoyevitch, PhD^{3*}, Sudipto Mukherjee, MD, PhD, MPH⁴, Kimberly Bell, MBA, RN, BSN^{5*}, Anjali S. Advani, MD⁴, Aaron T. Gerds, MD, MS⁶, Aziz Nazha, MD⁷, Bhumika J. Patel, MD⁴, Hetty E. Carraway, MD, MBA⁴ and Mikael A. Sekeres, MD, MS⁶

¹Cancer Biostatistics, Cleveland Clinic, Shaker Heights, OH

²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

515 Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Program: Oral and Poster Abstracts

Type: Oral

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Disease Monitoring and Management of Post-HCT Relapse

Hematology Disease Topics & Pathways: AML, multiple myeloma, ALL, Leukemia, Diseases, Therapies, CML, Adverse Events, MDS, Plasma Cell Disorders, Lymphoid Malignancies, Myeloid Malignancies

Sunday, Dec 8, 2019: 5:30 PM; Sunburst Room (W340) (Orange County Convention Center)

Ehsan Malek, MD¹, Petra Martin^{2*}, Paolo F Caimi, MD^{3*}, Benjamin K. Tomlinson, MD⁴, Michael Caldwell^{5*}, Gayathri Ravi, MD⁶, Sowjanya Vuyyala, MD^{7*}, Hannah Schmikla, RN^{2*}, Robert Fox^{8*}, Marcos de Lima, MD⁶, Navid Sadri, MD^{9*} and James Driscoll, MD, PhD¹⁰

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH

²University Hospitals Cleveland Medical Center, Cleveland, OH

³University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Tempus Inc., Chicago, IL

⁶University Hospitals Seidman Cancer Center, Cleveland, OH

⁷University Hospitals Cleveland Medical Center, Cleveland, OH

⁸University Hospitals Seidman Cancer Center, Adult Hematologic Malignancies & Stem Cell Transplant Section, Cleveland, Oman

⁹University Hospitals Cleveland Medical Center, Department of Pathology, Cleveland, OH

¹⁰Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

557 A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

Program: Oral and Poster Abstracts

Type: Oral

Session: 634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies

Hematology Disease Topics & Pathways: Diseases, Biological Processes, MPN, erythropoiesis, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019: 8:00 AM; W304EFGH, Level 3 (Orange County Convention Center)

Aaron T. Gerds, MD, MS¹, Alessandro M. Vannucchi, MD², Francesco Passamonti, MD^{3*}, Marina Kremyanskaya^{4*}, Jason R. Gotlib^{5*}, Jeanne M. Palmer⁶, Kelly McCaul^{7*}, Vincent Ribrag⁸, Adam J. Mead, MD, PhD⁹, Claire N Harrison, Professor¹⁰, Ruben A Mesa, MD¹¹, Jean-Jacques Kiladjian, MD, PhD¹², Giovanni Barosi¹³, Robert Peter Gale, MD, PhD, DSc^{14,15*}, Abderrahmane Laadem¹⁵, Joseph Pariseau, PharmD^{15*}, Torsten Gericke, MD^{15*}, Jennie Zhang^{15*}, Peter G. Linde¹⁶, Joseph G. Reynolds, PhD^{16*} and Srdan Verstovsek, MD, PhD¹⁷

¹Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy

³Department of Medicine and Surgery, University of Insubria, Varese, Italy

⁴Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, NY

⁵Stanford Cancer Institute, Stanford, CA

⁶Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ

⁷Avera Cancer Institute, Sioux Falls, SD

⁸Institut Gustave Roussy, Villejuif, France

⁹Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

¹⁰Guy's and Saint Thomas' NHS Foundation Trust, London, United Kingdom

¹¹UT Health San Antonio Cancer Center, San Antonio, TX

¹²Hopital Saint-Louis, Paris, France

¹³IRCCS Policlinico San Matteo Foundation, Pavia, Italy

¹⁴Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom

¹⁵Celgene Corporation, Summit, NJ

¹⁶Acceleron Pharma, Cambridge, MA

¹⁷University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

667 Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Program: Oral and Poster Abstracts

Type: Oral

Session: 634: Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies

Hematology Disease Topics & Pathways:

therapy sequence, antibodies, Biological, Diseases, drug-drug interaction, Therapies, Combinations, MPN, Clinically relevant, Myeloid Malignancies, transplantation, TKI

Monday, Dec 9, 2019, 10:30 AM; W311EFGH, Level 3 (Orange County Convention Center)

Aaron T. Gerds, MD, MS¹, Michael R. Savona, MD², Bart L. Scott, MD³, Moshe Talpaz, MD⁴, Miklos Egyed^{5*}, Claire N Harrison, Professor⁶, Abdulraheem Yacoub, MD^{7*}, Alessandro M. Vannucchi, MD⁸, Adam J. Mead, MD, PhD⁹, Jennifer O'Sullivan^{9*}, Sarah A Buckley, MD^{10*}, Diane R. Mould, PhD^{11*}, Shanthakumar Tyavanagimatt, PhD^{10*}, Jennifer A. Smith, PhD^{10*} and John Mascarenhas, MD¹²

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

²Department of Medicine and Program in Cancer Biology, Vanderbilt University Medical Center, Nashville, TN

³Fred Hutchinson Cancer Center, Seattle, WA

⁴University of Michigan, Ann Arbor, MI

⁵Department of Internal Medicine/Hematology, Kaposi Mor Teaching Hospital, Kaposvar, Hungary

⁶Department of Clinical Haematology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom

⁷Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS

⁸CRIMM; Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Firenze, Italy

⁹University of Oxford, Oxford, United Kingdom

¹⁰CTI BioPharma, Seattle, WA

¹¹Projections Research Inc, Phoenixville, PA

¹²Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

785 Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)?

Program: Oral and Poster Abstracts

Type: Oral

Session: 731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation:

Lymphoma and Plasma Cell Disorders

Hematology Disease Topics & Pathways: multiple myeloma, Diseases, Biological, Therapies, smoldering myeloma, Lymphoma (any), Plasma Cell Disorders, Lymphoid Malignancies, transplantation

Monday, Dec 9, 2019, 3:45 PM; W311ABCD, Level 3 (Orange County Convention Center)

Deepa Jagadeesh, MD, MPH¹, Navneet S. Majhail, MD, MS¹, He Yizeng^{2*}, Kwang Woo Ahn, PhD^{3*}, Carlos Litovich, MPH^{3*}, Timothy S. Fenske, MD⁴, Anna Sureda, MD, PhD^{5*}, Mohamed A Kharfan-Dabaja, MD, MBA⁶ and Mehdi Hamadani, MD²

¹Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Medical College of Wisconsin, Milwaukee, WI

³CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁴Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁵Hematology Department, Institut Catala d'Oncologia- Hospitalet, Barcelona, Spain

⁶Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL

ORAL ABSTRACTS – NON-CASE CCC PRESENTER (with CASE CCC/CLEVELAND CO-AUTHORS)

4 Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic

Program: General Sessions

Session: Plenary Scientific Session

Hematology Disease Topics & Pathways: Adult, Diseases, autoimmune disorders, Bleeding and clotting, Biological Processes, Genetic Disorders, Thrombosis, Immune Disorders, Study Population, Clinically relevant, Thromboembolism, Thrombotic Disorders, pathogenesis

Sunday, Dec 8, 2019, 2:00 PM-4:00 PM; Hall D, Level 2 (Orange County Convention Center)

Shruti Chaturvedi, MBBS, MS¹, Evan M Braunstein, MD, PhD², Xuan Yuan, MD, MSc³, Hang Chen^{2}, Ravi Kumar Alluri, PhD^{4*}, Michael B. Streiff, MD⁵, Michelle Petri, MD, MPH^{6,7*}, Mark Crowther, MD, MSc, FRCPC^{8*}, Keith R McCrae, MD^{9,10} and Robert A. Brodsky, MD¹¹*

¹Johns Hopkins University School of Medicine, BALTIMORE, MD

²Johns Hopkins University School of Medicine, Baltimore, MD, MD

³Hematology/Medicine, Johns Hopkins University School Medicine, Baltimore, MD

⁴Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, OH

⁵Division of Hematology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD

⁶Johns Hopkins, Johns Hopkins Hospital, MD

⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

⁸McMaster University, Hamilton, ON, Canada

⁹Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

¹⁰Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹¹Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD

19 Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Program: Oral and Poster Abstracts

Type: Oral

Session: 621. Lymphoma—Genetic/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomagenesis

Hematology Disease Topics & Pathways: Follicular Lymphoma, Diseases, Non-Hodgkin Lymphoma, Lymphoid Malignancies

Saturday, Dec 7, 2019, 7:30 AM; W230, Level 2 (Orange County Convention Center)

Xiang Li^{1}, Rachel Kositsky^{1*}, Anupama Reddy, PhD^{1*}, Cassandra Love¹, Kikkeri Naresh^{2*}, Jean L. Koff, MD³, Ilja Nystrand^{4*}, Sirpa Leppä, MD, PhD⁵, Annika Pasanen, MD, PhD^{5*}, Marja-Liisa Karjalainen-Lindsberg, MD, PhD^{6*}, Johannes Dunkel^{7*}, Panu Kovanen, MD, PhD^{8*}, Qiu Qin^{1*}, Govind Bhagat, M.D.⁹, Rebecca J Leeman-Neill, MD, PhD¹⁰, Rashmi S. Goswami, MD, PhD^{11*}, Sarah Wildeman^{12*}, Jan Delabie, MD, PhD^{13*}, Richard Burack, MD, PhD¹⁴, Andrew M Evens, DO, MSc¹⁵, Catalina Amador, MD^{16*}, Ji Yuan^{17*}, Hina Naushad Qureishi^{18*}, Shaoying Li, MD^{19*}, Jie Xu^{20*}, C. Cameron Yin, MD, PhD¹⁹, Anne Ortvad Gang^{21*}, Peter H. Norgaard, MD, PhD²², Mette Ø Pedersen, MD^{23*}, Jason Yongsheng Chan, MBBS, MRCP²⁴, Daryl Ming Zhe Cheah, BSc^{25*}, Shin Yeu Ong, MD, FRCPath^{26*}, Chee Leong Cheng, FRCPA, FRCPath, MBBS^{27*}, Lianne Lee^{26*}, Felik Paulua^{26*}, Sarah L. Ondrejka, DO²⁸, Eric D. Hsi, MD²⁹, Magdalena Czader, MD, PhD³⁰, Lin Wang, PhD^{31*}, Amber Landis^{32*}, Michael C. Churnetski^{33*}, David L. Jaye, MD³⁴, Christopher R. Flowers, MD, MS³⁵, Chad M. McCall, MD, PhD^{36*}, Jadee Neff, MD, PhD^{1*}, Matthew S. McKinney, MD³⁷, Yuri Fedoriw^{38*}, Eric Powers^{39*}, Nathan D Montgomery, MD^{40*}, Agata M. Bogusz, MD, PhD^{41*}, Andrea Stafford Hintz, HSLT^{42*}, Alexandra E. Kovach, MD⁴³, Nishitha Reddy, MD⁴², Mary Ann Thompson Arildsen, MD, PhD^{44*}, Emily F Mason, MD, PhD^{42*}, Ridas Juskevicius, MD⁴⁵, William Choi, MBBS, MRCP⁴⁶, Rex Au-Yeung^{47*}, Eric Tse, MBBS, PhD, FRCP, FRCPath⁴⁸, Vincent Sarno^{49*}, Amy Chadburn, MD⁴⁹, Rafael Lopez, MD⁵⁰, Jennifer R Chapman, MD^{51*}, Amir Behdad, MD^{52*}, Neta Goldschmidt, MD^{53*}, John Goodlad, MD^{54*}, Cathy Burton^{55*}, Raju Pillai, MD^{56*}, Abner Louissaint Jr., MD, PhD⁵⁷, Dina Sameh Soliman, MD, MB, MMSc^{58*}, Razvan Panea^{1*}, Tushar Dave^{1*}, Barbara Xiong^{1*}, Eileen Smith^{1*} and Sandeep Dave, MD⁵⁹*

¹Duke University, Durham, NC

²Hammersmith Hospital & Imperial College, London, GBR

³Division of Bone Marrow and Stem Cell Transplantation, Winship Cancer Institute of Emory University, Atlanta, GA

⁴TURKU UNIVERSITY HOSPITAL, TURKU, FIN

⁵Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland

⁶Department of Pathology, Helsinki University Hospital, Helsinki, Finland

⁷University of Helsinki, Helsinki, Finland

⁸Helsinki University Hospital, HUSLAB, Department of Pathology, and University of Helsinki, Haartman Institute, Helsinki, Finland

⁹Columbia University Medical Center, New York, NY
¹⁰VC14-236, Columbia University Medical Center, New York, NY
¹¹Sunnybrook Health Sciences Centre, Toronto, ON, Canada
¹²University of Toronto, Toronto, Canada
¹³Department of Pathology, University Health Network, Toronto, ON, Canada
¹⁴Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY
¹⁵Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
¹⁶University of Neb, Chicago, IL
¹⁷University of Nebraska Medical Center College of Medicine, Omaha, NE
¹⁸University of Nebraska, Omaha
¹⁹Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
²⁰Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Sugar Land, TX
²¹Dept. of Haematology, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
²²Dept. of Pathology, Copenhagen University Hospital Herlev, Herlev, Denmark
²³Department of Pathology, Copenhagen University Hospital Herlev, Herlev, Denmark
²⁴Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
²⁵Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, Singapore
²⁶National Cancer Centre Singapore / Singapore General Hospital, Singapore, Singapore
²⁷Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore
²⁸Cleveland Clinic, Cleveland, OH
²⁹Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
³⁰Indiana University School of Medicine, Indianapolis, IN
³¹Indiana University, Indianapolis
³²Indiana University St., Indianapolis, IN
³³Winship Cancer Institute, Emory University Medical Center, Atlanta, GA
³⁴Department of Pathology, Emory University, Atlanta, GA
³⁵Winship Cancer Institute, Emory University, Atlanta, GA
³⁶Department of Pathology, Duke University, Durham, NC
³⁷Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
³⁸University of North Carolina, Chapel Hill, NC
³⁹University of North Carolina, Chapel Hill
⁴⁰University of North Carolina at Chapel Hill, Chapel Hill, NC
⁴¹Hospital of University of Pennsylvania, Philadelphia, PA
⁴²Vanderbilt University Medical Center, Nashville, TN
⁴³Department of Pathology, Vanderbilt University, Nashville, TN
⁴⁴Vanderbilt Univ. Med. Ctr., Nashville, TN
⁴⁵Vanderbilt University, Nashville, TN
⁴⁶Tuen Mun Hospital, Kwun Tong, HKG
⁴⁷Department of Pathology, The University of Hong Kong, Hongkong, China
⁴⁸Department of Medicine, The University of Hong Kong, Hong Kong, China
⁴⁹Weill Cornell Medicine, New York, NY
⁵⁰University of Miami, Coral Gables, FL
⁵¹Department of Pathology, University of Miami/, Miami, FL
⁵²Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL
⁵³Hematology Department, Hadassah University Hospital Ein Kerem, Jerusalem, Israel
⁵⁴Western General Hospital, Edinburgh, GBR
⁵⁵Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds, United Kingdom
⁵⁶Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA
⁵⁷Department of Pathology, Massachusetts General Hospital, Boston, MA
⁵⁸Department of Laboratory Medicine and Pathology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
⁵⁹Duke University, Chapel Hill, NC

90 Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Program: Oral and Poster Abstracts

Type: Oral

Session: 311. Disorders of Platelet Number or Function: Clinical Insights into ITP and TTP

Hematology Disease Topics & Pathways: antibodies, Biological, autoimmune disorders, Diseases, Therapies, Bleeding and clotting, Immune Disorders, Clinically relevant, TTP

Saturday, Dec 7, 2019, 10:45 AM; W308, Level 3 (Orange County Convention Center)

Mazepa A. Marshall, MD¹, Michael Evans, MS^{2*}, Elizabeth Davis, MD^{3*}, Andrew Johnson, MD^{4*}, Ana G. Antun, MD⁵, Andrew M. Farland, MD⁶, Ryan R Woods, MD^{7*}, Ara Metjian, MD⁸, Kristin Bagby^{9*}, Yara Park, MD^{10*}, Jay S Raval, MD^{11*}, Gustaaf de Ridder, MD^{12*}, Briana Gibson, MD^{12*}, Raj S. Kasthuri, MD^{13*}, Darla K Liles, MD¹⁴, Susan Eubanks^{15*}, Frank Akwaa, MD^{16*}, Lisa B. Kreuziger, MD, MS^{17*}, J. Evan Sadler,

MD, PhD¹⁸, Meera Sridharan, MD¹⁹, Ronald S. Go, MD²⁰, **Keith R McCrae, MD²¹**, Shruti Chaturvedi, MBBS, MS²², Harsh Vardhan Upreti^{23*}, Rahil Kohli, MD^{24*}, Ming Y. Lim, MBBChir, MA²⁵, X. Long Zheng, MD, PhD²⁶, Nicole K. Kocher^{27*}, Radhika Gangaraju, MD²⁸ and Spero Cataland, MD²⁹

¹University of Minnesota, Minneapolis, MN

²Clinical and Translational Research Institute, University of Minnesota, Minneapolis, NC

³University of Minnesota, Minneapolis, MN

⁴Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN

⁵Atlanta VA Medical Center, Decatur, GA

⁶Wake Forest University, Winston Salem, NC

⁷Wake Forest University, Winston-Salem, NC

⁸Duke University School of Medicine, Durham, NC

⁹Duke University, Durham, NC

¹⁰University of North Carolina At Chapel Hill, Chapel Hill, NC

¹¹Department of Pathology, University of New Mexico, Albuquerque, NM

¹²University of North Carolina, Chapel Hill, NC

¹³Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC

¹⁴Division of Hematology–Oncology, Vidant Medical Center/East Carolina University, Greenville, NC

¹⁵East Carolina University, Greenville, NC

¹⁶University of Rochester Medical Center, Rochester, NY

¹⁷Blood Research Institute, Versiti, Menomonee Falls, WI

¹⁸Washington University in St. Louis, Clayton, MO

¹⁹Mayo Clinic, Rochester, MN

²⁰Mayo Clinic, Onalaska, WI

²¹Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

²²Johns Hopkins University School of Medicine, BALTIMORE, MD

²³Maulana Azad Medical College, University of Delhi, New Delhi, MD, India

²⁴University of Pittsburgh Medical Center, Pittsburgh, PA

²⁵Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT

²⁶Division of Laboratory Medicine, Department of Pathology, The University of Alabama At Birmingham, Birmingham, AL

²⁷Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL

²⁸Division of Hematology and Oncology, Department of Medicine, University Of Alabama, Birmingham, AL

²⁹Division of Hematology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH

103 Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

Program: Oral and Poster Abstracts

Type: Oral

Session: 508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment

Hematology Disease Topics & Pathways: aplasia, Anemias, Diseases, aplastic anemia, Bone Marrow Failure, Diamond Blackfan Anemia, Biological Processes, Genetic Disorders, Fanconi Anemia, DNA repair, PNH, genomics, pathogenesis

Saturday, Dec 7, 2019, 9:30 AM; Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)

Bhavuk Garg, PhD^{1*}, Hrishikesh M Mehta, PhD¹, Ralph Kamel^{2*}, Marshall S. Horwitz, MD, PhD³ and **Seth J. Corey, MD⁴**

¹Cancer Biology, Cleveland Clinic, Cleveland, OH

²Virginia Commonwealth University, Richmond, VA

³University of Washington, Seattle, WA

⁴Departments of Pediatrics, Cancer Biology, THOR, Cleveland Clinic, Cleveland, OH

108 T Cell Landscape of Immune Aplastic Anemia Reveals a Convergent Antigen-Specific Signature

Program: Oral and Poster Abstracts

Type: Oral

Session: 508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment

Hematology Disease Topics & Pathways: aplasia, Anemias, Diseases, aplastic anemia, Bone Marrow Failure, Diamond Blackfan Anemia, Biological Processes, Genetic Disorders, Fanconi Anemia, DNA repair, PNH, genomics, pathogenesis

Saturday, Dec 7, 2019, 10:45 AM; Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)
Jani Huuhtanen, BMed^{1,2,3}, Sofie Lundgren, BMed^{1,3*}, Mikko A Keränen, MD, PhD^{1,3*}, Xingmin Feng, PhD⁴, Cassandra M Kerr, MS^{5*}, Emmi Jokinen, MSc^{2*}, Markus Heinonen, PhD^{2,6*}, Paula Savola, MD, PhD^{1,3*}, Tiina Kelkka, PhD^{1,3*}, Freja Ebeling, MD, PhD^{7*}, Georgina L Ryland^{8*}, Lucy Fox, MD^{9*}, Piers Blombery, MBBS^{8*}, Eva Hellstrom Lindberg, MD, PhD¹⁰, Neal S. Young, MD⁴, Jaroslaw P. Maciejewski, MD, PhD⁵, Harri Lähdesmäki, PhD^{2*} and Satu Mustjoki, MD, PhD^{1,3,11}*

¹Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

²Department of Computer Science, Aalto University School of Science, Espoo, Finland

³Translational Immunology Research program, University of Helsinki, Helsinki, Finland

⁴National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Helsinki Institute for Information Technology, Helsinki, Finland

⁷Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

⁸Molecular Haematology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia

⁹Peter MacCallum Cancer Centre, Melbourne, Australia

¹⁰Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden

¹¹Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland

115 Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction and Post-Remission Therapy

Hematology Disease Topics & Pathways: Adult, AML, Diseases, Non-Biological, Therapies, Elderly, chemotherapy, Study Population, Clinically relevant, Myeloid Malignancies

Saturday, Dec 7, 2019, 9:30 AM; W304, Level 3 (Orange County Convention Center)

James M. Foran, MD¹, Zhuoxin Sun^{2}, David F. Claxton, MD³, Hillard M Lazarus, MD⁴, Daniel A. Arber, MD⁵, Jacob M. Rowe, MB, BS⁶, Elisabeth Paietta, PhD⁷, Janis Racevskis, PhD^{7*}, Jessica K. Altman⁸, Selina M. Luger, MD, FRCPC⁹, Aref Al-Kali, MD¹⁰, Hong Zheng, MD, PhD¹¹, Keith W. Pratz, MD^{12,13}, Edward R. Broun, MD¹⁴, Bayard L Powell, MD¹⁵, Kristen Marie O'Dwyer, MD¹⁶, John E. Godwin, MD¹⁷, Yishai Ofran, MD¹⁸, Mark Litzow, MD¹⁰ and Martin S. Tallman, MD¹⁹*

¹Mayo Clinic Florida, Jacksonville, FL

²Dana-Farber Cancer Institute, Boston, MA

³Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center, Hershey, PA

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Cleveland Medical Center, Cleveland, OH

⁵University of Chicago, Chicago, IL

⁶The Ruth and Bruce Rappaport Faculty of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

⁷Cancer Center, Montefiore Medical Center, Bronx, NY

⁸Northwestern University, Chicago, IL

⁹Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

¹⁰Division of Hematology, Mayo Clinic, Rochester, MN

¹¹Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA

¹²John Hopkins University, Baltimore, MD

¹³Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

¹⁴OHC, Inc., Cincinnati, OH

¹⁵Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC

¹⁶University of Rochester Medical Center, Rochester, NY

¹⁷Providence Portland Medical Center, Portland, OR

¹⁸Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel

¹⁹Memorial Sloan Kettering Cancer Center, New York, NY

146 No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results: Alternative Donors, Novel Regimens

Hematology Disease Topics & Pathways: Biological, Adult, AML, ALL, Leukemia, Diseases, Therapies, CML, MDS, Pediatric, MPN, Young Adult, Study Population, Clinically relevant, Lymphoid Malignancies, Myeloid Malignancies, transplantation, stem cells

Saturday, Dec 7, 2019, 9:45 AM; W307, Level 3 (Orange County Convention Center)

*Filippo Milano, MD, PhD^{1,2}, Andrew R Rezvani, MD³, Joanne Kurtzberg, MD⁴, Chatchada Karanes, MD⁵, Jonathan A Gutman, MD⁶, Christine Duncan, MD^{7,8}, Alla Keyzner, MD⁹, **Rabi Hanna, MD^{10,11}**, Tonya Kimberly Marmon, PhD^{12*}, Ann Dahlberg, MD^{2*} and Colleen Delaney, MD, MSc^{13,14}*

¹Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

³Stanford University Medical Center, Stanford, CA

⁴Pediatric Stem Cell Transplantation Department, Duke University Medical Center, Durham, NC

⁵Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA

⁶Clinical Research, University of Colorado, Aurora, CO

⁷Boston Children's Hospital, Boston, MA

⁸Dana-Farber Cancer Institute, Boston, MA

⁹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

¹⁰Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, University of Washington, Cleveland, OH

¹¹Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹²NOHLA, South San Francisco, CA

¹³Nohla Therapeutics, Seattle, WA

¹⁴Fred Hutchinson Cancer Research Center, Seattle, WA

[**245 Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor \(CAR\) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium**](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Results from CAR T-Cell Trials

Hematology Disease Topics & Pathways: Diseases, Non-Hodgkin Lymphoma, Lymphoid Malignancies

Saturday, Dec 7, 2019, 3 PM; Hall E2, Level 2 (Orange County Convention Center)

Michael D. Jain, MD, PhD¹, Miriam T. Jacobs, MD², Loretta J. Nastoupil, MD, MSc³, Jay Y. Spiegel, MD, FRCPC⁴, Gao Feng^{5}, Yi Lin, MD, PhD⁶, Matthew A. Lunning, DO, FACP⁷, Saurabh Dahiya, MD⁸, Lazaros J Lekakis, MD^{9*}, Patrick M Reagan, MD¹⁰, Olalekan O. Oluwole, MBBS, MPH¹¹, Joseph P. McGuirk, DO¹², Abhinav Deol, MD¹³, Andre Goy, MD¹⁴, **Brian T. Hill, MD¹⁵**, Javier Munoz, MD^{16*}, Julio Chavez^{17*}, Aaron P. Rapoport¹⁸, Julie M Vose, MD MBA¹⁹, David B Miklos, MD, PhD²⁰, Sattva S Neelapu, MD³, N. Nora Bannani, MD⁶, Charalambos Andreadis, MD, MSCE^{21*}, Alison R. Sehgal, MD²², Armin Ghobadi, MD²³ and Frederick L. Locke, MD¹*

¹Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

²Department of Oncology, Washington University in St. Louis, St Louis, MO

³Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

⁴Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA

⁵Washington University in St. Louis, St. Louis, MO

⁶Division of Hematology, Mayo Clinic, Rochester, MN

⁷University of Nebraska Medical Center, Omaha, NE

⁸University of Maryland School of Medicine, Ellicott City, MD

⁹University of Miami, Sylvester Comprehensive Care Center, Miami, FL

¹⁰Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

¹¹Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN

¹²Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS

¹³Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI

¹⁴Department of Hematology & Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

¹⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁶Banner MD Anderson Cancer Center, Gilbert, AZ

¹⁷Dept. of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

¹⁸University of Maryland Greenebaum Comprehensive Cancer Center and School of Medicine, Baltimore, MD

¹⁹Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE

²⁰Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA

²¹Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

²²UPMC Hillman Cancer Center, Pittsburgh, PA

261 Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results: Outcomes

Hematology Disease Topics & Pathways: Diseases, Young Adult, Study Population, Lymphoid Malignancies, Clinically relevant

Saturday, Dec 7, 2019, 2:30 PM; W307, Level 3 (Orange County Convention Center)

Matthew J. Wieduwilt, MD, PhD¹, Wendy Stock, MD², Anjali S. Advani, MD³, Selina M. Luger, MD, FRCPC⁴, Richard A. Larson, MD², Martin S. Tallman, MD⁵, Frederick R. Appelbaum, MD⁶, Mei-Jie Zhang^{7*}, Khalid Bo-Subait^{8*}, Brenda M. Sandmaier, MD^{9,10}, **Marcos de Lima, MD¹¹, Partow Kebriaei, MD¹², Mark Litzow, MD¹³, Wael Saber, MD, MS⁷ and Daniel J. Weisdorf, MD¹⁴**

¹Moore's Cancer Center, University of California, San Diego, La Jolla, CA

²Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

⁵Memorial Sloan Kettering Cancer Center, New York, NY

⁶Departments of Oncology and Hematology, University of Washington, Seattle, WA

⁷CIBMTR, Medical College of Wisconsin, Milwaukee, WI

⁸CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁹Fred Hutchinson Cancer Research Center and Dept. of Medicine, University of Washington, Seattle, WA

¹⁰Division of Medical Oncology, Department of Medicine, Fred Hutchinson Cancer Rsch. Ctr., Seattle, WA

¹¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

¹²Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, TX

¹³Division of Hematology, Mayo Clinic, Rochester, MN

¹⁴Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

253 Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Program: Oral and Poster Abstracts

Type: Oral

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity in Allogeneic Transplantation--Does It Matter?

Hematology Disease Topics & Pathways: Biological, Therapies, transplantation

Saturday, Dec 7, 2019, 2:00 PM; W331, Level 3 (Orange County Convention Center)

Betul Oran, MD, MS¹, Kwang Woo Ahn, PhD^{2,3*}, Caitrin Fretham^{4*}, Mithun Vinod Shah, MD, PhD⁵, Ryotaro Nakamura, MD⁶, Bart L. Scott, MD⁷, **Ronald Sobecks, MD⁸, Uday Popat, MD⁹ and Wael Saber, MD, MS¹⁰**

¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX

²Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI

³Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI

⁴National Marrow Donor Program/Be The Match, Minneapolis, MN

⁵Division of Hematology, Mayo Clinic, Rochester, MN

⁶Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

⁷Fred Hutchinson Cancer Research Center, Seattle, WA

⁸Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹The University of Texas MD Anderson Cancer Center, Houston, TX

¹⁰CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

261 Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results: Outcomes

Hematology Disease Topics & Pathways: Diseases, Young Adult, Study Population, Lymphoid Malignancies, Clinically relevant

Saturday, Dec 7, 2019, 2:30 PM; W307, Level 3 (Orange County Convention Center)

Matthew J. Wieduwilt, MD, PhD¹, Wendy Stock, MD², Anjali S. Advani, MD³, Selina M. Luger, MD, FRCPC⁴, Richard A. Larson, MD², Martin S. Tallman, MD⁵, Frederick R. Appelbaum, MD⁶, Mei-Jie Zhang^{7}, Khalid Bo-Subait^{8*}, Brenda M. Sandmaier, MD^{9,10}, Marcos de Lima, MD¹¹, Partow Kebriaei, MD¹², Mark Litzow, MD¹³, Wael Saber, MD, MS⁷ and Daniel J. Weisdorf, MD¹⁴*

¹Moore's Cancer Center, University of California, San Diego, La Jolla, CA

²Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

⁵Memorial Sloan Kettering Cancer Center, New York, NY

⁶Departments of Oncology and Hematology, University of Washington, Seattle, WA

⁷CIBMTR, Medical College of Wisconsin, Milwaukee, WI

⁸CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁹Fred Hutchinson Cancer Research Center and Dept. of Medicine, University of Washington, Seattle, WA

¹⁰Division of Medical Oncology, Department of Medicine, Fred Hutchinson Cancer Rsch. Ctr., Seattle, WA

¹¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

¹²Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, TX

¹³Division of Hematology, Mayo Clinic, Rochester, MN

¹⁴Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

270 The Prognostic Factors for Early Fatal Outcome in Patients with Multiple Myeloma

Program: Oral and Poster Abstracts

Type: Oral

Session: 902. Health Services Research—Malignant Conditions (Lymphoid Disease): Treatment-Based Outcomes

Hematology Disease Topics & Pathways: Clinically relevant

Saturday, Dec 7, 2019, 3:15 PM; W308, Level 3 (Orange County Convention Center)

Sowjanya Vuyyala, MD^{1}, Kamal Chamoun, MD², Pingfu Fu^{3*}, Shufen Cao^{3*}, Molly M Gallogly, MD, PhD⁴, Marcos de Lima, MD⁴ and Ehsan Malek, MD⁵*

¹University Hospitals Cleveland Medical Center, Cleveland, OH

²University Hospitals Cleveland Medical Center, Adult Stem Cell Program, Cleveland, OH

³Case Western Reserve University, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH

360 A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Program: Oral and Poster Abstracts

Type: Oral

Session: 642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment

Hematology Disease Topics & Pathways: Leukemia, Diseases, Therapies, CLL, Combinations, Lymphoid Malignancies, Clinically relevant

Sunday, Dec 8, 2019, 8:45 AM; Hall E1, Level 2 (Orange County Convention Center)

Paul M. Barr, MD₁, Brian T. Hill, MD₂, Shuo Ma, MD, PhD₃, Andrea M Baran, MS₄, Andrew Bui₄*, Philip J Meacham, MS₄*, Ashley Morrison₅*, Jane L. Liesveld, MD₄, Deborah A Mulford, MD₄*, Peter Sportelli, BS₆, Hari P Miskin, MSc₆*, Michael S Weiss₆*, Jonathan W. Friedberg, MD₇ and Clive S Zent, MD₄*

¹Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY

²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL

⁴Wilmot Cancer Institute, University of Rochester, Rochester, NY

⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶TG Therapeutics, Inc., New York, NY

⁷Division of Hematology/Oncology, University of Rochester, Rochester, NY

332 Increased Toxicity Among Adolescents and Young Adults Treated for Acute Myeloid Leukemia at US Children's Hospitals

Program: Oral and Poster Abstracts

Type: Oral

Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Big Data in Studying Myeloid Malignancies

Hematology Disease Topics & Pathways:

Diseases, AML, Pediatric, Young Adult, Study Population, Myeloid Malignancies

Saturday, Dec 7, 2019, 4:15 PM; W308, Level 3 (Orange County Convention Center)

Mohamad G. Sinno, MD₁, Sneha Butala, MD₂ and Jignesh Dalal, MD₃*

¹Pediatric Hematology/Oncology, Rainbow Babies & Children's Hospital, Shaker Heights, OH

²University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

³Rainbow Babies & Children's Hospital, Cleveland, OH

397 The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population-Based Outcomes

Hematology Disease Topics & Pathways: Diseases, Non-Hodgkin Lymphoma, DLBCL, Lymphoid Malignancies

Sunday, Dec 8, 2019, 9:30 AM; W224, Level 2 (Orange County Convention Center)

Andrew M. Evens, DO, MSc₁, Alexey Danilov, MD, PhD₂, Deepa Jagadeesh, MD, MPH₃, Amy Sperling, BS₄, Seo-Hyun Kim, MD₅, Ryan Vaca, MD₆, Catherine Wei, MD, MA₁, Daniel Rector₇*, Suchitra Sundaram, MD₈, Nishitha Reddy, MD₉, Yong Lin, PhD₁*, Umar Farooq, MD₁₀, Christopher D'Angelo, MD₁₁, David A. Bond, MD₁₂, Stephanie Berg, DO₁₃, Michael C. Churnetski₁₄*, Amandeep Godara, MD₁₅, Nadia Khan, MD₁₆, Yun Kyong Choi, MD₁₇*, Maryam Yazdy, MD₁₈, Emma Rabinovich, MD₁₉*, Gaurav Varma, MD, MSPH₂₀*, Reem Karmali, MD₂₁, Agrima Mian, MBBS, MD₃*, Jeremy Ramdial, MD₂₂, Madelyn Burkart, MD₂₃*, Peter Martin, FRCPC, MD, MS₂₀, Albert Ren₁₉*, Ayushi Chauhan, MBBS₁₈*, Catherine Diefenbach, MD₁₇*, Allandria Straker-Edwards, MS₁₆*, Andreas Klein, MD₁₅, Kristie A. Blum, MD₁₄, Kirsten M Boughan, DO₂₄, Scott E. Smith, MD, PhD₁₃, Brad M. Haverkos, MD, MPH, MS₂₅, Victor M. Orellana-Noia, MD₂₆, Vaishalee P. Kenkre, MD₁₁, Adam Zayac, MD₂₇*, Seth M Maliske, MD₁₀, Narendranath Epperla, MD, MS₂₈, Parameswaran Venugopal, MD₅, Tatyana A. Feldman, MD₇, Stephen D. Smith, MD₄*, Andrzej Stadnik, MPH, BS₂*, Izidore S. Lossos, MD₂₂, Kevin A. David, MD₁, Seema Naik, MD₆*, **Paolo Caimi, MD₂₄**, Manali Kamdar, MD₂₅, Craig A. Portell, MD₂₉, Adam J Olszewski, MD₂₇ and Juan Pablo Alderuccio, MD₂₂*

¹Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

²Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

⁵Rush University Medical Center, Chicago, IL

⁶Penn State Cancer Institute, Penn State University College of Medicine, Hershey, PA

⁷John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
⁸Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁹Vanderbilt University Medical Center, Nashville, TN
¹⁰Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
¹¹Carbone Cancer Center, University of Wisconsin, Madison, WI
¹²James Cancer Center, The Ohio State University Hospital, Columbus, OH
¹³Loyola University Medical Center, Maywood, IL
¹⁴Winship Cancer Institute, Emory University Medical Center, Atlanta, GA
¹⁵Tufts Medical Center, Boston, MA
¹⁶Fox Chase Cancer Center, Philadelphia, PA
¹⁷New York University School of Medicine, NYU Cancer Institute, New York, NY
¹⁸Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC
¹⁹University of Illinois at Chicago, Chicago, IL
²⁰Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY
²¹Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
²²Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
²³Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
²⁴University Hospitals Seidman Cancer Center, Cleveland, OH
²⁵Division of Hematology, University of Colorado, Denver, CO
²⁶University of Virginia Cancer Center, Charlottesville, VA
²⁷Brown University, Providence, RI
²⁸The Ohio State University Comprehensive Cancer Center, Columbus, OH
²⁹Division of Hematology and Oncology, University of Virginia, Charlottesville, VA

[402 Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma \(BL\) and Central Nervous System \(CNS\) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Population-Based Outcomes
 Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, Lymphoma (any), chemotherapy, CNS Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies

Sunday, Dec 8, 2019, 10:45 AM; W224, Level 2 (Orange County Convention Center)

Adam Zayac, MD¹, Andrew Matthew Evens, DO, MMSc², Andrzej Stadnik, MPH, BS^{3*}, Stephen D. Smith, MD⁴, **Deepa Jagadeesh, MD, MPH⁵**, Lori A. Leslie, MD⁶, Catherine Wei, MD, MA², Seo-Hyun Kim, MD⁷, Seema Naik, MD^{8*}, Suchitra Sundaram, MD⁹, Nishitha Reddy, MD¹⁰, Umar Farooq, MD¹¹, Vaishalee P. Kenkre, MD¹², Narendranath Epperla, MD, MS¹³, Kristie A. Blum, MD¹⁴, Nadia Khan, MD¹⁵, Daulath Singh, MD¹⁶, Juan Pablo Alderuccio, MD¹⁷, Amandeep Godara, MD¹⁸, Maryam Yazdy, MD¹⁹, Catherine Diefenbach, MD^{20*}, Emma Rabinovich, MD^{21*}, Gaurav Varma, MD, MPH^{22*}, Reem Karmali, MD²³, Yusra Shao, MD^{5*}, Asaad Trabolsi, MD^{24*}, Madelyn Burkart, MD^{25*}, Peter Martin, FRCP, MD, MS²⁶, Sarah Stettner^{21*}, Ayushi Chauhan, MBBS^{19*}, Yun Kyong Choi, MD²⁰, Allandria Straker-Edwards, MS^{15*}, Andreas Klein, MD¹⁸, Michael C. Churnetski^{27*}, Kirsten M Boughan, DO²⁸, Stephanie Berg, DO¹⁶, Brad M. Haverkos, MD, MPH, MS²⁹, Victor M. Orellana-Noia, MD³⁰, Christopher D'Angelo, MD¹², David A. Bond, MD³¹, Seth M Maliske, MD¹¹, Ryan Vaca, MD⁸, Gabriela Magarelli, APN^{6*}, Amy Sperling, BS^{4*}, Max J. Gordon, MD³², Kevin A. David, MD², Paolo Caimi, MD²⁸, Manali Kamdar, MD³³, Craig A. Portell, MD³⁴, Parameswaran Venugopal, MD⁷, Izidore S. Lossos, MD¹⁷ and Adam J Olszewski, MD^{1,35}

¹Alpert Medical School of Brown University, Providence, RI
²Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
³Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
⁴University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
⁵Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁶John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
⁷Rush University Medical Center, Chicago, IL
⁸Penn State Cancer Institute, Penn State University College of Medicine, Hershey, PA
⁹Roswell Park Comprehensive Cancer Center, Buffalo, NY
¹⁰Vanderbilt University Medical Center, Nashville, TN
¹¹Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
¹²Carbone Cancer Center, University of Wisconsin, Madison, WI

¹³The Ohio State University Comprehensive Cancer Center, Columbus, OH
¹⁴Winship Cancer Institute, Emory University, Atlanta, GA
¹⁵Fox Chase Cancer Center, Philadelphia, PA
¹⁶Loyola University Medical Center, Maywood, IL
¹⁷Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
¹⁸Tufts Medical Center, Boston, MA
¹⁹Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC
²⁰New York University School of Medicine, NYU Cancer Institute, New York, NY
²¹University of Illinois at Chicago, Chicago, IL
²²Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY
²³Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
²⁴Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
²⁵Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
²⁶Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY
²⁷Winship Cancer Institute, Emory University Medical Center, Atlanta, GA
²⁸University Hospitals Seidman Cancer Center, Cleveland, OH
²⁹Division of Hematology, University of Colorado, Denver, CO
³⁰University of Virginia School of Medicine, Charlottesville, VA
³¹James Cancer Center, The Ohio State University Hospital, Columbus, OH
³²Oregon Health and Science University, Portland, OR
³³Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO
³⁴Division of Hematology and Oncology, University of Virginia, Charlottesville, VA
³⁵Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI

424 Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients

Program: Oral and Poster Abstracts

Type: Oral

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies

Hematology Disease Topics & Pathways:

multiple myeloma, ALL, Diseases, survivorship, Lymphoma (any), Elderly, Adverse Events, Young Adult, Study Population, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant, Quality Improvement

Sunday, Dec 8, 2019, 10:15 AM; W314, Level 3 (Orange County Convention Center)

Gayathri Ravi, MD¹, Kamal Chamoun, MD², Kirsten M Boughan, DO³, Shufen Cao^{4*}, Pingfu Fu^{4*}, Marcos de Lima, MD³ and Ehsan Malek, MD⁵

¹University Hospitals Seidman Cancer Center, Cleveland, OH

²University Hospitals Cleveland Medical Center, Adult Stem Cell Program, Cleveland, OH

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Case Western Reserve University, Cleveland, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

452 FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults

Program: Oral and Poster Abstracts

Type: Oral

Session: 508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure

Hematology Disease Topics & Pathways: Biological, aplasia, Anemias, Diseases, Non-Biological, Therapies, aplastic anemia, Bone Marrow Failure, Diamond Blackfan Anemia, Biological Processes, Genetic Disorders, Fanconi Anemia, DNA repair, PNH, Clinically relevant, hematopoiesis, pharmacology, stem cells

Sunday, Dec 8, 2019, 12:15 PM; Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)

Jibran Durrani^{1*}, Hassan Awada, MD¹, Wenyi Shen, MD^{2*}, Cassandra M Kerr, MS^{1*}, Vera Adema, PhD^{1*}, Sunisa Kongkiatkamon^{1*}, Ashwin Kishtagari, MBBS¹, Samuel Li^{3*}, Yasunobu Nagata, MD, PhD^{1*}, Sanghee Hong, MD^{4*}, Aziz Nazha, MD⁵, Bhumiika J. Patel, MD⁶, Yogenthiran Saunthararajah, MD⁷, Hetty E.

Carraway, MD, MBA⁶, Valeria Visconte, PhD⁸, Seth J. Corey, MD¹, Mikkael A. Sekeres, MD, MS⁹, Thomas Laframboise, PhD^{3*} and Jaroslaw P. Maciejewski, MD, PhD¹⁰

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

³Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁴Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁰Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

453 Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Program: Oral and Poster Abstracts

Type: Oral

Session: 508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure

Hematology Disease Topics & Pathways: HSCs, Diseases, Anemias, aplastic anemia, platelets, Bone Marrow Failure, Biological Processes, Cell Lineage, epigenetics, iron metabolism, pathway

Sunday, Dec 8, 2019, 12:30 PM; Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)

Yihong Guan, PhD^{1*}, Bhumi J. Patel, MD², Metis Hasipek, PhD^{1*}, Dale Grabowski, BS^{1*}, Hassan Awada, MD¹, Cassandra M Kerr, MS^{1*}, Valeria Visconte, PhD¹, Aziz Nazha, MD³, Yogenthiran Saunthararajah, MD¹, Mikkael A. Sekeres, MD, MS⁴, Jaroslaw P. Maciejewski, MD, PhD⁵ and Babal K. Jha, PhD^{1*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

502 Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Program: Oral and Poster Abstracts

Type: Oral

Session: CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL

Hematology Disease Topics & Pathways: Biological, Leukemia, Diseases, Therapies, CLL, Combinations, CAR-Ts, Lymphoid Malignancies, Clinically relevant, TKI

Sunday, Dec 8, 2019, 5:15 PM; Hall D, Level 2 (Orange County Convention Center)

Anthony R. Mato, MD MSCE^{1,2}, Lindsey E. Roeker, MD³, Toby A. Eyre, MBBChir, MRCP^{4*}, Ryan Jacobs, MD⁵, Brian T. Hill, MD⁶, Nicole Lamanna, MD⁷, Danielle M. Brander, MD⁸, Mazyar Shadman, MD⁹, Chaitra Ujjani, MD^{10*}, Maryam Yazdy, MD¹¹, Guilherme Fleury Perini, MD^{12*}, Javier Pinilla Ibarz, MD, PhD¹³, Jacqueline C Barrientos, MD¹⁴, Alan Skarbnik, MD¹⁵, Pallawi Torka, MD¹⁶, Jeffrey J Pu, MD, PhD¹⁷, John M. Pagel, MD, PhD, DSc¹⁸, Satyen Gohil, BSc, MBBS, MRCP, FRCPATH¹⁹, Bita Fakhri, MD, MPH²⁰, Michael Y. Choi, MD²¹, Catherine C. Coombs, MD²², Joanna Rhodes, MD²³, Paul M. Barr, MD²⁴, Craig A. Portell, MD²⁵, Helen Parry, MB ChB, MRCP, PhD^{26*}, Christine Ann Garcia, MD, MPH²⁷, Kate J Whitaker, BA^{3*}, Allison M. Winter, MD²⁸, Andrea Sitlinger, MD²⁹, Sirin Khajavian, MD^{9*}, Ariel F Grajales-Cruz, MD^{13*}, Krista Isaac, DO, MS^{25*}, Pratik Shah^{30*}, Othman S. Akhtar, MD^{31,32}, Rachael Pocock, MD^{33*}, Kentson Lam, MD, PhD²¹, Timothy J Voorhees, MD²², Stephen J. Schuster, MD²³, Thomas David Rodgers, MD^{34*}, Nicolas Martinez-Calle, MD, MSc^{35*}, Talha Munir, MD^{36*}, Erica B Bhavsar, BS^{37*}, Neil Bailey, MSc^{18*}, Jason C. Lee, MD⁷, Hanna Weissbrot, BS^{7*}, Chadi Nabhan, MD, MBA, FACP³⁸, Julie Goodfriend^{3*}, Amber C. King, PharmD, BCOP³⁹, Andrew D. Zelenetz, MD, PhD⁴⁰, Colleen Dorsey, BSN, RN^{41*}, Kayla Bigelow^{3*}, Bruce D. Cheson, MD⁴², Christopher P Fox, MBChB(Hons), MRCP, FRCPATH, PhD^{43*} and John N. Allan, MD⁴⁴

¹Center for CLL, Memorial Sloan-Kettering Cancer Center, New York, NY
²CLL Program, Leukemia Service, Hematologic Malignancies Division, Memorial Sloan Kettering Cancer Center, New York, NY
³Memorial Sloan Kettering Cancer Center, New York, NY
⁴Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, HP11 2TJ, United Kingdom
⁵Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC
⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
⁷Herbert Irving Comprehensive Cancer Center (New York-Presbyterian Columbia University Medical Center), New York, NY
⁸Duke University Medical Center, Durham, NC
⁹Fred Hutchinson Cancer Research Center, Seattle, WA
¹⁰Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle
¹¹Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC
¹²Hospital Israelita Albert Einstein, Sao Paulo, PA, Brazil
¹³Division of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
¹⁴North Shore University Hospital, Northwell Health, Manhasset, NY
¹⁵Novant Health, Charlotte, NC
¹⁶Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
¹⁷SUNY Upstate Medical University, Syracuse, NY
¹⁸Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
¹⁹University College London, London, United Kingdom
²⁰Dept of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA
²¹Moore's Cancer Center, University of California San Diego, La Jolla, CA
²²Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
²³Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
²⁴Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY
²⁵Division of Hematology and Oncology, University of Virginia, Charlottesville, VA
²⁶Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
²⁷Hillman Cancer Pavilion, Division of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA
²⁸Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
²⁹Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC
³⁰Northwell Health, New York, NY
³¹Department of Medicine, State University of New York at Buffalo, Buffalo, NY
³²Roswell Park Comprehensive Cancer Center, Buffalo, NY
³³University of College of London, London, United Kingdom
³⁴University of Rochester Medical Center, Rochester, NY
³⁵Nottingham University Hospitals NHS Trust, Nottingham, ENG, United Kingdom
³⁶Department of Haematology, St James's University Hospital, Leeds, United Kingdom
³⁷Weill Cornell Medicine, New York, NY
³⁸Aptitude Health and University of South Carolina, Atlanta, GA
³⁹Clinical Pharmacy Specialist-Leukemia, Memorial Sloan Kettering Cancer Center, New York, NY
⁴⁰Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁴¹Memorial Sloan-Kettering Cancer Center, New York, NY
⁴²Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC
⁴³Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
⁴⁴Weill Cornell Medicine, Long Island City, NY

537 Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacitidine

Program: Oral and Poster Abstracts

Type: Oral

Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies

Hematology Disease Topics & Pathways: Diseases, AML, therapy sequence, Therapies, Non-Biological, drug-drug interaction, Combinations, MDS, MPN, Myeloid Malignancies, pharmacology

Monday, Dec 9, 2019, 7:30 AM, W307, Level 3 (Orange County Convention Center)

Xiaorong Gu, PhD^{1*}, Rita Tohme, PhD^{1*}, Benjamin K. Tomlinson, MD², Lisa Durkin^{3*}, Caroline Schuerger^{4*}, Asmaa M Zidan, MB, BCh^{5,6*}, Tomas Radivoyevitch, PhD^{4,7*}, Hetty E. Carraway, MD, MBA^{8,9}, Ronald Sobecks, MD¹⁰, Betty K. Hamilton, MD¹¹, Alan Lichtin, MD¹², Jaroslaw P. Maciejewski, MD, PhD^{13,14} and Yogenthiran Sauntharajah, MD¹⁵

¹Taussig Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Taussig Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, CLEVELAND, OH

⁶South Egypt Cancer Institute, Assiut University, Assiut, Egypt

⁷Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

⁸Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁰Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹¹Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹²Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

¹³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁴Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

¹⁵Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

556 A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Program: Oral and Poster Abstracts

Type: Oral

Session: 634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies

Hematology Disease Topics & Pathways: Diseases, MPN, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019, 7:45 AM; W304EFGH, Level 3 (Orange County Convention Center)

Kristen Pettit, MD¹, Aaron T. Gerds, MD, MS², Abdulraheem Yacoub, MD³, Justin M. Watts, MD⁴, Maciej Tartaczuch, MD^{5*}, Terrence J Bradley, MD⁶, Jake Shortt, MBBS FRACP FRCPA PhD^{7*}, William S. Stevenson, MBBS, PhD⁸, Natasha Joan Curtin, MD, FRACP, FRCPA^{5*}, James M. Rossetti, DO⁹, Kate Burbury, MBBS, FRACP, FRCPA, DPhil^{10*}, Georges Natsoulis, Ph.D.^{11*}, Amber Jones, MA^{11*}, Moshe Talpaz, MD¹², Jennifer Peppe, BS^{13*}, David M Ross, MD PhD^{14*} and Hugh Young Rienhoff Jr., MD¹⁵

¹Rogel Cancer Center, The University of Michigan, Ann Arbor, MI

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

³Malignant Hematology and Cellular Therapeutics, Kansas University Cancer Center, Leawood, KS

⁴Department of Oncology, University of Miami Health System, Miami, FL

⁵Monash Health, Monash University, Melbourne, Australia

⁶University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

⁷Department of Haematology, Monash Health, Clayton, Australia

⁸Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia

⁹UPMC Hillman Cancer Center, Pittsburgh, PA

¹⁰Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

¹¹Imago Biosciences, Inc., San Carlos, CA

¹²University of Michigan, Ann Arbor, MI

¹³Imago BioSciences, Inc., San Carlos, CA

¹⁴Haematology and Genetic Pathology, Flinders University, Adelaide, SA, Australia

¹⁵Imago Biosciences, San Francisco

564 Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Mechanisms and Potential Therapeutic Targets in MDS

Hematology Disease Topics & Pathways: Diseases, MDS, Biological Processes, epigenetics, Myeloid Malignancies, genomics, pathogenesis

Monday, Dec 9, 2019, 8:15 AM; W311ABCD, Level 3 (Orange County Convention Center)

Valeria Visconte, PhD¹, Vera Adema, PhD^{2*}, Anand D. Tiwari, PhD^{2*}, Cassandra M Kerr, MS^{2*}, Hassan Awada^{2*}, Bartłomiej Przychodzen^{3*}, Allison Noe^{2*}, Rachel Toth^{3*}, Christina Snider^{3*}, Yvonne Parker^{4*}, Yuriy Fedorov^{5*}, Drew Adams^{5*}, **Hetty E. Carraway, MD, MBA⁶, Anjali S. Advani, MD⁷, Kevin R Kelly, MD, PhD^{8*}, Steffan T. Nawrocki, PhD⁹, Jennifer S. Carew, PhD¹⁰, Heesun J. Rogers, MD, PhD¹¹, **Daniel J. Lindner, MD, PhD^{3*}, Mikkael A. Sekeres, MD, MS¹², James G Phillips, PhD^{2*} and Jaroslaw P. Maciejewski, MD, PhD¹³****

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁴Cleveland Clinic, Cleveland, OH

⁵Department of Genetics and Genome Sciences, Small-Molecule Drug Development Core, Case Western Reserve University School of Medicine, Cleveland

⁶Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷Leukemia Program, Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁸Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA
⁹Division of Translational and Regenerative Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ
¹⁰The University of Arizona Cancer Center, Tucson, AZ
¹¹Department of Hematopathology, Cleveland Clinic, Cleveland
¹²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
¹³Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

633 Extended Mutational Profiling By MSK-IMPACT™ Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Program: Oral and Poster Abstracts

Type: Oral

Session: 331. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis

Hematology Disease Topics & Pathways: multiple myeloma, Drug-induced thrombocytopenia, Bleeding Disorders, Diseases, Adult, Therapies, Hemostasis, Bleeding and clotting, HIT, Adverse Events, Pediatric, Thrombosis, Young Adult, Study Population, Lymphoid Malignancies, Thromboembolism, Clinically relevant, Myeloid Malignancies, Quality Improvement, Thrombotic Disorders, Vascular Wall, VTE

Monday, Dec 9, 2019, 11 AM' Valencia BC (W415BC), Level 4 (Orange County Convention Center)

Andrew Dunbar, MD¹, Kelly L Bolton, MD, PhD¹, Sean M. Devlin, PhD^{2*}, Francisco Sanchez-Vega, PhD^{3*}, Jianjiong Gao, PhD^{2*}, Jodi V. Mones, MD^{4*}, Jonathan M. Wills, BA^{5*}, Daniel Kelly, MS^{5*}, Mirko Farina, MD^{6*}, Sirish Kishore, MD^{7*}, Krishna Juluru, MD^{7*}, Neil Iyengar, MD^{8*}, David M. Hyman, MD^{9*}, Ahmet Zehir, PhD^{10*}, Wungki Park, MD^{11*}, **Alok A Khorana, MD¹²**, Gerald A. Soff, MD¹³ and Simon Mantha, MD, MPH⁴

¹Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Information Systems, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Memorial Sloan Kettering Cancer Center, New York, NY
⁷Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Department of Medicine, Breast Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁹Department of Medicine, Developmental Therapeutics Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹²Cleveland Clinic, Cleveland, OH
¹³Department of Medicine, Hematology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

673 Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Targeting Gene Mutations in MDS

Hematology Disease Topics & Pathways: Diseases, drug-drug interaction, Non-Biological, Therapies, Combinations, chemical interactions, MDS, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019, 10:30 AM; W311ABCD, Level 3 (Orange County Convention Center)

David P. Steensma, MD¹, Martin Wermke, MD^{2*}, Virginia M. Klimek, MD³, Peter L Greenberg, MD⁴, Patricia Font^{5*}, Rami S. Komrokji, MD^{6,7,8}, Jay Yang, MD⁹, Andrew M. Brunner, MD¹⁰, **Hetty E. Carraway, MD, MBA¹¹**, Lionel Ades, MD, PhD¹², Aref Al-Kali, MD¹³, Juan Manuel Alonso Dominguez, MD, PhD, MSc^{14*}, Ana Alonso, MD^{15*}, Catherine C. Coombs, MD¹⁶, H. Joachim Deeg, MD¹⁷, William B. Donnellan, MD¹⁸, James M. Foran, MD¹⁹, Guillermo Garcia-Manero, MD²⁰, Michael B. Maris, MD²¹, Malgorzata McMasters, MD^{22*}, Jean-Baptiste Micol, MD²³, Jaime Perez De Oteyza, MD, PhD²⁴, Felicitas Thol, MD²⁵, Eunice S. Wang, MD²⁶, Justin M. Watts, MD²⁷, Silvia Buonamici, PhD²⁸, Amy Kim, MSPH PhD^{28*}, Vikram Gourineni, MS, PharmD^{28*}, Alyssa J Marino^{28*}, Nathalie Rioux, MSc, PhD^{28*}, Joanne Schindler, MD²⁸, Sherri Smith, MS^{28*}, Huilan Yao, PhD^{28*}, Xiaobin Yuan^{29*}, Kun Yu, PhD^{28*} and Uwe Platzbecker^{30*}

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Department of Internal Medicine I, University Hospital Dresden, Dresden, Germany

³Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA
⁵Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
⁶Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁷Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
⁸Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁹Karmanos Cancer Institute, Detroit, MI
¹⁰Massachusetts General Hospital, Boston, MA
¹¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
¹²Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris, France
¹³Division of Hematology, Mayo Clinic, Rochester, MN
¹⁴Hospital Universitario Fundación Jiménez Díaz- IISFJD-UAM, Madrid, Madrid, Spain
¹⁵Clinica Universidad Navarra, Pamplona, ESP
¹⁶UNC Health Care, New York, NY
¹⁷Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
¹⁸Tennessee Oncology / Sarah Cannon Research Institute, Nashville, TN
¹⁹Mayo Clinic Florida, Jacksonville, FL
²⁰University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
²¹Colorado Blood Cancer Institute, Denver, CO
²²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
²³Gustave Roussy cancer center, Villejuif, France
²⁴Hospital Universitario San Ginés, Madrid, Spain
²⁵Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany
²⁶Roswell Park Comprehensive Cancer Center, Buffalo, NY
²⁷Department of Oncology, University of Miami Health System, Miami, FL
²⁸H3 Biomedicine, Cambridge, MA
²⁹Eisai, Inc, Woodcliff Lake, NJ
³⁰Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany, Germany

676 Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Targeting Gene Mutations in MDS
Hematology Disease Topics & Pathways: AML, Diseases, Therapies, Combinations, MDS, Myeloid Malignancies

Monday, Dec 9, 2019, 11:15 AM; W311ABCD, Level 3 (Orange County Convention Center)

David A Sallman, MD^{1,2}, Amy E. DeZern, MD³, Guillermo Garcia-Manero, MD⁴, David P. Steensma, MD⁵, Gail J. Roboz, MD⁶, Mikkael A. Sekeres, MD, MS⁷, Thomas Cluzeau, MD, PhD⁸, Kendra L. Sweet, MD⁹, Amy F McLemore, M.S.^{9*}, Kathy McGraw, PhD⁹, John Puskas, PhD^{9*}, Ling Zhang, MD^{10*}, Jiqiang Yao, PhD^{11*}, Qianxing Mo, PhD^{12*}, Lisa Nardelli^{9*}, Najla Al Ali, M.Sc^{9*}, Eric Padron, MD⁹, Greg Korbel, PhD, MBA^{13*}, Eyal C. Attar¹³, Hagop M. Kantarjian, MD¹⁴, Jeffrey E. Lancet, MD⁹, Pierre Fenaux, MD, PhD¹⁵, Alan F. List, MD¹⁶ and Rami S. Komrokji, MD^{1,9,17}

¹Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
²Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
³Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
⁴University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY
⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁸CHU of Nice, Hematology department, Cote D'Azur University, Nice Sophia Antipolis University, Nice, France
⁹Malignant Hematology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
¹⁰Department of Hematopathology and Lab Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹¹Department of Biostatistics & Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa
¹²Department of Biostatistics & Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
¹³Apria Therapeutics, Boston, MA
¹⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁵Hôpital St Louis/ Paris 7 University, PARIS, FRA
¹⁶Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹⁷Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

[**678 Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes \(MDS\)**](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Targeting Gene Mutations in MDS
Hematology Disease Topics & Pathways: Adult, therapy sequence, Biological, AML, Diseases, Non-Biological, Therapies, Combinations, Elderly, CMML, chemotherapy, MDS, enzyme inhibitors, Study Population, Clinically relevant, Myeloid Malignancies

Guillaume Richard-Carpentier, MD¹, Amy E. DeZern, MD², Koichi Takahashi, MD¹, Marina Y Konopleva, MD, PhD¹, Sanam Loghavi, MD³, Lucia Masarova, MD^{1}, Yesid Alvarado, MD¹, Farhad Ravandi, MD¹, Guillermo Montalban Bravo, MD^{1*}, Kiran Naqvi, MD, MPH¹, Koji Sasaki, MD¹, Ricardo Delumpo, BSN^{1*}, Monica Kwari, BSN¹, Mikkael A. Sekeres, MD, MS⁴, Aziz Nazha, MD⁵, Gail J. Roboz, MD⁶, Hagop M. Kantarjian, MD¹, Guillermo Garcia-Manero, MD¹ and Courtney D. DiNardo, MD, MSc⁷*

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

³Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁶Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York

⁷Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX

[**697 Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research \(CIBMTR\)**](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects

Hematology Disease Topics & Pathways: sickle cell disease, Diseases, Genetic Disorders, Hemoglobinopathies, Lymphoid Malignancies, Myeloid Malignancies

Monday, Dec 9, 2019, 10:30 AM; W304EFGH, Level 3 (Orange County Convention Center)

Elizabeth Stenger, MD^{1}, Rachel Phelan, MD, MPH^{2*}, Bronwen E. Shaw, PhD, MRCP, FRCPath³, Minoo Battiwalla, MD⁴, Stephanie Bo-Subait, MPH^{5*}, Ruta Brazauskas, PhD^{6,7*}, David K. Buchbinder, MD, MSHS⁸, Betty K. Hamilton, MD⁹, Shalini Shenoy, MD¹⁰ and Lakshmanan Krishnamurti, MD¹¹*

¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA

²Department of Pediatrics, Division of Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI

³Medical College of Wisconsin, Milwaukee, WI

⁴Hematology Branch, Sarah Cannon BMT Program, Nashville, TN

⁵CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN

⁶CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁷Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

⁸Department of Hematology, CHOC Children's Hospital, Orange, CA

⁹Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Pediatrics, Washington University Medical Center, Saint Louis, M

[**706 Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant: A Report from the Center for International Blood and Marrow Transplant Research \(CIBMTR\)**](#)

Program: Oral and Poster Abstracts

Type: Oral

Session: 906. Outcomes Research—Malignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid Diseases

Hematology Disease Topics & Pathways: AML, Diseases, Therapies, CML, MPN, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019, 11:15 AM; Valencia D (W415D), Level 4 (Orange County Convention Center)

Neel S. Bhatt¹, Ruta Brazauskas, PhD^{2,3*}, Stephanie Bo-Subait, MPH^{4*}, Rachel B. Salit, MD⁵, Karen Syrjala, PhD^{5*}, Heather R. Tecca^{6*}, Minoo Battiwalla, MD⁷, David K. Buchbinder, MD, MSHS⁸, Betty K. Hamilton, MD⁹, Rachel Phelan, MD, MPH^{10*} and Bronwen E. Shaw, PhD, MRCP, FRCPath³

¹Department of Oncology, Division of Cancer Survivorship, St. Jude Children's Research Hospital, Memphis, TN

²Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI

³CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

⁴CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN

⁵Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

⁶University of Minnesota Twin Cities, Minneapolis, MN

⁷Hematology Branch, Sarah Cannon BMT Program, Nashville, TN

⁸Department of Hematology, CHOC Children's Hospital, Orange, CA

⁹Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁰Department of Pediatrics, Division of Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI

733 Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Program: Oral and Poster Abstracts

Type: Oral

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease

Hematology Disease Topics & Pathways: CRS, Biological, AML, Diseases, Therapies, Adverse Events, immunotherapy, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019, 2:45 PM; Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)

Geoffrey L. Uy, MD¹, Ibrahim Aldoss, MD², Matthew C Foster, MD³, David A Sallman, MD^{4,5}, Kendra L. Sweet, MD⁶, David A. Rizzieri, MD⁷, Peter H. Sayre, MD, PhD⁸, Anjali S. Advani, MD⁹, Ashkan Emadi, MD¹⁰, Matthew J. Wieduwilt, MD, PhD¹¹, Norbert Vey, MD, PhD¹², Fabio Ciceri, MD^{13*}, Matteo Giovanni Carrabba, MD^{14*}, Tamara Moyo, MD, PhD¹⁵, Sarah E. Church, PhD^{16*}, Michael P. Rettig, PhD¹⁷, Martha L. Arellano, MD¹⁸, John E. Godwin, MD¹⁹, Bob Löwenberg, MD, PhD²⁰, Gerwin Huls, MD, PhD^{21*}, Farhad Ravandi, MD²², John Muth, MS^{23*}, Kathy Tran^{23*}, Mojca Jongen-Lavrencic, MD, PhD²⁴, Erin Timmeny^{23*}, Max S. Topp, MD²⁵, Stefania Paolini, MD, PhD^{26*}, Kuo Guo, MSc^{27*}, Teia Curtis^{23*}, Jian Zhao, PhD^{27*}, Jayakumar Vadakekolathu, PhD^{28*}, Jon M. Wigginton, MD^{23*}, Ezio Bonvini, MD²³, Sergio Rutella, MD, PhD, FRCPath²⁹, Roland B. Walter, MD, PhD, MS³⁰, Jan K Davidson-Moncada, MD, PhD³¹ and John F. DiPersio, MD, PhD³²

¹Division of Oncology, Washington University School of Medicine, Saint Louis, MO

²Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA

³Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC

⁴Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

⁵Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁶Division of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

⁷Dept. of Medicine, Div. of Hematological Malignancies & Cellular Therapy, Duke Univ. Med. Ctr., Durham, NC

⁸Division of Hematology and Blood and Marrow Transplantation, University of California San Francisco, San Francisco, CA

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁰University of Maryland, School of Medicine, Marlene & Stewart Greenebaum Cancer, Baltimore, MD

¹¹Moore's Cancer Center, University of California, San Diego, La Jolla, CA

¹²Hematologie clinique, Institut Paoli Calmettes, Marseille, France

¹³Ospedale San Raffaele, Milano, Italy

¹⁴Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy

¹⁵Vanderbilt University, Nashville, TN

¹⁶NanoString Technologies, Inc., Seattle, WA

¹⁷Department of Internal Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO

¹⁸Winship Cancer Institute, Winship Cancer Institute of Emory University, Atlanta, GA

¹⁹Providence Portland Medical Center, Portland, OR

²⁰Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands

²¹Hematology, University Medical Center Groningen, Groningen, Netherlands

²²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²³MacroGenics, Inc., Rockville, MD

²⁴Erasmus MC, Leiden, Netherlands

²⁵Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany

²⁶Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy, Italy

²⁷MacroGenics, Rockville, MD

²⁸John van Geest Cancer Centre School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom

²⁹John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, ENG, United Kingdom

³⁰Fred Hutchinson Cancer Research Center, Seattle, WA

³¹MacroGenics, Inc., Washington, DC

³²Department of Medicine, Washington University School of Medicine, Saint Louis, MO

753 Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma

Program: Oral and Poster Abstracts

Type: Oral

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies

Hematology Disease Topics & Pathways: antibodies, Biological, Diseases, Therapies, Non-Biological, CAR-Ts, Mantle Cell Lymphoma, Combinations, Non-Hodgkin Lymphoma, chemotherapy, enzyme inhibitors, B-Cell Lymphoma, Lymphoid Malignancies, Clinically relevant

Monday, Dec 9, 2019, 3:15 PM; Hall D, Level 2 (Orange County Convention Center)

David A. Bond, MD¹, Jeffrey M. Switchenko, PhD, MS^{2*}, Kami J. Maddocks, MD³, Michael C. Churnetski^{4*}, Subir Goyals^{5*}, Krithika Shanmugasundaram, MD⁶, Oscar Calzada, BS^{7*}, Bhaskar Kolla, MBBS⁸, Veronika Bachanova, MD, PhD⁸, James N. Gerson, MD⁹, Stefan K. Barta, MD, MRCP, MS¹⁰, Yazeed Sawalha, MD¹¹, **Brian T. Hill, MD¹², Peter Martin, FRCP, MD, MS¹³, Max J. Gordon, MD¹⁴, Alexey Danilov, MD, PhD¹⁵, Natalie S Grover, MD¹⁶, Stephanie Mathews, MD^{17*}, Madelyn Burkart, MD^{18*}, Reem Karmali, MD¹⁹, Nilanjan Ghosh, MD, PhD²⁰, Steven I Park, MD²¹, Narendranath Epperla, MD, MS³, Talha Badar, MD²², Jin Guo, MD²³, Mehdi Hamadani, MD²², Timothy S. Fenske, MD²⁴, Mary-Kate Malecek, MD²⁵, Brad S. Kahl, MD²⁶, Christopher R. Flowers, MD, MS²⁷, Kristie A. Blum, MD²⁷ and Jonathon B. Cohen, MD, MS²⁸**

¹James Cancer Center, The Ohio State University Hospital, Columbus, OH

²Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA

³The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Division of Hematology, Columbus, OH

⁴Winship Cancer Institute, Emory University Medical Center, Atlanta, GA

⁵Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA

⁶Emory University School of Medicine, Atlanta, GA

⁷Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

⁸Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

⁹Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

¹⁰Lymphoma Department, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

¹¹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

¹²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹³Weill Cornell Medicine, New York, NY

¹⁴Oregon Health and Science University, Portland, OR

¹⁵Knight Cancer Institute, Oregon Health & Science University, Portland, OR

¹⁶Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

¹⁷University of North Carolina, Chapel Hill, NC

¹⁸Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL

¹⁹Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL

²⁰Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC

²¹Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC

²²Medical College of Wisconsin, Milwaukee, WI

²³Department of Medicine, Weill Cornell Medicine, New York, NY

²⁴Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

²⁵Department of Medicine, Washington University School of Medicine, St. Louis, MO

²⁶Department of Medicine, Washington University School of Medicine in St. Louis, Saint Louis, MO

²⁷Winship Cancer Institute, Emory University, Atlanta, GA

²⁸Emory University, Atlanta, GA

754 KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies

Hematology Disease Topics & Pathways: Diseases, Biological, Adult, CRS, survivorship, Therapies, neurotoxicity, Adverse Events, CAR-Ts, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Monday, Dec 9, 2019, 3:30 PM; Hall D, Level 2 (Orange County Convention Center)

Michael L. Wang, MD¹, Javier Munoz, MD^{2}, Andre Goy, MD³, Frederick L. Locke, MD⁴, Caron A. Jacobson, MD, MMSc^{5*}, **Brian T. Hill, MD⁶**, John M. Timmerman, MD⁷, Houston Holmes, MD^{8*}, Samantha Jaglowski, MD, MPH⁹, Ian W. Flinn, MD, PhD¹⁰, Peter A. McSweeney, MD^{11*}, David B. Miklos, MD, PhD¹², John M. Pagel, MD, PhD, DSc¹³, Marie Jose Kersten, MD, PhD¹⁴, Weimin Peng, MS^{15*}, Lianqing Zheng, PhD^{15*}, John M. Rossi, MS^{15*}, Rajul K. Jain, MD^{15*}, Arati V. Rao, MD^{15*} and Patrick M Reagan, MD¹⁶*

¹The University of Texas MD Anderson Cancer Center, Houston, TX

²Banner MD Anderson Cancer Center, Gilbert, AZ

³Department of Hematology & Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

⁴Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁷UCLA David Geffen School of Medicine, Los Angeles, CA

⁸Texas Oncology, Dallas, TX

⁹The Ohio State Univ. Comprehensive Cancer Center, Columbus, OH

¹⁰Sarah Cannon Research Institute, Nashville, TN

¹¹Colorado Blood Cancer Institute, Denver, CO

¹²Stanford University School of Medicine, Stanford, CA

¹³Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

¹⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

¹⁵Kite, a Gilead Company, Santa Monica, CA

¹⁶Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

757 Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts

Type: Oral

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Novel Therapies in Relapsed/Refractory Disease
Hematology Disease Topics & Pathways: Therapies

Monday, Dec 9, 2019, 2:45 PM; W304ABCD, Level 3 (Orange County Convention Center)

*Carmelo Carlo-Stella, MD¹, Pier Luigi Luigi Zinzani, MD², Brad S. Kahl, MD³, **Paolo F Caimi, MD^{4*}**, Melhem Solh, MD⁵, William Townsend, MRCP, MD, FRCPath^{6*}, Anastasios Stathis, MD^{7*}, Elizabeth H. Cull, MD⁸, Mehdi Hamadani, MD⁹, Alexander I. Spira, PhD, MD, FACP^{10*}, Jay Feingold, MD, PhD^{11*}, David Ungar, MD¹¹, Shui He, PhD^{11*}, Yajuan Qin^{11*} and John Radford^{12*}*

¹Department of Hematology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milano, Italy

²Istituto Di Ematologia, Bologna, Italy

³Department of Medicine, Washington University School of Medicine in St. Louis, Saint Louis, MO

⁴University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH

⁵BMT Group of Georgia, Atlanta, GA

⁶Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

⁷Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

⁸Cancer Institute, Prisma Health, Greenville, SC

⁹Medical College of Wisconsin, Milwaukee, WI

¹⁰Virginia Cancer Specialists Research Institute, Fairfax, VA

¹¹ADC Therapeutics America Inc, Murray Hill, NJ

¹²Department of Medical Oncology, The University of Manchester, Manchester, United Kingdom

763 Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

Program: Oral and Poster Abstracts

Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Cellular Therapies
Hematology Disease Topics & Pathways: Biological, Therapies, CAR-Ts, transplantation

Monday, Dec 9, 2019, 2:45 PM; W230, Level 2 (Orange County Convention Center)

N. Nora Bennani, MD¹, Matthew J. Maurer, MS², Loretta J. Nastoupil, MD, MSc³, Michael D. Jain, MD, PhD⁴, Julio C. Chavez, MD⁵, Amanda F Cashen, MD⁶, Saurabh Dahiya, MD⁷, Lazaros J. Lekakis, MD^{8}, Patrick M Reagan, MD⁹, Olalekan O. Oluwole, MBBS, MPH¹⁰, Joseph P. McGuirk, DO¹¹, Abhinav Deol, MD¹², Alison R. Sehgal, MD¹³, Andre Goy, MD¹⁴, **Brian T. Hill, MD¹⁵**, Khoan Vu, MD¹⁶, Charalambos Andreadis, MD¹⁷, Javier Munoz, MD, MS, FACP¹⁸, Aaron P. Rapoport¹⁹, Julie M Vose, MD MBA²⁰, David B Miklos, MD, PhD²¹, Frederick L. Locke, MD⁴, Sattva S Neelapu, MD³ and Yi Lin, MD, PhD¹*

¹Division of Hematology, Mayo Clinic, Rochester, MN

²Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

³Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

⁴Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

⁵Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL

⁶Department of Medicine, Washington Univ. School of Med., Saint Louis, MO

⁷University of Maryland School of Medicine, Ellicott City, MD

⁸Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

⁹Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

¹⁰Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN

¹¹Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS

¹²Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI

¹³UPMC Hillman Cancer Center, Pittsburgh, PA

¹⁴Department of Hematology & Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

¹⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁶Hematology/Oncology, University of California, San Francisco, San Francisco, CA

¹⁷Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA

¹⁸Banner MD Anderson Cancer Center, Clinic, Gilbert, AZ

¹⁹University of Maryland Greenebaum Comprehensive Cancer Center and School of Medicine, Baltimore, MD

²⁰Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE

²¹Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA

769 The Biological and Clinical Implications of the Alternative Splicing Landscape of 1,258 Myeloid Neoplasm Cases

Program: Oral and Poster Abstracts

Type: Oral

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: RNA Processing and Signatures in MDS

Hematology Disease Topics & Pathways:

Diseases, MDS, Biological Processes, epigenetics, Myeloid Malignancies, genomics, inflammation

Monday, Dec 9, 2019, 2:45 PM; Tangerine 2 (WF2), Level 2 (Orange County Convention Center)

Courtney E Hershberger, BS^{1}, Devlin C Moyer, BS^{1*}, Wencke Walter, PhD^{2*}, Stephan Hutter, PhD^{2*}, Claudia Haferlach, MD², Torsten Haferlach, MD³, **Jaroslav P. Maciejewski, MD, PhD⁴** and Richard A Padgett, PhD^{1*}*

¹Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, OH

²MLL Munich Leukemia Laboratory, Munich, Germany

³MLL Munchner Leukamie Labor GmbH, Munchen, Germany

⁴Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

780 Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis

Program: Oral and Poster Abstracts

Type: Oral

Session: 704. Immunotherapies II

Hematology Disease Topics & Pathways:

Biological, Diseases, Therapies, CAR-Ts, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, checkpoint inhibitors, Lymphoid Malignancies, Clinically relevant, transplantation

Monday, Dec 9, 2019, 4 PM; Chapin Theater (W320), Level 3 (Orange County Convention Center)

Adam S. Kittai, MD¹, Max J. Gordon, MD², Agrima Mian, MBBS, MD^{3}, Lindsey Fitzgerald, MD⁴, Jennifer Bishop^{2*}, Deborah M. Stephens, DO⁵, Sarah J. Nagle, MD^{2*}, **Brian T. Hill, MD⁶** and Alexey Danilov, MD,*

PhD₂

¹Department of Hematology, The Ohio State University, Columbus, OH

²Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

⁵University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, Salt Lake City, UT

⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

791 Venous Thromboembolism (VTE) in Sickle Cell Disease (SCD) Is Associated with Neutrophilia

Program: Oral and Poster Abstracts

Type: Oral

Session: 901. Health Services Research—Non-Malignant Conditions: Improving Quality in Hematology
Hematology Disease Topics & Pathways:

Diseases, sickle cell disease, viral, Bleeding and clotting, Thrombosis, Hemoglobinopathies, Immune Disorders, Infectious Diseases, Thromboembolism, Clinically relevant, Quality Improvement

Monday, Dec 9, 2019, 3:45 PM; Valencia BC (W415BC), Level 4 (Orange County Convention Center)

Jahnvi Gollamudi, MD¹, Shashank Sarvepalli, MD^{2*}, Tara Alin, APRN-CNP^{1*}, Animesh Vadaparti, M.Binf^{3*}, Jane A. Little, MD^{4*} and Lalitha V. Nayak, MD^{5,6}

¹University Hospitals Cleveland Medical Center, Cleveland

²Baylor College of Medicine, Houston, TX

³Department of Integrative Biology, Guelph University, Guelph, Canada

⁴University of North Carolina, Chapel Hill, NC

⁵University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH

⁶University Hospitals Cleveland Medical Center, Cleveland, OH

841 Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Lower-Risk MDS and CMML

Hematology Disease Topics & Pathways: Diseases, MDS, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019 4:30 PM; W311ABCD, Level 3 (Orange County Convention Center)

Pierre Fenaux, MD, PhD^{1,2}, Ghulam J. Mufti^{3*}, Rena Buckstein, MD, FRCPC⁴, Valeria Santini, MD⁵, María Díez-Campelo, MD, PhD^{6*}, Carlo Finelli^{7*}, Mario Cazzola, MD⁸, Osman Ilhan, MD^{9*}, Mikkael A. Sekeres, MD, MS¹⁰, Rami S. Komrokji, MD^{11,12,13}, Alan F. List, MD¹¹, Amer M. Zeidan, MBBS, MHS¹⁴, Amit Verma, MBBS¹⁵, Abderrahmane Laadem¹⁶, Rodrigo Ito¹⁶, Jennie Zhang^{16*}, Anita Rampersad^{16*}, Daniel Sinsimer^{16*}, Peter G. Linde¹⁷, Guillermo Garcia-Manero, MD¹⁸ and Uwe Platzbecker, MD¹⁹

¹Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

²Université Paris 7, Paris, France

³Department of Haemato-Oncology, King's College London, London, United Kingdom

⁴Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

⁵MDS Unit, Azienda Ospedaliero Universitaria (AOU) Careggi, University of Florence, Florence, Italy

⁶Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain

⁷Department of Oncology and Hematology, S. Orsola-Malpighi University Hospital, Bologna, Italy

⁸Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy

⁹Department of Hematology, Ankara University School of Medicine, Ankara, Turkey

¹⁰Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹¹Moffitt Cancer Center, Tampa, FL

¹²Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

¹³Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

¹⁴Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT

¹⁵Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

¹⁶Celgene Corporation, Summit, NJ

¹⁷Acceleron Pharma, Cambridge, MA

¹⁸University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

¹⁹Medical Clinic and Polyclinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany

842 Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Lower-Risk MDS and CMML

Hematology Disease Topics & Pathways: Diseases, Therapies, Combinations, MDS, Myeloid Malignancies

Monday, Dec 9, 2019 4:45 PM; W311ABCD, Level 3 (Orange County Convention Center)

Alan F. List, MD¹, Zhuoxin Sun, PhD^{2}, Amit Verma, MBBS³, John M. Bennett, MD⁴, Kathy McGraw, PhD⁵, Jaroslaw P. Maciejewski, MD, PhD⁶, Rami S. Komrokji, MD^{1,7}, Timothy R. Wassenaar, MD^{8*}, Selina M. Luger, MD, FRCPC⁹, Ryan J. Mattison, MD¹⁰, Puneet S. Cheema, MD^{11*}, Jessica K. Altman¹², David F. Claxton, MD^{13*}, Charles A. Schiffer, MD¹⁴, Andrew S. Artz, MD¹⁵, Mark Litzow, MD¹⁶ and Martin S. Tallman, MD¹⁷*

¹Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

²ECOG-ACRIN Biostatistics Center, Dana Farber Cancer Institute, Boston, MA

³Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

⁴University of Rochester, Rochester, NY

⁵H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁶Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

⁷Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁸Waukesha Memorial Hospital, Waukesha, WI

⁹Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

¹⁰University of Wisconsin, Madison, WI

¹¹Saint John's Hospital, Maplewood, MN

¹²Northwestern University, Chicago, IL

¹³Penn State Cancer Center, Hershey, PA

¹⁴Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI

¹⁵University of Chicago, Chicago, IL

¹⁶Mayo Clinic, Rochester, MN

¹⁷Weill Cornell Medical College, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

844 Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Lower-Risk MDS and CMML

Hematology Disease Topics & Pathways: Diseases, Adult, therapy sequence, Therapies, Combinations, CMML, Study Population, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019 5:15 PM; W311ABCD, Level 3 (Orange County Convention Center)

Lisa Pleyer^{1,2,3}, Michael Leisch, MD^{2,3*}, Alexandra Kourakli, MD, PhD⁴, Eric Padron, MD⁵, Jaroslaw P. Maciejewski, MD, PhD⁶, Blanca Xicoy, MD, MSc^{7*}, Jennifer Kaivers, MD^{8*}, Johanna Ungerstedt, MD, PhD^{9*}, Sonja Heibl, MD^{10*}, Peristera Patiou, MD^{4*}, Anthony M. Hunter, MD^{11,12*}, Elvira Mora, MD^{13*}, Klaus Geissler, MD^{14*}, Maria Dimou, MD, PhD¹⁵, María-José Jimenez, MD^{7*}, David Kiesl, MD^{16*}, Nora-Athina Viniou, MD, PhD¹⁵, Bhumika J. Patel, MD¹⁷, Montserrat Arnan Sangerman^{18*}, Peter Valent, MD^{19,20}, Christoforos Roubakis, MD^{21*}, Teresa Bernal del Castillo, MD, PhD^{22*}, Athanasios Galanopoulos, MD, PhD^{21*}, Marisa Calabuig, MD^{23*}, Nicolas Bonadies, MD^{24*}, Antonio Medina de Almeida, MD, PhD^{25,26*}, Jaroslav Cermak, MD, PhD^{27*}, Andres Jerez^{28*}, Julia Montoro, MD^{29*}, Albert Cortés^{30*}, Alejandro Avendaño Pita, MD^{31*}, Bernardo López Andrade, MD^{32*}, Eva Hellstrom Lindberg, MD, PhD⁹, Ulrich Germing, MD^{8*}, Mikkael A. Sekeres, MD, MS³³, Alan F. List, MD¹¹, Argiris Symeonidis, MD, PhD³⁴, Guillermo F. Sanz, MD, PhD^{13,35} and Richard Greil, MD^{1,2,3}*

¹Cancer Cluster Salzburg (CCS), Salzburg, Austria
²3rd Medical Dept. with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria
³Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT), Salzburg, Austria
⁴Hematology Division, Dept. of Internal Medicine, University of Patras Medical School, Patras, Greece
⁵Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL
⁶Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
⁷Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Badalona, Spain
⁸Dept. of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
⁹HERM, Dept. of Medicine, Huddinge, Karolinska Institute, and PO Hematology, Karolinska University Hospital, Stockholm, Sweden
¹⁰Dept. of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria
¹¹Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹²University of South Florida Morsani School of Medicine, Tampa, FL
¹³Dept. of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
¹⁴Fifth Medical Dept., Hospital Hietzing, Vienna, Austria
¹⁵Hematology Dept., 1st Propedeutic Internal Medicine Clinic, Laikon General Hospital, Athens, Greece
¹⁶2nd Medical Dept., University clinic for hematology and internal oncology, Kepler University Hospital, Linz, Austria
¹⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
¹⁸Institut Català d'Oncologia-Hospital Duran y Reynals, Hospitalet de Llobregat, L Hospitalet De Llobregat (barcelona), Spain
¹⁹Dept. of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
²⁰Ludwig Boltzmann Institute for Hematology and Oncology, Vienna, Austria
²¹Dept. of Hematology, G. GENNIMATAS General Hospital, Athens, Greece
²²Hospital Universitario Central Asturias, Oviedo, Spain
²³Hospital Clínico Universitario de Valencia, Valencia, Spain
²⁴Dept. of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
²⁵Centro de Investigação Interdisciplinar em Saúde, Universidade Católica Portuguesa de Lisboa, Lisbon, Portugal
²⁶Hospital da Luz, Lisbon, Portugal
²⁷Institute of Hematology and Blood Transfusion, Prague, Czech Republic
²⁸Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB, Murcia, Spain
²⁹Dept. of Hematology, University Hospital Vall d'Hebron, University Autònoma of Barcelona, Barcelona, Spain
³⁰Hematology Dept., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
³¹Hematology Dept., Hospital Universitario de Salamanca, Salamanca, Spain
³²Hematology Department, Son Espases University Hospital, IdISBa, Palma Mallorca, Spain
³³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
³⁴University of Patras, Medical School, Patras, Greece
³⁵CIBERONC, Instituto Carlos III, Madrid, Spain

880 TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Program: Oral and Poster Abstracts

Type: Oral

Session: 802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening

Hematology Disease Topics & Pathways: AML, Diseases, Non-Biological, Therapies, MDS, Technology and Procedures, gene editing, Myeloid Malignancies, pharmacology, mass cytometry

Monday, Dec 9, 2019, 5:15 PM; W311EFGH, Level 3 (Orange County Convention Center)

Yihong Guan, PhD¹*, Anand D. Tiwari, PhD¹*, James G Phillips, PhD¹*, Metis Hasipek, PhD¹*, Dale Grabowski, BS¹*, Cassandra M Kerr, MS¹*, Vera Adema, PhD¹*, Yasunobu Nagata, MD, PhD¹*, Valeria Visconte, PhD¹, Tomas Radivoyevitch, PhD²*, **Daniel Lindner, MD, PhD¹*, Manja Meggendorfer, PhD³, **Mohamed Abazeed¹*, Mikkael A. Sekeres, MD, MS⁴**, Torsten Haferlach, MD⁵, **Jaroslav P. Maciejewski, MD, PhD¹ and Babal K. Jha, PhD¹*****

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

³MLL Munich Leukemia Laboratory, Munich, Germany

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵MLL Munchner Leukamie Labor GmbH, Munchen, Germany

881 Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Program: Oral and Poster Abstracts

Type: Oral

Session: 802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening

Hematology Disease Topics & Pathways: Diseases, Therapies, Non-Biological, MDS, Clinically relevant, Myeloid Malignancies, pharmacology

Monday, Dec 9, 2019, 5:30 PM; W311EFGH, Level 3 (Orange County Convention Center)

Sunisa Kongkiatkamon^{1}, Anand Tiwari^{2*}, Vera Adema, PhD^{1*}, Cassandra M Kerr, MS^{1*}, Bartłomiej Przychodzen^{2*}, Hassan Awada^{2*}, Jibran Durrani^{2*}, Yvonne Parker^{2*}, Drew Adams^{3*}, Yuriy Fedorov^{3*}, Hetty E. Carraway, MD, MBA⁴, Chao-Yie Yang^{5*}, Mikkael A. Sekeres, MD, MS⁴, Daniel J. Lindner^{2*}, James G Phillips, PhD^{1*}, Jaroslaw P. Maciejewski, MD, PhD¹ and Valeria Visconte, PhD²*

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

³Department of Genetics and Genome Sciences, Small-Molecule Drug Development Core, Case Western Reserve University School of Medicine, Cleveland

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁵University of Tennessee Health Science Center, Department of Pharmaceutical Sciences, Memphis, TN

894 High Levels of Peripheral Vasoconstriction Detected By Polysomnography Predict More Acute Severe Pain Episodes in Children with Sickle Cell Anemia

Program: Oral and Poster Abstracts

Type: Oral

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Predicting Risk: A Focus on Disease Severity and Fertility

Hematology Disease Topics & Pathways: sickle cell disease, Diseases, Therapies, Pediatric, Pregnancy,

Hemoglobinopathies, Young Adult, Study Population, Clinically relevant

Monday, Dec 9, 2019, 7:30 PM; W304ABCD, Level 3 (Orange County Convention Center)

Patjanaporn Chalacheva, PhD^{1}, Yunhua Ji, MS^{1*}, Carol L. Rosen, MD^{2*}, Michael R. DeBaun, MD, MPH³, Michael C.K. Khoo, PhD^{1*} and Thomas Coates, MD⁴*

¹Biomedical Engineering, University of Southern California, Los Angeles, CA

²Division of Pediatric Pulmonology and Sleep Medicine, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH

³Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University Children's Hospital, Nashville, TN

⁴Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA

914 Novel Molecular Pathogenesis and Therapeutic Target in Acute Erythroid Leukemia

Program: Oral and Poster Abstracts

Type: Oral

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Advances in Understanding the Pathophysiology of AML

Hematology Disease Topics & Pathways: AML, Diseases, Biological Processes, genomics, Myeloid Malignancies, integrative -omics, pathogenesis, pathways

Monday, Dec 9, 2019, 6:30 PM; Tangerine 2 (WF2), Level 2 (Orange County Convention Center)

June Takeda, MD^{1}, Kenichi Yoshida, MD, PhD^{2*}, Yasuhito Nannya, MD, PhD², Lee-Yung Shih, MD³, Ayana Kon, MD, PhD^{2*}, Akinori Yoda, PhD^{2*}, Yotaro Ochi, MD^{4*}, Yusuke Shiozawa, MD, PhD^{2*}, Tetsuichi Yoshizato, MD, PhD², Cassandra M Kerr, MS^{5*}, Yuichi Shiraishi, PhD^{6*}, Kenichi Chiba, PhD^{7*}, Yasunobu Nagata, MD, PhD^{5*}, Akira Hangaishi, MD, PhD^{8*}, Toshiyuki Kitano, MD, PhD^{9*}, Ken Ishiyama¹⁰, Hisashi Tsurumi, MD, PhD¹¹, Yasushi Miyazaki, MD, PhD¹², Nobuhiro Hiramoto, MD^{13*}, Takayuki Ishikawa, MD, PhD¹⁴, Akifumi Takaori-Kondo, MD, PhD¹⁵, Masahiro Nakagawa, MD, PhD^{2*}, Masashi Sanada, MD¹⁶, Hideyuki Nakazawa, MD, PhD^{17*}, Keisuke Kataoka, MD, PhD¹⁸, Ryunosuke Saiki^{2*}, Hiroko Tanaka, BA^{7*}, Kensuke Usuki, MD, PhD⁸, Shuichi Miyawaki, MD, PhD^{19*}, Satoru Miyano, PhD^{7*}, Arnold Ganser, MD²⁰, Michael Heuser, MD²⁰, Jaroslaw P. Maciejewski, MD, PhD²¹, Felicitas Thol, MD²², Hideki Makishima, MD, PhD²³ and Seishi Ogawa, MD, PhD^{2,24}*

¹Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, KYO, Japan

²Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

³Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hosp., Taipei, Taiwan

⁴Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kobe, HYO, Japan

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan

⁷Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

⁸Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan
⁹Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan
¹⁰Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan
¹¹Hematology, Gifu University Graduate School of Medicine, Gifu, Japan
¹²Atomic Bomb Disease Institute, Nagasaki University Hospital, Nagasaki, Japan
¹³Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe, Japan
¹⁴Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
¹⁵Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
¹⁶Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
¹⁷Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan
¹⁸Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
¹⁹Department of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan
²⁰Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
²¹Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
²²Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany
²³Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
²⁴Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Huddinge, Sweden

1130 Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

Program: Special-Interest Sessions

Session: Hemostasis and Thrombosis Poster Walk for Trainees

Hematology Disease Topics & Pathways: Diseases, Adult, Non-Biological, Therapies, Bleeding and clotting, coagulant drugs, Study Population, Clinically relevant, VWD

Saturday, Dec 7, 2019, 7:30 AM-9 AM; Hall B, Level 2 (Orange County Convention Center)

Margaret V. Ragni, MD, MPH¹, Craig D. Seaman, MD, MS², Diana Gilligan, MD^{3}, Claire S. Philipp, MD⁴, Anne T. Neff, MD⁵, Robert F. Sidonio Jr., MD, MSc⁶, Philip Kuriakose, MD⁷, Tzu-Fei Wang, MD, MPH⁸, Lynn M. Malec, MD⁹, Rajiv K. Pruthi, MBBS¹⁰, Elaine Majerus, MD, PhD¹¹, George M. Rodgers, MD, PhD¹², Danielle Nance, MD¹³, Nina Hwang, MD^{14*}, Barbara A. Konkle, MD¹⁵, Andrew D. Leavitt, MD¹⁶, Joseph Lasky, MD^{17*}, Allison P. Wheeler, MD¹⁸, Roshni Kulkarni, MD¹⁹, Tammueella Singleton, MD²⁰, Dana Ivanco^{21*}, Elynna Youm, BA^{21*}, Glory Koerbel, MSN, RN^{22*}, Scott Rothenberger, PhD^{22*} and Doris M. Rubio, PhD^{23*}*

¹Department Medicine and Clinical and Translational Research, University of Pittsburgh School of Medicine, Pittsburgh, PA
²University of Pittsburgh Medical Center and Hemophilia Center of Western PA, Pittsburgh, PA
³State University of New York Upstate Medical Center, Syracuse, NY
⁴Medicine, Rutgers University, UMDNJ - Robert Wood Johnson Medical School, New Brunswick, NJ
⁵Cleveland Clinic, Cleveland, OH
⁶Hemophilia of Georgia Center for Bleeding and Clotting Disorders, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Decatur, GA
⁷Division of Hematology and Oncology, Henry Ford Hospital/Wayne State University, Detroit, MI
⁸Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
⁹Dept Pediatrics, Division Hematology, Children's Hospital of Pittsburgh, Pittsburgh, PA
¹⁰Division of Hematology, Mayo Clinic, Rochester, MN
¹¹Washington University Medical School, Saint Louis, MO
¹²Univ. of Utah Medical Center, Salt Lake City, UT
¹³Banner MD Anderson Cancer Center, Gilbert, AZ
¹⁴Center for Inherited Blood Disorders (CIBD), Orange, CA
¹⁵Bloodworks Northwest, Seattle, WA
¹⁶Department of Laboratory Medicine, UCSF, San Francisco, CA
¹⁷Cure 4 the Kids Foundation, Las Vegas, NV
¹⁸Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN
¹⁹Michigan State University, East Lansing, MI
²⁰Mississippi Center for Advanced Medicine, Madison, MS
²¹Institute for Transfusion Medicine, Hemophilia Center of Western PA, Pittsburgh, PA
²²Center for Research on Health Care Data Center, University of Pittsburgh, Pittsburgh, PA
²³Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA

1309 Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed *FLT3* Mutated Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts

Type: Oral

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease
Hematology Disease Topics & Pathways: antibodies, Biological, AML, Diseases, Adult, Non-Biological, Therapies, Combinations, chemotherapy, immunotherapy, Study Population, Clinically relevant, Myeloid Malignancies, TKI

Monday, Dec 9, 2019, 2:45-4:15 PM; Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)
Selina M. Luger, MD, FRCPC¹, Zhuoxin Sun, PhD^{2*}, Sanam Loghavi, MD³, Hillard M Lazarus, MD⁴, Jacob M. Rowe, MB, BS⁵, Martin S. Tallman, MD⁶, Keith W. Pratz, MD⁷ and Mark Litzow, MD⁸

¹Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

²ECOG-ACRIN statistical center, Boston

³Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

⁴Case Western Reserve University School of Medicine, Cleveland, OH

⁵Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel

⁶Memorial Sloan Kettering Cancer Center, New York, NY

⁷Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

⁸Division of Hematology, Mayo Clinic, Rochester, MN

POSTER PRESENTATIONS

1066 African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura

Program: Oral and Poster Abstracts

Type: Poster

Session: 311. Disorders of Platelet Number or Function: Poster I

Hematology Disease Topics & Pathways: Diseases, Adult, Bleeding and clotting, Study Population, Clinically relevant, Thrombotic Disorders, TTP

Saturday, Dec 7, 2019: 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Angela Liu^{1*}, Marshall Mazepa, MD^{2*}, Elizabeth Davis, MD^{2*}, Andrew Johnson, MD^{3*}, Ana G Antun, MD^{4*}, Andrew M. Farland, MD⁵, Ryan R Woods, MD^{6*}, Ara Metjian, MD⁷, Kristin Bagby^{8*}, Yara Park, MD^{9*}, Jay S Raval, MD^{10*}, Gustaaf de Ridder, MD^{11*}, Briana Gibson, MD^{11*}, Raj S. Kasthuri, MD^{12*}, Darla K Liles, MD¹³, Susan Eubanks^{14*}, Frank Akwaa, MD^{15*}, Lisa B. Kreuziger, MD, MS^{16*}, J Evan Sadler^{17*}, Meera Sridharan, MD¹⁸, Ronald S. Go, MD¹⁹, Rahil Kohli, MD^{20*}, Harsh Vardhan Upreti^{21*}, **Keith R McCrae, MD²², Ming Y. Lim, MBBChir, MA²³, X. Long Zheng, MD, PhD²⁴, Nicole K. Kocher^{25*}, Radhika Gangaraju, MD²⁶, Spero Cataland, MD²⁷ and Shruti Chaturvedi, MBBS, MS²⁸**

¹Johns Hopkins University, Baltimore, MD

²University of Minnesota, Minneapolis, MN

³Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN

⁴Emory Healthcare, Atlanta, GA

⁵Wake Forest University, Winston Salem, NC

⁶Wake Forest University, Winston-Salem, NC

⁷Duke University School of Medicine, Durham, NC

⁸Duke University, Durham, NC

⁹University of North Carolina At Chapel Hill, Chapel Hill, NC

¹⁰Department of Pathology, University of New Mexico, Albuquerque, NM

¹¹University of North Carolina, Chapel Hill, NC

¹²HHT Center of Excellence, University of North Carolina at Chapel Hill, Chapel Hill, NC

¹³Division of Hematology-Oncology, East Carolina University, Greenville, NC

¹⁴East Carolina University, Greenville, NC

¹⁵University of Rochester Medical Center, Rochester, NY

¹⁶Blood Research Institute, Versiti, Menomonee Falls, WI

¹⁷Washington University School of Medicine, St Louis, MO

¹⁸Mayo Clinic, Rochester, MN

¹⁹Mayo Clinic, Onalaska, WI

²⁰University of Pittsburgh Medical Center, Pittsburgh, PA

²¹Maulana Azad Medical College, University of Delhi, New Delhi, MD, India

²²Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

²³Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT

²⁴Division of Laboratory Medicine, Department of Pathology, The University of Alabama At Birmingham, Birmingham, AL

²⁵Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL

²⁶Division of Hematology and Oncology, Department of Medicine, University Of Alabama, Birmingham, AL

²⁷Division of Hematology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH

²⁸Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

1076 The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster I

Hematology Disease Topics & Pathways:

Diseases, Non-Biological, Therapies, Bleeding and clotting, Thrombocytopenias, pharmacology

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

James B. Bussel, MD¹, Alexandra Kruse^{2*}, Caroline Kruse^{2*}, Jody Shy^{3*}, Kavita Aggarwal, PharmD^{4*}, Michael Vredenburg, PhD^{5*} and Keith R McCrae, MD⁶

¹Weill Cornell Medicine, New York, NY

²Platelet Disorder Support Association, Cleveland, OH

³Platelet Disorder Support Association, Cleveland

⁴Dova Pharmaceuticals, Durham

⁵Dova Pharmaceuticals, Cary, NC

⁶Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

1084 Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster I

Hematology Disease Topics & Pathways: Diseases, Biological, antibodies, Bleeding and clotting,

Therapies, Non-Biological, chemotherapy, Clinically relevant, TTP

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Mouhamed Yazan Abou-Ismael, MD^{1,2}, Yasmin Arafah, MD^{2,3*}, Pingfu Fu, PhD^{2*}, Shufen Cao^{2*}, Alvin H. Schmaier, MD^{2,3} and Lalitha V. Nayak, MD^{2,3,4}

¹University Hospitals Seidman Cancer Center, Cleveland, OH

²Case Western Reserve University, Cleveland, OH

³University Hospitals Cleveland Medical Center, Cleveland, OH

⁴University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH

1104 Restore the Secretion and Activity of Factor VIII Mutants By Proteostasis Regulator

Program: Oral and Poster Abstracts

Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster I

Hematology Disease Topics & Pathways: Diseases, Hemophilia, Bleeding and clotting

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Wei Wei, MD, PhD^{1,2*}, Zhigang Liu, PhD^{3*} and Bin Zhang, PhD⁴

¹Genomic Medicine Institute, Lerner Research Institute, Cleveland, OH

²Children's Hospital, Ascension St John Hospital, Detroit, MI

³Genomic Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, OH

⁴Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH

1105 Characterization of Recombinant β 2GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography

Program: Oral and Poster Abstracts

Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster I

Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, Thrombosis,

Thromboembolism, Thrombotic Disorders, Vascular Wall, VTE

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Ravi Kumar Alluri, PhD^{1*}, Nicholas Arce^{2*}, Philip Klenotic^{3*}, Chih Chia Su, PhD^{3*}, Suman Kundu, MBA^{4*}, Edward Yu, PhD^{3*}, Renhao Li, PhD⁵ and Keith R McCrae, MD^{4,6}

¹Cleveland Clinic Lerner Research Institute, Department of Cardiovascular and Metabolic Sciences, Cleveland, OH

²Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Atlanta, GA

³Department of Pharmacology, Case Western Reserve University, Cleveland, OH

⁴Cardiovascular & Metabolic Sciences, Cleveland Clinic, Cleveland, OH

⁵Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA

⁶Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1130 Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

Program: Special-Interest Sessions

Session: Hemostasis and Thrombosis Poster Walk for Trainees

Hematology Disease Topics & Pathways: Diseases, Adult, Non-Biological, Therapies, Bleeding and clotting, coagulant drugs, Study Population, Clinically relevant, VWD

Saturday, Dec 7, 2019, 7:30-9:00 AM; Hall B, Level 2 (Orange County Convention Center)

Margaret V. Ragni, MD, MPH¹, Craig D. Seaman, MD, MS², Diana Gilligan, MD³*, Claire S. Philipp, MD⁴, Anne T. Neff, MD⁵, Robert F. Sidonio Jr., MD, MSc⁶, Philip Kuriakose, MD⁷, Tzu-Fei Wang, MD, MPH⁸, Lynn M. Malec, MD⁹, Rajiv K. Pruthi, MBBS¹⁰, Elaine Majerus, MD, PhD¹¹, George M. Rodgers, MD, PhD¹², Danielle Nance, MD¹³, Nina Hwang, MD¹⁴*, Barbara A. Konkle, MD¹⁵, Andrew D. Leavitt, MD¹⁶, Joseph Lasky, MD¹⁷*, Allison P. Wheeler, MD¹⁸, Roshni Kulkarni, MD¹⁹, Tammueella Singleton, MD²⁰, Dana Ivanco²¹*, Elynna Youm, BA²¹*, Glory Koerbel, MSN, RN²²*, Scott Rothenberger, PhD²²* and Doris M. Rubio, PhD²³*

¹Department Medicine and Clinical and Translational Research, University of Pittsburgh School of Medicine, Pittsburgh, PA

²University of Pittsburgh Medical Center and Hemophilia Center of Western PA, Pittsburgh, PA

³State University of New York Upstate Medical Center, Syracuse, NY

⁴Medicine, Rutgers University, UMDNJ - Robert Wood Johnson Medical School, New Brunswick, NJ

⁵Cleveland Clinic, Cleveland, OH

⁶Hemophilia of Georgia Center for Bleeding and Clotting Disorders, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Decatur, GA

⁷Division of Hematology and Oncology, Henry Ford Hospital/Wayne State University, Detroit, MI

⁸Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

⁹Dept Pediatrics, Division Hematology, Children's Hospital of Pittsburgh, Pittsburgh, PA

¹⁰Division of Hematology, Mayo Clinic, Rochester, MN

¹¹Washington University Medical School, Saint Louis, MO

¹²Univ. of Utah Medical Center, Salt Lake City, UT

¹³Banner MD Anderson Cancer Center, Gilbert, AZ

¹⁴Center for Inherited Blood Disorders (CIBD), Orange, CA

¹⁵Bloodworks Northwest, Seattle, WA

¹⁶Department of Laboratory Medicine, UCSF, San Francisco, CA

¹⁷Cure 4 the Kids Foundation, Las Vegas, NV

¹⁸Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN

¹⁹Michigan State University, East Lansing, MI

²⁰Mississippi Center for Advanced Medicine, Madison, MS

²¹Institute for Transfusion Medicine, Hemophilia Center of Western PA, Pittsburgh, PA

²²Center for Research on Health Care Data Center, University of Pittsburgh, Pittsburgh, PA

²³Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA

1143 Cancer Associated Thrombosis Is Associated with Higher Mortality across All Khorana Score Risk Levels

Program: Oral and Poster Abstracts

Session: 331 Pathophysiology of Thrombosis: Poster I

Type: Poster

Hematology Disease Topics & Pathways: Drug-induced thrombocytopenia, Bleeding Disorders, Diseases, Hemostasis, Bleeding and clotting, Therapies, HIT, Adverse Events, Thrombosis, Platelet Disorders, Study Population, Thromboembolism, Clinically relevant, Thrombocytopenias, Quality Improvement, Thrombotic Disorders, Vascular Wall, VTE

Saturday, Dec 7, 2019: 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Alok A Khorana, MD¹, Keith R McCrae, MD², Nicole M. Kuderer³, Dejan Milentijevic⁴*, François Laliberté⁵*, Guillaume Germain, MSc⁵*, Sean D. MacKnight⁵*, Patrick Lefebvre⁵*, Gary H. Lyman, MD⁶ and Michael B. Streiff, MD⁷

¹Cleveland Clinic, Cleveland, OH

²Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

³Advanced Cancer Research Group, Seattle, WA

⁴Janssen Scientific Affairs, LLC, Titusville, NJ

⁵Groupe d'analyse, Ltée, Montréal, QC, Canada

⁶Fred Hutchinson Cancer Research Center, Seattle, WA

⁷Johns Hopkins University School of Medicine, Baltimore, MD

1200 TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins

Program: Oral and Poster Abstracts

Session: 503. Clonal Hematopoiesis: Aging and Inflammation: Poster I

Type: Poster

Hematology Disease Topics & Pathways: Diseases, Biological Processes, DNA damage, DNA repair, epigenetics, genomics, Myeloid Malignancies, molecular interactions, pathogenesis

Saturday, Dec 7, 2019: 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Ashwin Kishtagari, MBBS¹, Yihong Guan, PhD^{1*}, Cassandra M Kerr, MS^{1*}, Hassan Awada, MD¹, Jibran Durrani^{1*}, Edward F Greenberg, MD², Xiaorong Gu, PhD^{3*}, Feng Pan, PhD^{4*}, Valeria Visconte, PhD⁵, Dewen You, PhD^{2*}, Guangbo Qu, PhD^{6*}, Amy C Graham, BS, MS^{2*}, Bartłomiej P. Przychodzen^{1*}, **Thomas Laframboise, PhD^{7*}, Hideki Makishima, MD, PhD⁸, Daniel Gackowski, PhD^{9*}, Ryszard Ólinski, Professor^{9*}, Yu-Wei Cheng, PhD^{10*}, **Mikael A. Sekeres, MD, MS¹¹**, Mingjiang Xu, MD, PhD¹², **Babal K. Jha, PhD^{1*}** and **Jaroslav P. Maciejewski, MD, PhD¹³****

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Taussig Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

⁴Stanford University, Stanford, CA

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH

⁶Institute of Urban Environment, Chinese Academy of Sciences, Xiamen, China

⁷Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁸Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

⁹Department of Clinical Biochemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

¹⁰Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic Department of Molecular Pathology, Cleveland, OH

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹²Indiana University School of Medicine, San Antonio, TX

¹³Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

1220 15-PGDH Inhibition Mitigates Aplastic Anemia Severity

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster I

Hematology Disease Topics & Pathways: Anemias, Diseases, Therapies, aplastic anemia, Bone Marrow Failure, Clinically relevant

Saturday, Dec 7, 2019: 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Julianne N. P. Smith, PhD¹, Folashade Otegbeye, MD, MPH², Alvin Jogasuria^{1*}, Sanford Markowitz, MD, PhD^{1*} and **Amar Desai, PhD¹**

¹Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Beachwood, OH

1226 Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster I

Hematology Disease Topics & Pathways:

Diseases, Leukemia, LGLL, Elderly, Study Population, Lymphoid Malignancies, Clinically relevant

Saturday, Dec 7, 2019: 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Hassan Awada^{1*}, Reda Z. Mahfouz, MD, PhD^{2,3*}, Jibran Durrani^{1*}, Ashwin Kishtagari, MBBS¹, **Deepa Jagadeesh, MD, MPH⁴, Alan Lichtin, MD⁵, **Brian T. Hill, MD⁴, Betty K. Hamilton, MD⁴, Hetty E.****

Carraway, MD, MBA⁶, Navneet S. Majhail, MD, MS⁷, Ronald Sobecks, MD⁴, Valeria Visconte, PhD¹, Matt Kalaycio, MD⁸, Mikkael A. Sekeres, MD, MS⁹ and Jaroslaw P. Maciejewski, MD, PhD¹⁰

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Clinical Pathology, Faculty of Medicine/ Menoufia University Hospitals, Shebin Elkom, Egypt

³Taussig Cancer Institute/ Translational Hematology Oncology Research, Cleveland Clinic, Cleveland, OH

⁴Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Hematologic Malignancies and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁷Taussig Cancer Institute/ Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland

⁸Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁰Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

1404 Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Hematology Disease Topics & Pathways: Diseases, AML, Genetic Disorders, Biological Processes, Technology and Procedures, epigenetics, cytogenetics, Clinically relevant, Myeloid Malignancies, genetic profiling, molecular testing, NGS, pathogenesis, pathways, signal transduction

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Hassan Awada, MD¹, Jibran Durrani^{1*}, Tariq Zuheir Kewan, MD^{2*}, Ashwin Kishtagari, MBBS¹, Valeria Visconte, PhD³ and Reda Z. Mahfouz, MD, PhD^{1,4*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Internal Medicine, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁴Clinical Pathology, Faculty of Medicine/ Menoufia University Hospitals, Shebin Elkom, Egypt

1405 Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Hematology Disease Topics & Pathways: AML, Diseases, Bone Marrow Failure, Myeloid Malignancies
Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Hassan Awada^{1,2*}, Teodora Kuzmanovic^{1*}, Ashwin Kishtagari, MBBS¹, Jibran Durrani^{1*}, Arda Durmaz^{3,4*}, Sanghee Hong, MD^{5*}, Cassandra M Kerr, MS^{1*}, Vera Adema, PhD^{1*}, Yihong Guan, PhD^{1*}, Sonia Sandhu^{2*}, Aziz Nazha, MD⁶, Manja Meggendorfer, PhD⁷, Torsten Haferlach, MD⁸, Hetty E. Carraway, MD, MBA⁹, Mikkael A. Sekeres, MD, MS¹⁰, Valeria Visconte, PhD¹¹ and Jaroslaw P. Maciejewski, MD, PhD¹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Cleveland Clinic Akron General Hospital, Akron

³Department of Systems biology and Bioinformatics, CWRU, Cleveland, OH

⁴Translational hematology and Oncology research, Taussig Cancer Center, Cleveland Clinic, Cleveland

⁵Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁷MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

⁸MLL Munchner Leukamie Labor GmbH, Munchen, Germany

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH

1406 Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Hematology Disease Topics & Pathways: Diseases, AML, Bone Marrow Failure, Myeloid Malignancies
Saturday, Dec 7, 2019, 5:30 PM-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Hassan Awada^{1*}, **Arda Durmaz**^{2,3*}, **Yasunobu Nagata, MD, PhD**^{4*}, **Teodora Kuzmanovic**^{4*}, **Ashwin Kishtagari, MBBS**⁴, **Jibran Durrani**^{4*}, **Cassandra M Kerr, MS**^{4*}, **Anjali S. Advani, MD**⁵, **Hetty E. Carraway, MD, MBA**⁵, **Tomas Radivoyevitch, PhD**^{6*}, **Manja Meggendorfer, PhD**⁷, **Aziz Nazha, MD**⁸, **Valeria Visconte, PhD**¹, **Mikael A. Sekeres, MD, MS**^{9,10}, **Torsten Haferlach, MD**¹¹ and **Jaroslav P. Maciejewski, MD, PhD**¹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

²Department of Systems Biology and Bioinformatics, CWRU, Cleveland, OH

³Translational Hematology and Oncology research, Taussig Cancer Center, Cleveland Clinic, Cleveland

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

⁷MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

⁸Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

¹¹MLL Munchner Leukamie Labor GmbH, Munchen, Germany

1448 Predicting Minimal Residual Disease in Acute Myeloid Leukemia through Stochastic Modeling of Clonality

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Hematology Disease Topics & Pathways: therapy sequence, Therapies, Combinations, Clinically relevant
Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Khanh Dinh^{1*}, **Roman Jaksik, PhD**^{2*}, **Marek Kimmel, PhD, DSc**^{3*} and **Seth J. Corey, MD**⁴

¹Mathematics, Rice University, Houston, TX

²Silesian University of Technology, Gliwice, Poland

³Department of Statistics, Rice University, Houston, TX

⁴Departments of Pediatrics, Cancer Biology, THOR, Cleveland Clinic, Cleveland, OH

1270 Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

Program: Oral and Poster Abstracts

Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I

Hematology Disease Topics & Pathways: Diseases, Non-Biological, Therapies, MDS, Clinically relevant, Myeloid Malignancies, pharmacology

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Vera Adema, PhD^{1*}, **Cassandra M Kerr, MS**^{1*}, **Wencke Walter, PhD**^{2*}, **Stephan Hutter, PhD**^{2*}, **Yasunobu Nagata, MD, PhD**^{1*}, **Hassan Awada, MD**¹, **Sunisa Kongkiatkamon**^{1*}, **Christina A. Snider, BA**¹, **Milo Co**^{1*}, **Rainey Magdalena**^{3*}, **Arda Durmaz**^{3,4*}, **Manja Meggendorfer, PhD**², **Aziz Nazha, MD**⁵, **Jacob Scott, MD**^{1,6*}, **Hetty E. Carraway, MD, MBA**⁷, **Mikael A. Sekeres, MD, MS**⁸, **Francesc Sole, PhD**⁹, **Torsten Haferlach, MD**¹⁰, **Valeria Visconte, PhD**¹ and **Jaroslav P. Maciejewski, MD, PhD**^{11,12}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²MLL Munich Leukemia Laboratory, Munich, Germany

³Translational hematology and Oncology research, Taussig Cancer Center, Cleveland Clinic, Cleveland

⁴Department of Systems biology and Bioinformatics, CWRU, Cleveland

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Radiation Oncology, and CWRU department of systems biology and bioinformatics and Physics, CWRU, CLEVELAND

⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁸Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

¹⁰MLL Munchner Leukamie Labor GmbH, Munchen, Germany

¹¹Leukemia Program, Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

1279 Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Program: Oral and Poster Abstracts

Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I

Hematology Disease Topics & Pathways: Adult, Therapies, Non-Biological, chemotherapy, Biological Processes, epigenetics, Study Population, Clinically relevant, pharmacology

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Ashwin Kishtagari, MBBS¹, Hassan Awada^{1*}, Reda Z. Mahfouz, MD, PhD^{2*}, Teodora Kuzmanovic^{1*}, Jibran Durrani^{1*}, Cassandra M Kerr, MS^{1*}, Bhumika J. Patel, MD³, Valeria Visconte, PhD⁴, Tomas Radivoyevitch, PhD^{5*}, Alan Lichtin, MD⁶, Hetty E. Carraway, MD, MBA³, Jaroslaw P. Maciejewski, MD, PhD⁷ and Yogenthiran Sauntharajah, MD⁸

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Taussig Cancer Institute/ Translational Hematology Oncology Research, Cleveland Clinic, Cleveland, OH

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH

⁵Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Cleveland, OH

⁷Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

⁸Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1281 CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Program: Oral and Poster Abstracts

Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I

Hematology Disease Topics & Pathways: Diseases, Therapies, Non-Biological, MDS, Clinically relevant, Myeloid Malignancies, pharmacology, signal transduction

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Vera Adema, PhD^{1*}, Cassandra M Kerr, MS^{1*}, Sunisa Kongkiatkamon^{1*}, Jibran Durrani^{1*}, Hassan Awada, MD¹, Stephan Hutter, PhD^{2*}, Kevin Fung^{1*}, Francesca Gould^{1*}, Christina A. Snider, BA¹, Anjali S. Advani, MD³, Hetty E. Carraway, MD, MBA⁴, Kevin R Kelly, MD, PhD^{5*}, Steffan T. Nawrocki, PhD⁶, Yogenthiran Sauntharajah, MD⁷, Jennifer S. Carew, PhD⁸, Manja Meggendorfer, PhD², James G Phillips, PhD^{1*}, Mikkael A. Sekeres, MD, MS⁹, Michael R. Savona, MD^{10,11}, Torsten Haferlach, MD¹², Jaroslaw P. Maciejewski, MD, PhD^{13,14} and Valeria Visconte, PhD¹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²MLL Munich Leukemia Laboratory, Munich, Germany

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁵Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA

⁶Division of Translational and Regenerative Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ

⁷Department of Translational hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁸The University of Arizona Cancer Center, Tucson, AZ

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁰Department of Medicine and Program in Cancer Biology, Vanderbilt University Medical Center, Nashville, TN

¹¹Department of Medicine and Cancer Biology, Vanderbilt University Medical Center, Nashville, TN

¹²MLL Munchner Leukamie Labor GmbH, Munchen, Germany

¹³Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

¹⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

1302 Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin

Program: Oral and Poster Abstracts

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster I

Hematology Disease Topics & Pathways: Biological, ALL, Leukemia, Diseases, antibodies, Therapies, Lymphoid Malignancies, transplantation, TKI

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Talha Badar, MD¹, Aniko Szabo, PhD^{2*}, Martha Wadleigh, MD^{3*}, Michaela Liedtke, MD⁴, Shukaib Arslan, MD^{5*}, Caitlin Siebenaller, PharmD^{6*}, Ibrahim Aldoss, MD⁷, Elizabeth Schultz^{8*}, Mehrdad Hefazi, MD⁹, Mark Litzow, MD¹⁰, Eric Kuo^{11*}, Amy Wang, MD, MPH¹², Emily K Curran, MD¹³, Rory M Shallis, MD¹⁴, Nikolai A. Podoltsev, MD, PhD¹⁵, Suresh Kumar Balasubramanian, MD¹⁶, Jay Yang, MD¹⁶, Ryan J. Mattison, MD¹⁷, Madelyn Burkart, MD^{18*}, Shira Dinner^{18*}, Anjali S. Advani, MD¹⁹ and Ehab L. Atallah, MD²⁰

¹Medical College of Wisconsin, Milwaukee, WI

²Medical College of Wisconsin, Milwaukee

³Dana-Farber Cancer Institute, Boston, MA

⁴Stanford University Cancer Center, Stanford, CA

⁵Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA

⁶Department of Pharmacy, Cleveland Clinic, Cleveland, OH

⁷Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA

⁸Dana Farber Cancer Institute, Boston

⁹Division of Hematology, Mayo Clinic, Rochester, MN

¹⁰Mayo Clinic, Rochester

¹¹University of Stanford, Stanford

¹²University of Chicago, Chicago

¹³Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

¹⁴Department of Internal Medicine, Section of Hematology, Yale School of Medicine, West Haven, CT

¹⁵Yale University, New Haven

¹⁶Karmanos Cancer Institute/ Wayne State University, Detroit

¹⁷University of Wisconsin Carbone Cancer Center, Madison, WI

¹⁸Northwestern University, Chicago

¹⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²⁰Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, WI

1309 Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed *FLT3* Mutated Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Hematology Disease Topics & Pathways: Adult, Diseases, AML, Therapies, Study Population, Clinically relevant, Myeloid Malignancies

Saturday, Dec 7, 2019, 5:30 - 7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Selina M. Luger, MD, FRCPC¹, Zhuoxin Sun, PhD^{2*}, Sanam Loghavi, MD³, Hillard M Lazarus, MD⁴, Jacob M. Rowe, MB, BS⁵, Martin S. Tallman, MD⁶, Keith W. Pratz, MD⁷ and Mark Litzow, MD⁸

¹Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA

²ECOG-ACRIN statistical center, Boston

³Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

⁴Case Western Reserve University School of Medicine, Cleveland, OH

⁵Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel

⁶Memorial Sloan Kettering Cancer Center, New York, NY

⁷Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

⁸Division of Hematology, Mayo Clinic, Rochester, MN

1344 Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Program: Oral and Poster Abstracts

Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: antibodies, Biological, Therapies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Hagop M. Kantarjian, MD¹, Wendy Stock, MD², Ryan D. Cassaday, MD³, Daniel J. DeAngelo, MD, PhD⁴, Elias Jabbour¹, Susan M. O'Brien, MD⁵, Matthias Stelljes, MD⁶, Tao Wang^{7*}, M. Luisa Paccagnella^{7*}, Kevin Nguyen^{8*}, Barbara Sleight, MD^{7*}, Erik R. Vandendries, MD, PhD^{9*}, Alexander Neuhof, MD^{10*}, A. Douglas Laird, PhD^{11*} and Anjali S. Advani, MD¹²

¹MD Anderson Cancer Center, Houston, TX

²Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

³University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA

⁴Dana-Farber Cancer Institute, Boston, MA

⁵Chao Family Comprehensive Cancer Center, Division of Hematology / Oncology, Department of Medicine, University of California Irvine Health, Orange, CA

⁶Universitätsklinikum Münster, Münster, Germany

⁷Pfizer Inc, Groton, CT

⁸Navigate BioPharma Services, Inc., a Novartis subsidiary, Carlsbad, CA

⁹Pfizer Inc, Cambridge, MA

¹⁰Pfizer Pharma GmbH, Berlin, Germany

¹¹Pfizer Inc, San Francisco, CA

¹²Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

1499 Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 621. Lymphoma—Genetic/Epigenetic Biology: Poster I

Hematology Disease Topics & Pathways: Diseases, Non-Hodgkin Lymphoma, Biological Processes, Technology and Procedures, DLBCL, Lymphoid Malignancies, Clinically relevant, genetic profiling, genomics, molecular testing, NGS, molecular interactions, RNA sequencing

Saturday, Dec 7, 2019, 5:30 PM-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Maher Albitar, MD¹, Zijun Yidan Xu-Monette, PhD², Wanlong Ma³, Yingjun Wang², Deng Manman, MD⁴, Alexandar Tzankov, MD⁵, Carlo Visco⁶, Govind Bhagat, M.D.⁷, Karen Dybkær, PhD⁸, Ivan De Dios, BS⁹, Wayne Tam, MD, PhD⁹, Eric D. Hsi, MD¹⁰, Maurilio Ponzoni, MD¹¹, Andres JM Ferreri, MD¹², Michael Boe Møller¹³, Miguel A. Piris¹⁴, Joannes H.J.M. Van Krieken, PhD, MD¹⁵, Youli Zu, MD, PhD¹⁶, Hagop M. Kantarjian, MD¹⁷, Yong Li, PhD¹⁸ and Ken H. Young¹⁹

¹Genomic Testing Cooperative, Valley Center, CA

²Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX

³Genomic Testing Cooperative, Irvine, CA

⁴MD Anderson Cancer Center, Houston, TX

⁵University Hospital Basel, Basel, Switzerland

⁶San Bortolo Hospital, Vicenza, Italy

⁷Columbia University Medical Center, New York, NY

⁸Department of Hematology, Aalborg University Hospital, Aalborg, Denmark

⁹Department of Pathology and Laboratory Medicine, Well Cornell Medical College, New York, NY

¹⁰Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH

¹¹Pathology Unit, San Raffaele Scientific Institute, Milano, Italy

¹²Onco-Hematology Department, Fondazione Centro San Raffaele, Milan, Italy

¹³Department of Pathology, Odense University Hospital, Odense, Denmark

¹⁴Instituto de Investigación Marqués De Valdecilla, Santander, Spain

¹⁵University Hospital Nijmegen, Nijmegen, NLD

¹⁶Houston Methodist Hospital, Houston, TX

¹⁷M.D. Anderson Cancer Center, Houston, TX

¹⁸Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

¹⁹Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

1515 Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Program: Oral and Poster Abstracts

Session: 622. Lymphoma Biology—Non-Genetic Studies: Poster I

Hematology Disease Topics & Pathways: Diseases, antibodies, Biological, Therapies, Combinations, Biological Processes, enzyme inhibitors, immune cells, T-Cell Lymphoma, epigenetics, Study Population, Xenograft models, Clinically relevant, Lymphoid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Neetha Parameswaran, PhD¹, Xiaoxian Zhao, PhD², Juraj Bodo, PhD³, Lisa Durkin³, Yvonne Parker⁴, Daniel Lindner, MD, PhD¹, Eric D. Hsi, MD² and Deepa Jagadeesh, MD, MPH⁵

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH

³Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

⁴Cleveland Clinic, Cleveland, OH

⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1525 Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I
Hematology Disease Topics & Pathways: antibodies, Diseases, Biological, Therapies, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Clinically relevant, Lymphoid Malignancies
Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Brian T. Hill, MD¹, Jeffrey M. Switchenko, PhD, MS^{2*}, Peter Martin, FRCPC, MD, MS³, Michael C. Churnetski^{4*}, Yazeed Sawalha, MD⁵, Subir Goyal^{6*}, Krithika Shanmugasundaram, MD⁷, Oscar Calzada, BS^{8*}, Bhaskar Kolla, MBBS⁹, Veronika Bachanova, MD, PhD⁹, James N. Gerson, MD¹⁰, Stefan K. Barta, MD, MRCP, MS¹¹, Max J. Gordon, MD¹², Alexey Danilov, MD, PhD¹³, Natalie S Grover, MD¹⁴, Stephanie Mathews, MD^{15*}, Madelyn Burkart, MD^{16*}, Reem Karmali, MD¹⁷, Nilanjan Ghosh, MD, PhD¹⁸, Steven I Park, MD¹⁹, Narendranath Epperla, MD, MS²⁰, David A. Bond, MD²¹, Talha Badar, MD²², Kristie A. Blum, MD²³, Jin Guo, MD²⁴, Mehdi Hamadani, MD²², Timothy S. Fenske, MD²⁵, Mary-Kate Malecek, MD²⁶, Brad S. Kahl, MD²⁷, Christopher R. Flowers, MD, MS²³ and Jonathon B. Cohen, MD, MS²⁸

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

²Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA

⁴Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY

⁵Winship Cancer Institute, Emory University Medical Center, Atlanta, GA

⁶Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

⁷Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA

⁸Emory University School of Medicine, Atlanta, GA

⁹Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

¹⁰Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

¹¹Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

¹²Lymphoma Department, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

¹³Oregon Health and Science University, Portland, OR

¹⁴Knight Cancer Institute, Oregon Health & Science University, Portland, OR

¹⁵Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

¹⁶University of North Carolina, Chapel Hill, NC

¹⁷Northwestern University; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago

¹⁸Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL

¹⁹Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC

²⁰Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC

²¹Marshfield Clinic, Columbus, OH

²²James Cancer Center, The Ohio State University Hospital, Columbus, OH

²³Medical College of Wisconsin, Milwaukee, WI

²⁴Winship Cancer Institute, Emory University, Atlanta, GA

²⁵Department of Medicine, Weill Cornell Medicine, New York, NY

²⁶Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

²⁷Department of Medicine, Washington University School of Medicine, St. Louis, MO

²⁸Department of Medicine, Washington University School of Medicine in St. Louis, Saint Louis, MO

²⁹Emory University, Atlanta, GA

1554 Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I
Hematology Disease Topics & Pathways: Diseases, Hodgkin Lymphoma, Lymphoid Malignancies
Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Narendranath Epperla, MD, MS¹, Luciano J. Costa, MD, PhD², John L Vaughn, MD³, Walter Hanel, MD, PhD^{4*}, Saba Raya, MD^{5*}, Amanda F Cashen, MD⁶, Rehan Sarmad, MD, MBBS⁷, Talha Badar, MD⁸, Mehdi Hamadani, MD⁸, Yang Liu, MD^{9*}, Stefan K. Barta, MD, MRCP, MS¹⁰, **Paolo Caimi, MD¹¹**, Tarsheen K. Sethi, MD^{12*}, Nishitha Reddy, MD¹³, Madelyn Burkart, MD^{14*}, Reem Karmali, MD¹⁵, Celeste Bello, MD¹⁶, Julio C. Chavez, MD¹⁷, Shalin K. Kothari, MD¹⁸, Francisco J. Hernandez-Ilizaliturri, MD¹⁹, Hatcher J. Ballard, BS^{20*},

Jakub Svoboda, MD²⁰, Lukas Emery, DO²¹, Frederick Lansigan, MD²², Martha Glenn, MD²³, Michael C. Churnetski²⁴, Jonathon B. Cohen, MD, MS²⁵, Caryn Sorge, MD²⁶ and Ana C. Xavier, MD²⁷

¹The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Division of Hematology, Columbus, OH

²O' Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Vestavia, AL

³Hematology, The Ohio State University, Columbus, OH

⁴Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH

⁵Siteman Cancer Center, Washington University, St Louis, MO

⁶Department of Medicine, Washington Univ. School of Med., Saint Louis, MO

⁷University of Alabama at Birmingham, BIRMINGHAM, AL

⁸Medical College of Wisconsin, Milwaukee, WI

⁹Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA

¹⁰Lymphoma Department, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

¹¹University Hospitals Seidman Cancer Center, Cleveland, OH

¹²Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN

¹³Vanderbilt University Medical Center, Nashville, TN

¹⁴Northwestern University; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago

¹⁵Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL

¹⁶Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

¹⁷Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL

¹⁸Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

¹⁹Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

²⁰Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

²¹Dartmouth-Hitchcock Medical Center, Lebanon, NH

²²Dartmouth Hitchcock Medical Center, Lebanon, NH

²³Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT

²⁴Winship Cancer Institute, Emory University Medical Center, Atlanta, GA

²⁵Emory University, Atlanta, GA

²⁶University of Kentucky, Lexington, KY

²⁷University of Alabama at Birmingham, Vestavia Hills, A

1572 Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Program: Oral and Poster Abstracts

Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I

Hematology Disease Topics & Pathways: Diseases, T-Cell Lymphoma, Lymphoid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Xiaoxian Zhao, PhD¹, Bartlomiej Przychodzen², Juraj Bodo, PhD³, Lisa Durkin³, Daniel Lindner, MD, PhD⁴, Neetha Parameswaran, PhD⁵, Michael Clemente, MS⁶, Sarah L. Ondrejka, DO⁷, Jaroslaw P. Maciejewski, MD, PhD⁸, Deepa Jagadeesh, MD, MPH⁹ and Eric D. Hsi, MD¹

¹Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

³Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

⁴Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Taussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland

⁷Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH

⁸Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

⁹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1583 Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways: Diseases, Non-Hodgkin Lymphoma, Clinically relevant, Lymphoid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

*Miriam T. Jacobs, MD¹, Michael D. Jain, MD, PhD², Jay Y. Spiegel, MD, FRCPC³, Loretta J. Nastoupil, MD, MSc⁴, Yibo Li, MD⁵, Gao Feng⁶, Matthew A. Lunning, DO, FACP⁷, Lazaros J Lekakis, MD⁸, Saurabh Dahiya, MD⁹, Patrick M Reagan, MD¹⁰, Olalekan O. Oluwole, MBBS, MPH¹¹, Joseph P. McGuirk, DO¹², Abhinav Deol, MD¹³, Alison R. Sehgal, MD¹⁴, Andre Goy, MD¹⁵, **Brian T. Hill, MD¹⁶**, Charalambos Andreadis, MD, MSCE¹⁷, Javier Munoz, MD¹⁸, Julio Chavez¹⁹, N. Nora Bennani, MD²⁰, Aaron P. Rapoport²¹, Julie M Vose, MD MBA²², David B Miklos, MD, PhD²³, Sattva S Neelapu, MD²⁴, Armin Ghobadi, MD²⁴ and Frederick L. Locke, MD²⁵*

¹Department of Oncology, Washington University in St. Louis, St Louis, MO

²Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

³Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA

⁴Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

⁵Moffitt, Tampa, FL

⁶Washington University in St. Louis, St. Louis, MO

⁷University of Nebraska Medical Center, Omaha, NE

⁸University of Miami, Sylvester Comprehensive Care Center, Miami, FL

⁹University of Maryland School of Medicine, Ellicott City, MD

¹⁰Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

¹¹Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN

¹²Department of Blood and Bone Marrow Transplant, The University of Kansas Medical Center, Kansas City, KS

¹³Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI

¹⁴UPMC Hillman Cancer Center, Pittsburgh, PA

¹⁵Department of Hematology & Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

¹⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁷Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

¹⁸Banner MD Anderson Cancer Center, Gilbert, AZ

¹⁹Dept. of Malignant Hematology, Moffitt Cancer Center, Washington, DC

²⁰Division of Hematology, Mayo Clinic, Rochester, MN

²¹University of Maryland Greenebaum Comprehensive Cancer Center and School of Medicine, Baltimore, MD

²²Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE

²³Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University Medical Center, Stanford, CA

²⁴Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO

²⁵Dept., H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

1593 A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

Hematology Disease Topics & Pathways: multiple myeloma, Adult, Diseases, smoldering myeloma, Hodgkin Lymphoma, Study Population, Lymphoid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

*Sarit Assouline, MD¹, Amitkumar Mehta, MD², **Paolo F Caimi, MD³**, Bingxia Wang, PhD⁴, Chirag Patel⁴, Mi-Sook Kim⁴, Dennis Huszar⁴, Allison J Berger, PhD⁴, Sharon Friedlander⁴, Alejandro Gomez-Pinillos⁵ and Igor Proscurshim⁴*

¹Division of Hematology, McGill University Jewish General Hospital, Montreal, QC, Canada

²Department of Hematology/Oncology Medicine, University of Alabama At Birmingham, Birmingham, AL

³Clinical Trials Unit, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA

⁵Research and Development at Takeda Pharmaceutical Company Limited, Madrid, Spain

1703 Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Hematology Disease Topics & Pathways: Diseases, MDS, Myeloid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Cassandra M Kerr, MS¹, Vera Adema, PhD¹, Wencke Walter, PhD², Stephan Hutter, PhD², Christina A. Snider, BA¹, Yasunobu Nagata, MD, PhD¹, Manja Meggendorfer, PhD², Claudia Haferlach, MD², Valeria

Visconte, PhD¹, **Mikael A. Sekeres, MD, MS³**, **Thomas Laframboise, PhD^{4*}**, Torsten Haferlach, MD⁵ and **Jaroslav P. Maciejewski, MD, PhD⁶**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²MLL Munich Leukemia Laboratory, Munich, Germany

³Leukemia Program, Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁴Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁵MLL Munchner Leukamie Labor GmbH, Munchen, Germany

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

[1715 Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes](#)

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Hematology Disease Topics & Pathways: Diseases, MDS, Clinically relevant, Myeloid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Guillermo Montalban-Bravo, MD^{1*}, **Elias Jabbour²**, **Caleb Class, PhD^{3*}**, **Nicholas J. Short, MD⁴**, **Rashmi Kanagal-Shamanna, MD⁵**, **Tapan M. Kadia, MD¹**, **Gautam M. Borthakur, MD¹**, **Naveen Pemmaraju, MD⁶**, **Koji Sasaki, MD⁷**, **Zeev E. Estrov, MD²**, **Jorge E. Cortes, MD⁸**, **Farhad Ravandi, MD²**, **Yesid Alvarado, MD²**, **Rami S. Komrokji, MD^{9,10,11}**, **Mikael A. Sekeres, MD, MS¹²**, **David P. Steensma, MD¹³**, **Amy E. DeZern, MD¹⁴**, **Gail J. Roboz, MD¹⁵**, **Hui Yang, PhD, MD²**, **Hagop M. Kantarjian, MD¹⁶** and **Guillermo Garcia-Manero, MD¹**

¹University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

³Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

⁴The University of Texas MD Anderson Cancer Center, Houston, TX

⁵Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX

⁶University of Texas MD Anderson Cancer Center, Department of Leukemia, Bellaire, TX

⁷MD Anderson Cancer Center, Houston, TX

⁸UT Texas MD Anderson Cancer Center, Houston, TX

⁹Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

¹⁰Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

¹¹Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

¹²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

¹⁴Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

¹⁵Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY

¹⁶M.D. Anderson Cancer Center, Houston, TX

[1716 How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS](#)

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Hematology Disease Topics & Pathways: Diseases, MDS, Technology and Procedures, Clinically relevant, Myeloid Malignancies, genetic profiling

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Yasunobu Nagata, MD, PhD^{1*}, **Ran Zhao^{2*}**, **Hassan Awada^{3*}**, **Cassandra M Kerr, MS^{1*}**, **Abhinav Goyal^{1*}**, **Inom Mirzaev^{1*}**, **Sunisa Kongkiatkamon^{1*}**, **Aziz Nazha, MD⁴**, **Tomas Radivoyevitch, PhD^{1*}**, **Jacob Scott, MD^{1*}**, **Mikael A. Sekeres, MD, MS⁵**, **Brian P. Hobbs, PhD^{2*}** and **Jaroslav P. Maciejewski, MD, PhD⁶**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

[1751 Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients \(≥ 70 Years of Age\) with Chronic Lymphocytic Leukemia \(CLL\)](#)

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: Diseases, Leukemia, CLL, Lymphoid Malignancies, Clinically relevant

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Jennifer Woyach, MD¹, Amy S. Ruppert, MAS, PhD^{2}, Gabriela Perez, MS^{3*}, Allison M Booth^{3*}, Diane Feldman^{4*}, Elie G Dib, MD^{5*}, Aminah Jatoi, MD^{6*}, Jennifer Le-Rademacher, PhD^{6*}, Nyla A. Heerema, PhD², Gerard Lozanski, MD², Richard Little, MD^{7*}, Wei Ding, MD, PhD⁶, **Brian T. Hill, MD⁸**, Richard M. Stone, MD⁹, Sumithra J Mandrekar, PhD^{3*} and John C Byrd, MD^{1,10}*

¹The Ohio State University, Columbus, OH

²The Ohio State University Comprehensive Cancer Center, Columbus, OH

³Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

⁴University of Chicago, Chicago, IL

⁵St Joseph Mercy Health System, Ann Arbor, MI

⁶Mayo Clinic, Rochester, MN

⁷Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD

⁸Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁹Dana-Farber Cancer Institute, Boston, MA

¹⁰Comprehensive Cancer Center, The Ohio State University, Columbus, OH

1756 Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, Adverse Events, Study Population, Lymphoid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

***Anthony R. Mato, MD MSCE^{1,2}**, Kavita Sail, PhD^{3*}, Maryam Sarraf Yazdy, MD⁴, **Brian T. Hill, MD⁵**, Mazyar Shadman, MD, MPH^{6*}, Beenish S Manzoor, PhD^{3*}, Hande H. Tuncer, MD^{7*}, John N. Allan, MD⁸, Chaitra S. Ujjani, MD⁶, Simon Sharmokh, MPH, PharmD^{3*}, Daniel Dingfeng Jiang, MD, PhD^{3*}, German Pena, MD^{3*}, Thomas Marshall, PharmD, MS^{3*}, Jacqueline Nielsen, PhD^{3*}, Paul M. Barr, MD⁹, Jennifer R. Brown, MD, PhD^{10*}, Anna Schuh, MD¹¹, Toby A. Eyre, MD^{11*}, William G. Wierda, MD, PhD¹², Alan Skarbnik, MD¹³, Lindsey E. Roeker, MD¹, Rajat Bannerji, MD, PhD¹⁴, James M. Pauff, MD, PhD¹⁵, Stephen J. Schuster, MD¹⁶, George A Follows, MD, PhD^{17*}, Bruce D. Cheson, MD¹⁸, Barbara F. Eichhorst, MD¹⁹, Danielle M. Brander, MD²⁰, Irina Pivneva, PhD^{21*} and Nicole Lamanna, MD^{22*}*

¹CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

²CLL Program, Leukemia Service, Hematologic Malignancies Division, Memorial Sloan Kettering Cancer Center, New York, NY

³AbbVie, Inc., North Chicago, IL

⁴Georgetown University Hospital, Washington, DC

⁵Cleveland Clinic, Cleveland, OH

⁶Fred Hutchinson Cancer Research Center, Seattle, WA

⁷The Cancer Center at Lowell General Hospital, Lowell General Hospital, Lowell, MA

⁸Weill Cornell Medicine University Medical Center, New York, NY

⁹Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

¹¹Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

¹²MD Anderson Cancer Center, Houston, TX

¹³Novant Health, Charlotte, NC

¹⁴Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

¹⁵AbbVie, Chicago, IL

¹⁶Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

¹⁷Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom

¹⁸Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC

¹⁹Department of Internal Medicine, Center of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany

²⁰Duke Cancer Institute, Duke University Hospital, Durham, NC

²¹Analysis Group, Montreal, QC, Canada

²²Columbia University, New York, NY

1838 Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: Adult, Biological, antibodies, Diseases, Therapies, Study Population, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant, Quality Improvement
Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Nathaniel Rosko, PharmD^{1*}, Hanjie Mo, PharmD^{1*}, Joslyn Rudoni, PharmD^{1*}, Caitlin Siebenaller, PharmD^{1*}, Sarah S Lee, MD², Rajshekar Chakraborty, MD², Beth M. Faiman, PhD, CNP², Jack Khouri, MD², Alex V. Mejia Garcia, MD², Christy J. Samaras, DO², Faiz Anwer, MD² and Jason Valent, MD²

¹Department of Pharmacy, Cleveland Clinic, Cleveland, OH

²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1841 Risk of Serious Infections with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: Diseases, Therapies, Adverse Events, Infectious Diseases, Clinically relevant

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Somedeb Ball, MD¹, Tapas Ranjan Behera^{2*}, Soriya Wongsangsak, MD³, Nuvneet Khandelwal, MD^{1*} and Rajshekhar Chakraborty, MD⁴

¹Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX

²Department of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

³Department of Internal Medicine, Texas Tech University Health Science Center, Lubbock, TX

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1892 Risk of Progression in Patients with Smoldering Myeloma

Fahrettin Covut, MD¹, Kamal Chamoun, MD², Leland Metheny III, MD³, Kirsten M Boughan, DO³, James Driscoll, MD, PhD⁴, Marcos de Lima, MD⁵ and Ehsan Malek, MD⁶

¹Department of Internal Medicine, Case Western Reserve University, Cleveland, OH

²University Hospitals Cleveland Medical Center, Adult Stem Cell Program, Cleveland, OH

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

⁵University Hospitals Seidman Cancer Center, Cleveland, OH

⁶Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

1948 Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia

Program: Oral and Poster Abstracts

Session: 704. Immunotherapies: Poster I

Hematology Disease Topics & Pathways: Diseases, Adult, Leukemia, ALL, Biological, antibodies, Therapies, Study Population, Lymphoid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Leland Metheny III, MD¹, Ronald Sobecks, MD², Benjamin K. Tomlinson, MD¹, Folashade Otegbeye, MD, MPH³, Brenda Cooper, MD¹, Navneet S. Majhail, MD, MS², Paolo Caimi, MD^{1*}, Kirsten M Boughan, DO¹, Molly M Gallogly, MD, PhD¹, Ehsan Malek, MD⁴, Erin Galloway, RN BSN^{1*}, Betty K. Hamilton, MD⁵, Matt Kalaycio, MD², Aaron T. Gerds, MD, MS² and Marcos de Lima, MD¹

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

²Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Beachwood, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

⁵Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

2015 Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Program: Oral and Poster Abstracts

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I

Hematology Disease Topics & Pathways: therapy sequence, Biological, AML, Diseases, Therapies, Combinations, checkpoint inhibitors, MDS, Myeloid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Jacqueline S Garcia, MD¹, Lillian Werner^{2*}, Benjamin K. Tomlinson, MD³, Michael Keng, MD^{4*}, Myrna Nahas, MD⁵, Andrew Brunner, MD^{6*}, Samer K. Khaled, MD⁷, Alexandra Savell, BS^{1*}, Marlise Lusk, MD, MS¹, David P. Steensma, MD¹, Martha Wadleigh, MD^{8*}, Eric S. Winer, MD¹, Edwin P. Alyea III, MD¹, Corey Cutler, MD, MPH, FRCP⁹, Vincent T. Ho, MD^{10*}, Donna S Neuberg, ScD¹¹, Nicole Cullen^{2*}, Andreas Kantartzis^{2*}, Ana Lako^{12*}, Scott Rodig, MD, PhD^{12*}, R. Coleman Lindsley, MD, PhD^{2,13}, Yael Flamand^{2*}, Claire Manuszak^{13*}, Ryan Brennick^{2*}, Mariano Severgnini^{2*}, Stephanie Andrews^{2*}, Ilene Galinsky^{2*}, Pavan Bachiredy, MD¹, Yohei Arihara, MD, PhD^{10*}, Jerome Ritz, MD¹⁰, Matthew S. Davids, MD¹, Howard Streicher, MD^{14*}, Catherine J. Wu, MD¹, Richard M. Stone, MD², Daniel J. DeAngelo, MD¹⁵ and Robert J. Soiffer, MD¹⁶

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

²Dana-Farber Cancer Institute, Boston, MA

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴UVA, Charlottesville, VA

⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Brookline, MA

⁶Massachusetts General Hospital / Harvard Medical School, Boston, MA

⁷Department of Hematology and Hematopoietic Cell Transplantation (HCT), Beckman Research Institute, City of Hope, Duarte, CA

⁸Dana Farber Cancer Institute, Boston

⁹Dana-Farber Cancer Inst., Boston, MA

¹⁰Dana-Farber Cancer Institute, Department of Hematologic Malignancies and Harvard Medical School, Boston, MA

¹¹Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

¹²Department of Pathology, Brigham & Women's Hospital, Boston, MA

¹³Dana-Farber Cancer Institute, Boston

¹⁴Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

¹⁵Department of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA

¹⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

2036 Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster I

Hematology Disease Topics & Pathways: Diseases, Myeloid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Leland Metheny III, MD¹, Wael Saber, MD, MS², Daniel J. Weisdorf, MD³, Marcos de Lima, MD⁴, Natalie Scott Callander, MD⁵, Mark Litzow, MD⁶, Partow Kebriaei, MD⁷, Aric C. Hall, MD^{8*}, Brenda M Sandmaier, MD⁹, Mei-Jie Zhang^{2*}, Hai-Lin Wang, MPH^{10*} and Khalid Bo-Subait^{10*}

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Heights, OH

²CIBMTR, Medical College of Wisconsin, Milwaukee, WI

³Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

⁴University Hospitals Seidman Cancer Center, Cleveland, OH

⁵Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI

⁶Division of Hematology, Mayo Clinic, Rochester, MN

⁷Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, TX

⁸Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI

⁹Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁰CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

2089 Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Program: Oral and Poster Abstracts

Session: 803. Emerging Diagnostic Tools and Techniques: Poster I

Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, MDS, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Nathan Radakovich, BA¹, Mikkael A. Sekeres, MD, MS², Cameron Beau Hilton, BA³, Sudipto Mukherjee, MD, PhD, MPH⁴, Jacob Shreve, MD, MS⁵, Yazan Roupail⁶, Rachel Shirley⁵, Vera Adema, PhD⁷, Hassan Awada, MD⁷, Anjali S. Advani, MD⁴, Cassandra M Kerr, MS⁸, Yasunobu Nagata, MD, PhD⁷, Yihong Guan, PhD⁷, Teodora Kuzmanovic, BA⁷, Metis Hasipek, PhD⁷, Babal K. Jha, PhD⁹, Jaroslaw P. Maciejewski, MD, PhD¹⁰ and Aziz Nazha, MD¹¹

¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Bellingham, WA

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

³Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Heights, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Cleveland Clinic, Cleveland, OH

⁶Ohio State University, Columbus, OH

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

¹⁰Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

¹¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

2091 A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

Program: Oral and Poster Abstracts

Session: 803. Emerging Diagnostic Tools and Techniques: Poster I

Hematology Disease Topics & Pathways: Diseases, AML, Technology and Procedures, cytogenetics, Clinically relevant, Myeloid Malignancies, genetic profiling, molecular testing, NGS

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Jacob Shreve, MD, MS¹, Manja Meggendorfer, PhD², Hassan Awada, MD³, Sudipto Mukherjee, MD, PhD, MPH⁴, Wencke Walter, PhD⁵, Stephan Hutter, PhD⁵, Ahed Makhoul, MD⁶, Cameron Beau Hilton, BA⁷, Nathan Radakovich, BA⁸, Yasunobu Nagata, MD, PhD³, Yazan Roupail⁹, Vera Adema, PhD³, Cassandra M Kerr, MS³, Bhumika J. Patel, MD⁴, Teodora Kuzmanovic³, Jaroslaw P. Maciejewski, MD, PhD¹⁰, Claudia Haferlach, MD⁵, Mikkael A. Sekeres, MD, MS¹¹, Torsten Haferlach, MD¹² and Aziz Nazha, MD¹³

¹Department of Internal Medicine, Cleveland Clinic, Cleveland, OH

²MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵MLL Munich Leukemia Laboratory, Munich, Germany

⁶Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH

⁷Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Heights, OH

⁸Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Bellingham, WA

⁹Ohio State University, Rocky River, OH

¹⁰Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹²MLL Munchner Leukamie Labor GmbH, Munchen, Germany

¹³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

2173 Advancing Healthcare Outcomes for Sickle Cell Disease in Nigeria Using Mobile Health Tools

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Non-Malignant Conditions: Poster I

Hematology Disease Topics & Pathways: survivorship, Pediatric, Technology and Procedures, Young Adult, Study Population, Clinically relevant, Quality Improvement , newborn screening
 Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)
Arwa Fraiwan, PhD¹, Muhammad Noman Hasan, MS¹, Ran An, PhD¹, Amy J. Rezac², Nicholas J. Kocmich², Tolulope Oginni, BS³, Grace Mfon Olanipekun⁴, Fatimah Hassan-Hanga, MD⁵, Binta W. Jibir, MBBS MPH⁶, Safiya Gambo, MBBS⁷, Priyaleela Thota, MD⁸, Stephen K. Obaro, MD, PhD^{2,4} and Umut A. Gurkan, PhD⁹

¹Case School of Engineering, Case Western Reserve University, Cleveland, OH

²Division of Pediatric Infectious Diseases, University of Nebraska Medical Center, Omaha, NE

³Health Africa, Kano, Nigeria

⁴International Foundation Against Infectious Disease in Nigeria, Abuja, Nigeria

⁵Aminu Kano Teaching Hospital, Kano, Nigeria

⁶Hasiya Bayero Pediatric Hospital, Kano, Nigeria

⁷Murtala Mohammed Specialist Hospital, Kano, Nigeria

⁸Hemex Health Inc., Portland, OR

⁹Case Western Reserve University, Cleveland, OH

2196 Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I

Hematology Disease Topics & Pathways: Biological, Diseases, smoldering myeloma, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, Dec 7, 2019, 5:30-7:30 PM; Hall B, Level 2 (Orange County Convention Center)

Fahrettin Covut, MD¹, Tariq Zuheir Kewan, MD², Apoorva Anandan, MD³, Folashade Otegbeye, MD, MPH⁴, James Driscoll, MD, PhD⁵, Marcos de Lima, MD⁶ and Ehsan Malek, MD⁷

¹Department of Internal Medicine, Case Western Reserve University, Cleveland, OH

²Department of Internal Medicine, Cleveland Clinic, Cleveland, OH

³University Hospitals Cleveland Medical Center, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Beachwood, OH

⁵Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

⁶Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁷Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH

2226 Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Program: Oral and Poster Abstracts

Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II

Hematology Disease Topics & Pathways: Diseases, Anemias, Therapies, PNH

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Antonio M. Risitano, MD, PhD¹, Jong Wook Lee, MD, PhD², Rosario Notaro, MD^{3,4}, Robert A. Brodsky, MD⁵, Austin Kulasekararaj, MBBS MD MRCP FRCPath^{6,7}, Jaroslaw P. Maciejewski, MD, PhD⁸, Mingjun Huang, PhD⁹, Michael Geffner, MD¹⁰ and Peter Browett, BMedSci, MBChB, FRACP, FRCPA¹¹

¹Federico II University, Naples, Italy

²Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of (South)

³Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

⁴Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Firenze, Italy

⁵Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD

⁶Department of Haematology, King's College Hospital, London, GBR

⁷King's College London, London, United Kingdom

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁹Achillion Pharmaceuticals, Inc, New Haven, CT

¹⁰Achillion Pharmaceuticals Inc, Blue Bell, PA

¹¹Department of Molecular Medicine and Pathology, University of Auckland School of Medicine, Auckland, NZL

2284 Chronic Kidney Disease Is Under-Screened in SCD and Mild Albuminuria Is Associated with a Drop in Hemoglobin: A Report from the Grndad Sickle Cell Registry

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

Hematology Disease Topics & Pathways: Diseases, sickle cell disease, Hemoglobinopathies, Clinically relevant, Quality Improvement

Sunday, Dec 8, 2019, 6-8PM; Hall B, Level 2 (Orange County Convention Center)

Elizabeth Williams, BA^{1}, Elizabeth Brown^{1*}, Deepa Manwani, MD², Payal Desai, MD³, Joshua J. Field, MD⁴, Lynne D. Neumayr⁵, Susan Padrino, MD^{6*}, E. Leila Jerome Clay, MD, MCTS, FAAP⁷, Ze Cong, PhD^{8*}, Irene Agodoa, MD^{8*}, Carolyn Hoppe, MD⁹, Sophie M. Lanzkron, MD¹⁰ and Jane A. Little, MD^{11*}*

¹Johns Hopkins School of Medicine, Baltimore, MD

²Children's Hospital at Montefiore, Bronx, NY

³The Ohio State University, Columbus, OH

⁴Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI

⁵Dept. of Hematology/Oncology, Children's Hospital Oakland, Oakland, CA

⁶University Hospital Cleveland Medical Center, Cleveland, OH

⁷Department of Pediatrics, Division of Hematology / Oncology, Johns Hopkins University, St Petersburg, FL

⁸Global Blood Therapeutics, South San Francisco, CA

⁹Global Blood Therapeutics, San Francisco, CA

¹⁰Department of Medicine, Division of Hematology, Johns Hopkins Medicine, Baltimore, MD

¹¹University of North Carolina, Chapel Hill, NC

2305 An Analysis of Racial and Ethnic Backgrounds within the Casire International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

Hematology Disease Topics & Pathways: sickle cell disease, Diseases, Hemoglobinopathies, Clinically relevant

Sunday, Dec 8, 2019, 6-8PM; Hall B, Level 2 (Orange County Convention Center)

Andrew D. Campbell, MD¹, Raffaella Colombatti, MD, PhD², Biree Andemariam, MD³, Crawford John Strunk, MD⁴, Immacolata Tartaglione, MD^{5}, Connie M. Piccone, MD⁶, Deepa Manwani, MD⁷, Eugenia Vicky Asare, MBChB, BSc⁸, Fatimah Farooq^{9*}, Rebekah Urbonya^{10*}, Gifty Dankwah^{11*}, Silverio Perrotta^{12*}, Laura Sainati, MD^{13*}, Angela Rivers, MD¹⁴, Sudha Rao, MD^{15*}, William Zempsky, MD^{16*}, Fredericka Sey, MBChB^{17*}, Catherine Idara Segbefia, MBChB^{18*}, Baba PD Inusa, MD¹⁹ and Charles Antwi-Boasiako, PhD^{20*}*

¹Children's National Medical Center, Washington, DC

²Department of Womens' and Child Health, Clinic of Pediatric Hematology Oncology, Azienda Ospedaliera-Università di Padova, PADOVA, ITALY, Italy

³New England Sickle Cell Institute, Division of Hematology-Oncology, Neag Comprehensive Cancer Center, UCONN Health, University of Connecticut, Farmington, CT

⁴Promedica Toledo Children's Hospital, Toledo, OH

⁵Department of Woman, Child and General and Specialist Surgery, Università degli studi della Campania "Luigi Vanvitelli", Tbd, Italy

⁶University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH

⁷Children's Hospital at Montefiore, Bronx, NY

⁸Department of Haematology, Korle- Bu Teaching Hospital, Accra, Ghana

⁹University of Michigan, Ann Arbor

¹⁰University of Michigan, Ann Arbor, MI

¹¹Department of Physiology, University of Ghana Medical School, Accra, Ghana

¹²Università della Campania, Luigi Vanvitelli, Caserta, Italy

¹³Azienda Ospedaliera Universitaria, Padova, Italy

¹⁴Department of Pediatrics, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL

¹⁵Department of Child Health, University of Ghana Medical School, Accra, Ghana

¹⁶University of Connecticut School of Medicine, Connecticut Children's Medical Center, Hartford, CT

¹⁷Ghana Institute of Clinical Genetics, Korle-Bu Teaching Hospital, Accra, Ghana

¹⁸Department of Child Health, University of Ghana Medical School, Ghana, Ghana

¹⁹Paediatric Haematology, Evelina Children's Hospital, Guy's and St Thomas' Hospital, London, United Kingdom

²⁰University of Ghana Medical School, Accra, Ghana

2384 Host and Tumor Factor XII Drive Ovarian Cancer Maintenance and Progression

Program: Oral and Poster Abstracts

Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster II

Hematology Disease Topics & Pathways: Diseases, bioengineering, Non-Biological, Therapies, cellular interactions, Biological Processes, Technology and Procedures, Immune Disorders, pharmacology, immune mechanism, white blood cell disorders, inflammation, microenvironment, pathogenesis, pathways, signal transduction

Sunday, Dec 8, 2019, 6-8PM; Hall B, Level 2 (Orange County Convention Center)

Evi X Stavrou, MD^{1,2}, Kara L. Bane, M.Sc.^{1*}, Peronne Joseph, M.Sc.^{3*}, Anil Belur Nagaraj, Ph.D.^{4*} and Analisa Difeo, Ph.D.^{5*}

¹Case Western Reserve University School of Medicine, Cleveland, OH

²Section of Hematology-Oncology, Louis Stokes Veterans Administration Hospital, VA Northeast Ohio Healthcare System, Shaker Heights, OH

³Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH

⁴Mayo Clinic, Rochester, MN

⁵Rogel Cancer Center, University of Michigan, Ann Arbor, MI

[2423 Mice Deficient in \$\beta\$ 2-Glycoprotein I Have a Delayed Time to Thrombosis](#)

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster II

Hematology Disease Topics & Pathways: autoimmune disorders, Diseases, Bleeding and clotting, Hemostasis, Biological Processes, Technology and Procedures, Thrombosis, Immune Disorders, Thromboembolism, Clinically relevant, Thrombotic Disorders, immune mechanism, Vascular Wall, pathogenesis

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Ravi Kumar Alluri, PhD^{1*}, Gabriel L Forbes^{2*}, Suman Kundu, MBA^{3*}, **Alvin H. Schmaier, MD²** and **Keith R McCrae, MD^{3,4}**

¹Cleveland Clinic Lerner Research Institute, Department of Cardiovascular and Metabolic Sciences, Cleveland, OH

²Case Western Reserve University, Cleveland, OH

³Cardiovascular & Metabolic Sciences, Cleveland Clinic, Cleveland, OH

⁴Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

[2428 Prevalence of Venous Thromboembolism in Ambulatory and Non-Ambulatory Patients with Cerebral Palsy](#)

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster II

Hematology Disease Topics & Pathways: Diseases, Adult, Bleeding and clotting, Pediatric, Young Adult, VTE

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Michael Daunov, DO*, Justin Rondinelli, MD*, Sanjay P Ahuja, MD and Nathan Richard Stehouwer, MD*
University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

[2472 Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function](#)

Program: Oral and Poster Abstracts

Session: 502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: Poster II

Hematology Disease Topics & Pathways: HSCs, Therapies, Non-Biological, Biological Processes, Cell Lineage, Clinically relevant, pharmacology, hematopoiesis, senescence

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Sunisa Kongkiatkamon^{1*}, Yihong Guan, PhD^{2*}, Anand Tiwari^{2*}, Phillip J Maciejewski^{2*}, Dale Grabowski, BS^{2*}, Sergei Vatolin, PhD^{2*}, Vera Adema, PhD^{1*}, Cassandra M Kerr, MS^{1*}, Yasunobu Nagata, MD, PhD^{2*},

Milo Co^{1*}, Christina Snider^{2*}, Hassan Awada^{2*}, Jibrán Durrani^{2*}, Yvonne Parker^{2*}, **Daniel J. Lindner^{2*}, Mikkael A. Sekeres, MD, MS³, Valeria Visconte, PhD², James G Phillips, PhD^{1*}, Jarosław P. Maciejewski, MD, PhD² and Babal K. Jha, PhD^{2*}**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2486 Leukemia-Associated HSC Vascular Niche Is Negatively Regulated By PERK of Unfolded Protein Response (UPR)

Program: Oral and Poster Abstracts

Session: 506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells: Poster II

Hematology Disease Topics & Pathways: Diseases, Leukemia, ALL, Biological Processes, Lymphoid Malignancies, hematopoiesis, microenvironment, pathways

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Lan Zhou, MD¹, **Cui Liu, MBBS, PhD^{1*}**, Stanley A Adoro, PhD, BSc, MSc¹, Lechuang Chen, PhD^{2*}, Diana Ramirez, PhD^{3*} and Ge Jin, PhD^{2*}

¹Pathology, Case Western Reserve University, Cleveland, OH

²Department of Biological Sciences, School of Dental Medicine, Case Western Reserve University, Cleveland, OH

³Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH

2499 Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster II

Hematology Disease Topics & Pathways: Diseases, Biological Processes, Clinically relevant, genomics

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Hassan Awada, MD¹, **Shafia Rahman, MBBS², Cassandra M Kerr, MS^{1*}, Jibrán Durrani^{1*}, Vera Adema, PhD^{1*}, Ashwin Kishtagari, MBBS¹, Sunisa Kongkiatkamon^{1*}, Hetty E. Carraway, MD, MBA³, Mikkael A. Sekeres, MD, MS³, Jarosław P. Maciejewski, MD, PhD¹ and Valeria Visconte, PhD⁴**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

2525 Homeobox Transcription Factor Hhex Promotes Myeloid Leukemia in Cooperation with Mutant ASXL1

Program: Oral and Poster Abstracts

Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster II

Hematology Disease Topics & Pathways: Diseases, AML, MDS, Biological Processes, epigenetics, Myeloid Malignancies, molecular interactions, pathogenesis

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Reina Takeda, MD^{1*}, Shuhei Asada, MD, PhD^{1,2*}, Sung-Joon Park, PhD^{3*}, Akihiko Yokoyama, PhD^{4*}, Akinori Kanai, PhD^{5*}, Valeria Visconte, PhD⁶, Courtney Hershberger, BS^{7*}, Yasutaka Hayashi, MD, PhD^{1,8*}, Taishi Yonezawa, MSc^{1*}, Moe Tamura^{1*}, Tomofusa Fukuyama, MD, PhD¹, Akiko Matsumoto^{9*}, Satoshi Yamasaki, PhD⁹, Kenta Nakai, PhD^{3*}, Toshiya Inaba, MD, PhD^{5*}, Tatsuhiko Shibata, MD, PhD^{9*}, Daichi Inoue, MD, PhD^{8*}, Hiroaki Honda, MD, PhD^{2*}, Susumu Goyama, MD, PhD^{1*}, **Jarosław P. Maciejewski, MD, PhD¹⁰ and Toshio Kitamura, MD, PhD^{1,8}**

¹Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

²The Institute of Laboratory Animals, Tokyo Women's Medical University, Tokyo, Japan

³Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

⁴National Cancer Center Tsuruoka Metabolomics Laboratory, Yamagata, Japan

⁵Department of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

⁸Department of Hematology-Oncology, Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Japan

⁹Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

¹⁰Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

2553 Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II

Hematology Disease Topics & Pathways: AML, apoptosis, Biological, Leukemia, Diseases, Non-Biological, Therapies, Biological Processes, Myeloid Malignancies, pharmacology, molecular interactions

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Metis Hasipek, PhD^{1*}, Yihong Guan, PhD^{1*}, Dale Grabowski, BS^{1*}, Jaroslaw P. Maciejewski, MD, PhD², Hetty E. Carraway, MD, MBA³ and Babal K. Jha, PhD^{1*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2595 A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II

Hematology Disease Topics & Pathways: Diseases, AML, therapy sequence, Adult, Therapies, Elderly, Combinations, Study Population, Clinically relevant, Myeloid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Sudipto Mukherjee, MD, PhD, MPH¹, Hong Li^{2*}, Brian P. Hobbs, PhD^{2*}, Aaron T. Gerds, MD, MS³, Anjali S. Advani, MD¹, Hetty E. Carraway, MD, MBA¹, Aziz Nazha, MD⁴, Samjhana Bogati, RN^{5*}, Eric Parsons, RN^{3*}, Benjamin Pannell^{6*}, Matt Kalaycio, MD⁷, Yogenthiran Sauntharajah, MD⁸, Jaroslaw P. Maciejewski, MD, PhD⁹ and Mikkael A. Sekeres, MD, MS¹⁰

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁷Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁸Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

2607 Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II

Hematology Disease Topics & Pathways: Diseases, AML, Adult, Study Population, Myeloid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Jiasheng Wang, MD¹, Kirsten M Boughan, DO², Paolo F Caimi, MD³, Brenda Cooper, MD², Marcos de Lima, MD^{2,4}, Molly M Gallogly, MD, PhD², Ehsan Malek, MD⁵, Leland Metheny III, MD⁶, Folashade Otegbeye, MBBChir, MPH⁷, Shufen Cao^{8*}, Pingfu Fu, PhD^{8*} and Benjamin Tomlinson, MD²

¹Department of Medicine, Metrohealth Medical Center, Cleveland, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals of Cleveland, Cleveland, OH

⁴Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

⁶Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Heights, OH

⁷Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Beachwood, OH

⁸Case Western Reserve University, Cleveland, OH

2650 A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, Clinically relevant, Myeloid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Daniel J. DeAngelo, MD, PhD¹, Harry P. Erba, MD, PhD², Brian A Jonas, MD, PhD³, Michael E O'Dwyer, MD⁴, Paula Marlton, MBBS (Hons), FRACP, FRCPA⁵, Gerwin Huls, MD, PhD^{6*}, Jane L. Liesveld, MD⁷, **Brenda Cooper, MD⁸, Bhavana Bhatnagar, DO⁹, Geoffrey L. Uy, MD¹⁰, Gavin Cull, MB, BS, FRACP, FRCPA¹¹, Michael B. Armstrong, MD, PhD¹², William E. Fogler, PhD¹³, Mary M Chen, MD, PhD¹⁴, John L. Magnani, PhD¹⁵, Helen M Thackray, MD¹⁴, Eric J. Feldman, MD¹⁴, **Anjali S. Advani, MD¹⁶** and Pamela S. Becker, MD, PhD^{17,18,19}**

¹Dana-Farber Cancer Institute, Boston, MA

²Division of Hematologic Malignancy and Cell Therapy, Duke University, Durham

³UC Davis Comprehensive Cancer Center, Sacramento, CA

⁴National University of Ireland Galway, Galway City, Ireland

⁵Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane, Australia

⁶Hematology, University Medical Center Groningen, Groningen, Netherlands

⁷Wilmot Cancer Institute, University of Rochester, Rochester, NY

⁸Seidman Cancer Center, University Hospitals, Cleveland, OH

⁹Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

¹⁰Division of Oncology, Washington University School of Medicine, Saint Louis, MO

¹¹Department of Haematology, Sir Charles Gairdner Hospital Hematology Care Centre, Nedlands, WEA, Australia

¹²QVIA Biotech, Morrisville, NC

¹³Glycomimetics, Inc., Rockville, MD

¹⁴GlycoMimetics Inc., Rockville, MD

¹⁵GlycoMimetics, Inc., Rockville, MD

¹⁶Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁷Division of Hematology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁸University of Washington Institute for Stem Cell and Regenerative Medicine, Seattle, WA

¹⁹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

2651 SEL120 – a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: Adult, Diseases, AML, apoptosis, Therapies, cell regulation, MDS, Biological Processes, epigenetics, Study Population, Myeloid Malignancies, genomics, pathways, signal transduction

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Gautam M. Borthakur, MD¹, William B. Donnellan, MD^{2,3}, Scott R. Solomon, MD⁴, Camille Abboud, MD⁵, **Aziz Nazha, MD⁶, Milena Mazan, PhD^{7*}, Michal Mikula, MD, PhD^{8*}, Eliza Majewska, PhD^{7*}, Katarzyna Wiklik, PhD^{7*}, Aniela Golas, PhD^{7*}, Marcus Järås, PhD⁹, Marion Chapellier, PhD^{9*}, Anna Polak, PhD^{10*}, Arkadiusz Bialas, PhD^{7*}, Renata Windak, PhD^{7*}, Jerzy Ostrowski, Prof., MD, PhD^{8,11*}, Przemyslaw Juszczynski, Prof., MD, PhD^{10*}, **Pawel Chrom, MD, PhD^{7*}**, Tomasz Rzymiski, PhD^{7*} and Krzysztof Brzózka, PhD⁷**

¹University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

²Tennessee Oncology, PLLC, Nashville, TN

³Sarah Cannon Research Institute, Nashville, TN

⁴Leukemia Program, Northside Hospital Cancer Center Institute, Atlanta, GA

⁵Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁷Selvia S.A., Kraków, Poland

⁸Department of Genetics, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warszawa, Poland

⁹Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden

¹⁰Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warszawa, Poland

¹¹Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warszawa, Poland

2690 High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, Combinations, Clinically relevant, Myeloid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Daniel J. DeAngelo, MD, PhD^{1*}, Brian A Jonas, MD, PhD², Jane L. Liesveld, MD³, Dale L. Bixby, MD^{4*}, Anjali S. Advani, MD⁵, Paula Marlton, MBBS (Hons), FRACP, FRCPA⁶, Michael E O'Dwyer, MD⁷, William E. Fogler, PhD⁸, John L. Magnani, PhD⁹, Mary M Chen, MD, PhD¹⁰, Eric J. Feldman, MD¹⁰, Helen M Thackray, MD¹⁰ and Pamela S. Becker, MD, PhD^{11,12,13}

¹Dana-Farber Cancer Institute, Boston, MA

²UC Davis Comprehensive Cancer Center, Sacramento, CA

³Wilmot Cancer Institute, University of Rochester, Rochester, NY

⁴Comprehensive Cancer Center, University of Michigan, Grass Lake, MI

⁵Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁶Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane, Australia

⁷National University of Ireland Galway, Galway City, Ireland

⁸Glycomimetics, Inc., Rockville, MD

⁹GlycoMimetics, Inc., Rockville, MD

¹⁰GlycoMimetics Inc., Rockville, MD

¹¹Division of Hematology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

¹²University of Washington Institute for Stem Cell and Regenerative Medicine, Seattle, WA

¹³Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

2696 RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Hematology Disease Topics & Pathways: Diseases, AML, Myeloid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Christina A. Snider, BA¹, Kevin Fung^{2*}, Francesca Gould^{2*}, Vera Adema, PhD^{2*}, Cassandra M Kerr, MS^{2*}, Sunisa Kongkiatkamon^{2*}, Hassan Awada, MD², Milo Co^{2*}, Teodora Kuzmanovic, BA^{2*}, Bhumika J. Patel, MD³, Aaron T. Gerds, MD, MS⁴, Sudipto Mukherjee, MD, PhD, MPH³, Aziz Nazha, MD⁵, Hetty E. Carraway, MD, MBA³, Tomas Radivoyevitch, PhD^{6*}, Jaroslaw P. Maciejewski, MD, PhD⁷, Valeria Visconte, PhD², Mikkael A. Sekeres, MD, MS⁴ and Anjali S. Advani, MD³

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁶Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

⁷Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

2716 Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, Biological Processes, MDS, DNA damage, Clinically relevant, genomics, Myeloid Malignancies, pathogenesis

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Sanghee Hong, MD¹*, **Cassandra M Kerr, MS²***, **Lisa Rybicki, MS³***, **Valeria Visconte, PhD⁴**, **Jibran Durrani²***, **Hassan Awada, MD²**, **Betty K. Hamilton, MD¹**, **Ronald Sobecks, MD¹**, **Matt Kalaycio, MD⁵**, **Aaron T. Gerds, MD, MS¹**, **Mikkael A. Sekeres, MD, MS⁶**, **Hetty E. Carraway, MD, MBA⁷**, **Sudipto Mukherjee, MD, PhD, MPH⁷**, **Anjali S. Advani, MD⁷**, **Aziz Nazha, MD⁸**, **Navneet S. Majhail, MD, MS¹** and **Jaroslav P. Maciejewski, MD, PhD⁹**

¹Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH

⁵Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁸Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

2720 Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Hematology Disease Topics & Pathways: Diseases, AML, Biological Processes, genomics, Myeloid Malignancies, pathogenesis, signal transduction

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Hassan Awada¹*, **Ashwin Kishtagari, MBBS¹**, **Teodora Kuzmanovic¹***, **Jibran Durrani¹***, **Cassandra M Kerr, MS¹***, **Manja Meggendorfer, PhD²**, **Anjali S. Advani, MD³**, **Aziz Nazha, MD⁴**, **Hetty E. Carraway, MD, MBA³**, **Torsten Haferlach, MD⁵**, **Mikkael A. Sekeres, MD, MS⁶**, **Valeria Visconte, PhD⁷** and **Jaroslav P. Maciejewski, MD, PhD⁸**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁵MLL Munchner Leukamie Labor GmbH, Munchen, Germany

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH

⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

2831 Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways: Diseases, Non-Biological, Therapies, T-Cell Lymphoma, Clinically relevant, Lymphoid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Swaminathan P. Iyer, MD¹, Brad M. Haverkos, MD, MPH, MS², Jasmine Zain, MD³, Radhakrishnan Ramchandren, MD⁴, Mary Jo Lechowicz, MD⁵, Sumana Devata, MD⁶, Neil Korman, MD^{7}, Lauren C. Pinter-Brown, MD⁸, Kasi Viswanath Routhu, PhD^{9*}, Prajak Barde, MD^{9*}, Ajit Mohanchandran Nair^{10*} and Auris Huen, MD^{11*}*

¹Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

²Division of Hematology, University of Colorado, Denver, CO

³City of Hope Medical Center, Duarte, CA

⁴The University of Tennessee Graduate School of Medicine,, Knoxville,, TN

⁵Emory University, Atlanta, GA

⁶Internal Medicine/Hematology/Oncology, University of Michigan, Ann Arbor, MI

⁷Department of Dermatology at Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH

⁸University of California, Beverly Hills, CA

⁹Rhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, Switzerland

¹⁰Rhizen Pharmaceuticals S.A., Switzerland, Switzerland

¹¹The University of Texas MD Anderson Cancer Center, Houston, TX

2836 Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways: Biological, antibodies, Diseases, Therapies, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Lymphoid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Judah Friedman, MD^{1}, Hun Ju Lee, MD², Linda Ho^{3*} and Ian W. Flinn, MD, PhD⁴*

¹Case Western Reserve University, Cleveland, OH

²MD Anderson Cancer Center, Houston, TX

³Seattle Genetics, Inc., Bothell, WA

⁴Sarah Cannon Research Institute, Nashville, TN

2854 Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Hematology Disease Topics & Pathways: Diseases, therapy sequence, Adult, Non-Biological, Therapies, Combinations, chemotherapy, T-Cell Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant

Sunday, Dec 8, 2019, 6-8 P; Hall B, Level 2 (Orange County Convention Center)

Joanna M Rhodes, MD¹, Suchitra Sundaram, MD², Adam Zayac, MD³, Adam J Olszewski, MD⁴, Paolo Caimi, MD⁵, Zachary Braunstein, MD^{6}, Jonathan E Brammer, MD⁷, Waqas Jehangir, MD⁸, Elvira Umyarova, MD⁸, Sheenu Sheela, MD^{9*}, Nilanjan Ghosh, MD, PhD¹⁰, Sunita Dwivedy Nasta, MD¹ and Stefan K. Barta, MD, MRCP, MS¹¹*

¹Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

²Roswell Park Comprehensive Cancer Center, Buffalo, NY

³Division of Hematology/Oncology, The Warren Alpert Medical School of Brown University, Providence, RI

⁴Alpert Medical School of Brown University, Providence, RI

⁵University Hospitals Seidman Cancer Center, Cleveland, OH

⁶The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Division of Hematology, Columbus, OH

⁷The Ohio State University James Comprehensive Cancer Center, Columbus, OH

⁸The University of Vermont Medical Center, Burlington, VT

⁹Levine Cancer Institute, Atrium Health, Charlotte, NC

¹⁰Levine Cancer Institute, Charlotte, NC

¹¹Lymphoma Department, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

2891 Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster II

Hematology Disease Topics & Pathways: Diseases, Biological Processes, Technology and Procedures, B-Cell Lymphoma, DLBCL, Clinically relevant, Lymphoid Malignancies, genomics, NGS, RNA sequencing, pathways

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Maher Albitar, MD¹, Zijun Yidan Xu-Monette, PhD^{2*}, Babak Shahbaba, PhD^{3*}, Ivan De Dios, BS^{4*}, Yingjun Wang^{2*}, Deng Manman, MD^{5*}, Alexandar Tzankov, MD^{6*}, Carlo Visco^{7*}, Govind Bhagat, M.D.⁸, Karen Dybkær, PhD^{9*}, Wayne Tam, MD, PhD¹⁰, Eric D. Hsi, MD¹¹, Maurilio Ponzoni, MD¹², Andres JM Ferreri, MD¹³, Michael Moller^{14*}, Miguel A. Piris^{15*}, Joannes H.J.M. Van Krieken, PhD, MD^{16*}, Youli Zu, MD, PhD^{17*}, Wanlong Ma^{4*}, Hagop M. Kantarjian, MD¹⁸, Yong Li, PhD¹⁹ and Ken H. Young, MD, PhD²⁰

¹Genomic Testing Cooperative, Valley Center, CA

²Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX

³Donald Bren School of Information and Computer Sciences, University of California, Irvine, CA

⁴Genomic Testing Cooperative, Irvine, CA

⁵MD Anderson Cancer Center, Houston, TX

⁶University Hospital Basel, Basel, Switzerland

⁷Department of Medicine, section of Hematology, University of Verona, Verona, Italy

⁸Columbia University Medical Center, New York, NY

⁹Department of Hematology, Aalborg University Hospital, Aalborg, Denmark

¹⁰Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY

¹¹Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH

¹²Pathology Unit, San Raffaele Scientific Institute, Milano, Italy

¹³San Raffaele Hospital, Milan, Italy

¹⁴Odense University Hospital, Odense, Denmark

¹⁵Instituto de Investigación Marqués De Valdecilla, Santander, Spain

¹⁶University Hospital Nijmegen, Nijmegen, NLD

¹⁷Houston Methodist Hospital, Houston, TX

¹⁸M.D. Anderson Cancer Center, Houston, TX

¹⁹Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

²⁰Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

2984 Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways: Diseases, CMML, Xenograft models, Study Population, Clinically relevant, Myeloid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Hannah Newman, BS^{1*}, Anthony M. Hunter, MD^{2*}, Christopher Letson, BS¹, Amy E. DeZern, MD³, Maria E Balasis^{1*}, William Dominguez-Viqueira, PhD^{4*}, Alexis Vedder, BS^{1*}, Traci Kruer, PhD¹, Jeffrey E. Lancet, MD², Alan F. List, MD², Gail J. Roboz, MD⁵, David P. Steensma, MD⁶, Mikkael A. Sekeres, MD, MS⁷, Rami S. Komrokji, MD^{8,9,10} and Eric Padron, MD⁸

¹H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

²Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

³Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

⁴Small Animal Imaging Lab (SAIL), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁵Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY

⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁸Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁹Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

¹⁰Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

2985 Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II
Hematology Disease Topics & Pathways: Diseases, MDS, Biological Processes, Clinically relevant, Myeloid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Vera Adema, PhD^{1}, Courtney E Hershberger, BS^{2*}, Wencke Walter, PhD^{3*}, Cassandra M Kerr, MS^{4*}, Stephan Hutter, PhD^{3*}, Yasunobu Nagata, MD, PhD^{1,4*}, Hassan Awada^{1*}, Sunisa Kongkiatkamon^{4*}, Christina Snider^{1*}, Milo Co^{4*}, Manja Meggendorfer, PhD³, Aziz Nazha, MD⁵, Hetty E. Carraway, MD, MBA⁶, Mikkael A. Sekeres, MD, MS⁷, Francesc Sole, PhD⁸, Richard A Padgett, PhD^{2*}, Torsten Haferlach, MD⁹, Jaroslaw P. Maciejewski, MD, PhD^{10,11} and Valeria Visconte, PhD⁴*

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

²Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, OH

³MLL Munich Leukemia Laboratory, Munich, Germany

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁸MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

⁹MLL Munchner Leukämie Labor GmbH, Munchen, Germany

¹⁰Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

2992 Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II

Hematology Disease Topics & Pathways: Diseases, Biological Processes, MDS, Technology and Procedures, genomics, Myeloid Malignancies, genetic profiling, molecular testing, NGS, molecular interactions

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Yasunobu Nagata, MD, PhD^{1}, Hideki Makishima, MD, PhD², Cassandra M Kerr, MS^{3*}, Bhumika J. Patel, MD⁴, Hassan Awada^{5*}, Vera Adema, PhD^{1*}, Valeria Visconte, PhD¹, Sudipto Mukherjee, MD, PhD, MPH⁶, Thomas Laframboise, PhD^{7*}, Aziz Nazha, MD⁸, Tomas Radivoyevitch, PhD^{1*}, Mikkael A. Sekeres, MD, MS⁹, Seishi Ogawa, MD, PhD¹⁰ and Jaroslaw P. Maciejewski, MD, PhD¹¹*

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Dept. of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁶Leukemia Program, Dept. of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁷Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁸Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁰Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

¹¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

2999 Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Hematology Disease Topics & Pathways: Diseases, MDS, Biological Processes, Technology and Procedures, Myeloid Malignancies, genetic profiling, hematopoiesis

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Uwe Platzbecker^{1*}, *Diana Dunshee*^{2*}, *Rami S. Komrokji*, MD^{3,4,5}, *Ghulam J. Mufti*^{6*}, *Guillermo Garcia-Manero*, MD⁷, *Rena Buckstein*, MD, FRCPC⁸, *Valeria Santini*, MD⁹, *María Díez-Campelo*, MD, PhD^{10*}, **Mikael A. Sekeres, MD, MS**¹¹, *Wendy L. See*^{2*}, *Kevin Tsai*^{2*}, *Alberto Risueño*^{2*}, *Jianglin Ma*^{2*}, *Martin Schwickart*^{2*}, *Anita Rampersad*^{12*}, *Jennie Zhang*^{12*}, *Abderrahmane Laadem*¹², *Daniel Menezes*^{2*}, *Kyle MacBeth*, PhD², *Peter G. Linde*¹³, *Joseph G. Reynolds*, PhD^{13*}, *Alan F. List*, MD¹⁴ and *Pierre Fenau*, MD, PhD^{15,16}

¹Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany, Germany

²Celgene Corporation, San Francisco, CA

³Division of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

⁴Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

⁵Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁶Department of Haemato-Oncology, King's College London, London, United Kingdom

⁷Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

⁸Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

⁹MDS Unit, AOU Careggi-University of Florence, Firenze, FI, Italy

¹⁰Hematology Department, University Hospital of Salamanca, Salamanca, Spain

¹¹Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹²Celgene Corporation, Summit, NJ

¹³Acceleron Pharma, Cambridge, MA

¹⁴Moffitt Cancer Center, Tampa, FL

¹⁵Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

¹⁶Université Paris 7, Paris, France

3048 Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, Study Population, Lymphoid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Mazyar Shadman, MD, MPH^{1*}, *Kavita Sail*, PhD^{2*}, *Beenish S Manzoor*, PhD^{2*}, *Maryam Sarraf Yazdy*, MD³, **Brian T. Hill, MD**⁴, *Hande H. Tuncer*, MD^{5*}, *John N. Allan*, MD⁶, *Chaitra S. Ujjani*, MD¹, *Nnadozie Emechebe*, MPH^{2*}, *Rajesh Kamalakar*, MS^{2*}, *Simon Sharmokh*, MPH, PharmD^{2*}, *Daniel Dingfeng Jiang*, MD, PhD^{2*}, *German Pena*, MD^{2*}, *Thomas Marshall*, PharmD, MS^{2*}, *Jacqueline Nielsen*, PhD^{2*}, *Paul M. Barr*, MD⁷, *Jennifer R. Brown*, MD, PhD^{8*}, *Anna Schuh*, MD⁹, *Toby A. Eyre*, MD^{9*}, *Nicole Lamanna*, MD^{10*}, *William G. Wierda*, MD, PhD¹¹, *Alan Skarbnik*, MD¹², *Lindsey E. Roeker*, MD¹³, *Rajat Bannerji*, MD, PhD¹⁴, *James M. Pauff*, MD, PhD², *Stephen J. Schuster*, MD¹⁵, *George A Follows*, MD, PhD^{16*}, *Bruce D. Cheson*, MD¹⁷, *Barbara F. Eichhorst*, MD¹⁸, *Danielle M. Brander*, MD¹⁹, *Irina Pivneva*, PhD^{20*}, *Annie Guerin*, MSc^{20*} and *Anthony R. Mato*, MD MSCE^{13,21}

¹Fred Hutchinson Cancer Research Center, Seattle, WA

²AbbVie, Inc., North Chicago, IL

³Georgetown University Hospital, Washington, DC

⁴Cleveland Clinic, Cleveland, OH

⁵The Cancer Center at Lowell General Hospital, Lowell General Hospital, Lowell, MA

⁶Weill Cornell Medicine University Medical Center, New York, NY

⁷Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

⁸Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

⁹Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

¹⁰Columbia University, New York, NY

¹¹MD Anderson Cancer Center, Houston, TX

¹²Novant Health, Charlotte, NC

¹³CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

¹⁴Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

¹⁵Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

¹⁶Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom

¹⁷Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC

¹⁸Department of Internal Medicine, Center of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany

¹⁹Duke Cancer Center, Duke University Medical Center, Durham, NC

3148 External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: multiple myeloma, Diseases, Plasma Cell Disorders, Lymphoid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Fahrettin Covut, MD¹, Ramsha Ahmed, MD^{2}, Christy J. Samaras, DO³, Faiz Anwer, MD³, Alex V. Mejia Garcia, MD³, Dana E Angelini, MD⁴, Beth M. Faiman, PhD, CNP³, Janice Reed, RN^{3*}, Mary Ann Karam, RN^{3*}, Kristen Schlueter, RN^{3*}, Saveta Mathur, CNP^{3*}, Kimberly Hamilton, APRN/PA^{3*}, Nathaniel Rosko, PharmD^{3*}, Jason Valent, MD³ and Jack Khouri, MD³*

¹Department of Internal Medicine, Case Western Reserve University, Cleveland, OH

²Department of Internal Medicine, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

3150 Comparative Efficacy and Safety of Once Versus Twice Weekly Carfilzomib Based Therapies in Relapsed Refractory Multiple Myeloma- a Systematic Review

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: multiple myeloma, Biological, Diseases, Therapies, Adverse Events, chemotherapy, enzyme inhibitors, Plasma Cell Disorders, Lymphoid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Saif Ur Rehman, MBBS, MD^{1}, Saad Sharif, MBBS, MD^{2*}, Syeda Sabeeka Batool, MBBS, MD³, Hamza Bajwa, MBBS, MD^{1*}, Arafat Ali Ali Farooqui, MD^{1*}, Zahoor Ahmed, MBBS, MD^{1*}, Ahmad Anjum, MD^{4*}, Talha Bin Farooq, MD^{4*}, Samana Mukhtar, MBBS, MD^{5*}, Sibgha Gull Chaudhary, MD^{6*}, Muhammad Junaid Tariq, MD^{7*}, Tariq Iqtidar Sadiq Syed, MD^{8*}, Syed Maaz Abdullah, MBBS^{9*}, Muhammad Salman Faisal, MD, MBBS^{10*} and Faiz Anwer, MD¹¹*

¹King Edward Medical University, Lahore, Pakistan

²Farooq hospital, Lahore, Lahore, Pakistan

³UAB-Huntsville Regional Medical Campus, Huntsville, AL

⁴Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan

⁵Allama Iqbal Medical College, Lahore, Pakistan

⁶St. Luke's hospital, Chesterfield, MO

⁷Department of Internal Medicine, John H. Stroger Jr. Hospital of Cook County, Chicago, IL

⁸Cleveland Clinic, Taussig Center, Cleveland, OH

⁹King Edward Medical University, Lahore, Punjab, Pakistan

¹⁰Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA

¹¹Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

3174 Impact of Previous Cancer Therapy on Outcome of Patients with Multiple Myeloma or Smoldering Disease

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: Biological Processes, pathways

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

*Fahrettin Covut, MD¹, Gayathri Ravi, MD², **James Driscoll, MD, PhD³**, **Marcos de Lima, MD⁴** and **Ehsan Malek, MD⁵***

¹Department of Internal Medicine, Case Western Reserve University, Cleveland, OH

²University Hospitals Seidman Cancer Center, Cleveland, OH

³Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH

3232 Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF- β Signaling Pathway

Program: Oral and Poster Abstracts

Session: 704. Immunotherapies: Poster II

Hematology Disease Topics & Pathways: Biological Processes, Biological Processes, pathways, pathways
Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Ehsan Malek, MD¹, Sunjin Hwang, MD^{2*}, Marcos de Lima, MD³, Paolo Caimi, MD^{3*}, Molly M Gallogly, MD, PhD³, Leland Metheny III, MD³, Folashade Otegbeye, MBBChir, MPH⁴, Benjamin K. Tomlinson, MD³, Kirsten M Boughan, DO³, Brenda Cooper, MD³, James Driscoll, MD, PhD⁵ and John Letterio, MD^{6*}

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

²MedPacto, Suwon, KOR

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

⁵Division of Hematology & Oncology, University of Cincinnati, Cincinnati, OH

⁶Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

3264 Pre-Transplant Fecal Microbial Diversity Independently Predicts Critical Illness after Hematopoietic Cell Transplantation

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

Hematology Disease Topics & Pathways: Adult, Biological, Therapies, Biological Processes, Technology and Procedures, Study Population, Clinically relevant, immune mechanism, transplantation, NGS
Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Fatima I. Adhi, MD^{1,2*}, Eric R. Littmann, BA^{2*}, Ying Taur, MD, MPH^{3*}, Molly A. Maloy, MS^{4*}, Kate A Markey, PhD, MBBS, FRACP², Emily Fontana, BA^{5*}, Luigi A Amoretti, B.S.^{2*}, Roberta Wright, M.S., M.B.S.^{2*}, Miriam Sanchez-Escamilla, MD^{6*}, Nerea Castillo Flores, MD, PhD^{2*}, Ana Alarcon Tomas, MD^{2*}, Richard J Lin, MD, PhD², Lucrecia Yáñez, MD, PhD^{2*}, Daniel Brereton, B.A.^{2*}, Annelie Clurman, BA^{4*}, John B. Slingerland, BSc^{2*}, Gunjan L. Shah, MD⁶, Christina Cho, MD⁶, Michael Scordo, MD⁶, Ioannis Politikos, MD⁶, Boglarka Gyurkocza, MD², Doris M Ponce, MD⁴, Juliet Barker, MBBS⁴, Miguel-Angel Perales, MD⁴, Sergio A Giralt, MD⁶, Marcel R.M. van den Brink, MD, PhD⁴, Eric G. Pamer, MD^{3*} and Jonathan U. Peled, MD, PhD⁴

¹Cleveland Clinic, Cleveland, OH

²Memorial Sloan Kettering Cancer Center, New York, NY

³Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

⁴Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

⁵Sloan Kettering Institute, Lucille Castori Center for Microbes, Inflammation & Cancer, Memorial Sloan Kettering Cancer Center, New York, NY

⁶Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

3294 Cathelicidin Antimicrobial Peptide Expression Is Inversely Associated with Absolute Neutrophil Counts in Pediatric HCT Recipients

Program: Oral and Poster Abstracts

Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II

Hematology Disease Topics & Pathways: Diseases, Pediatric, Biological Processes, white blood cells, immunodeficiency, Cell Lineage, Immune Disorders, Study Population, Clinically relevant, Neutropenia, immune mechanism, white blood cell disorders

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Jos Domen, PhD^{1*}, Hung-Wen Yeh, PhD^{1*}, Nancy L Shreve^{1*}, Lei Sun, MD^{1*}, Yongwu Li, MD^{1*}, Katrina D Walters, CCRC^{1*}, Jignesh Dalal, MD² and Rakesh K. Goyal, MBBS, MD, MRCP¹

¹Children's Mercy Kansas City, Kansas City, MO

²Rainbow Babies & Children's Hospital, Cleveland, OH

3323 Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster II

Hematology Disease Topics & Pathways: Clinically relevant

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

BU, Mei-Jie Zhang^{2*}, Hany Elmariah, MD, MS³, Mariam H Johnson, MPH^{2*}, Andrew St. Martin, MS^{2*}, Asad Bashey, MD, PhD⁴, Javier Bolanos-Meade, MD⁵, Christopher Bredeson, MD, FRCPC, MSc⁶, Edward A Copelan⁷, Biju George, MD, DM⁸, Vikas Gupta, MD, FRCP, FRCPath⁹, Christopher G. Kanakry, MD^{10*}, Rohtesh S. Mehta, MD¹¹, Minoo Battiwalla, MD¹², Alberto Mussetti^{13*}, Ryotaro Nakamura, MD¹⁴, Taiga Nishihori, MD¹⁵, Wael Saber, MD, MS¹⁶, Melhem Solh, MD⁴, Benjamin K. Tomlinson, MD¹⁷, Daniel J. Weisdorf, MD¹⁸ and Mary Eapen, MBBS, MS²

¹Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC

²Medical College of Wisconsin, Milwaukee, WI

³H. Lee Moffitt Cancer Center, Tampa, FL

⁴Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA

⁵Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Kimmel Cancer Center, Ellicott City, MD

⁶Division of Hematology, Department of Medicine, University of Ottawa, The Ottawa Hospital and the Ottawa Hospital Research Institute, Ottawa, ON, Canada

⁷Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC

⁸Department of Haematology, Christian Medical College, Vellore, Tamilnadu, India

⁹Princess Margaret Cancer Centre, Toronto, ON, Canada

¹⁰Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

¹¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

¹²Hematology Branch, Sarah Cannon BMT Program, Nashville, TN

¹³Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

¹⁴Department of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, Beckman Research Institute., City of Hope Nat'l Med. Ctr., Duarte, CA

¹⁵Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

¹⁶CIBMTR, Medical College of Wisconsin, Milwaukee, WI

¹⁷Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

¹⁸Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

3373 International Multi-Site Clinical Validation of Point-of-Care Microchip Electrophoresis Test for Hemoglobin Variant Identification

Program: Oral and Poster Abstracts

Session: 803. Emerging Diagnostic Tools and Techniques: Poster II

Hematology Disease Topics & Pathways: sickle cell disease, Adult, Diseases, sickle cell trait, Pediatric, Hemoglobinopathies, Technology and Procedures, Young Adult, Study Population, Clinically relevant, newborn screening

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Arwa Fraiwan, PhD¹, Muhammad Noman Hasan, MS^{1*}, Ran An, PhD^{1*}, Julia Z. Xu, MD, MSc², Amy J. Rezac^{3*}, Nicholas J. Kocmich^{3*}, Tolulope Oginni, BS^{4*}, Grace Mfon Olanipekun^{5*}, Fatimah Hassan-Hanga, MD^{6*}, Binta W. Jibir, MBBS MPH^{7*}, Safiya Gambo, MBBS^{8*}, Anil K. Verma^{9*}, Praveen K. Bharti^{9*}, Suchada Riolveang, MSc^{10*}, Takdanai Ngimhung^{11*}, Thidarat Suksangpleng, PhD¹⁰, Priyaleela Thota, MD^{12*}, Rajasubramaniam Shanmugam, PhD^{9*}, Aparup Das, PhD^{9*}, Vip Viprakasit, MD, DPhil^{10*}, Connie M. Piccone, MD¹³, Jane A. Little, MD^{14*}, Stephen K. Obaro, MD, PhD^{3,5*} and Umut A. Gurkan, PhD¹⁵

¹Case School of Engineering, Case Western Reserve University, Cleveland, OH

²Department of Medicine, Duke University Medical Center, Durham, NC

³Division of Pediatric Infectious Diseases, University of Nebraska Medical Center, Omaha, NE
⁴Health Africa, Kano, Nigeria
⁵International Foundation Against Infectious Disease in Nigeria, Abuja, Nigeria
⁶Aminu Kano Teaching Hospital, Kano, Nigeria
⁷Hasiya Bayero Pediatric Hospital, Kano, Nigeria
⁸Murtala Mohammed Specialist Hospital, Kano, Nigeria
⁹ICMR-National Institute of Research in Tribal Health, Jabalpur, India
¹⁰Siriraj-Thalassemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
¹¹Siriraj Thalassemia Center, Mahidol University, Bangkok, Thailand
¹²Hemex Health Inc., Portland, OR
¹³University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH
¹⁴University of North Carolina, Chapel Hill, NC
¹⁵Case Western Reserve University, Cleveland, OH

3400 Lymphoma-Associated Pulmonary Embolism Burden in Hospital Admissions in the United States

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster II

Hematology Disease Topics & Pathways: Diseases, Adult, Bleeding and clotting, Lymphoma (any), Thrombosis, Study Population, Thromboembolism, Lymphoid Malignancies, VTE

Sunday, Dec 8, 2019, 6-8PM; Hall B, Level 2 (Orange County Convention Center)

Khalid Shalaby, MBBCh¹, Adriana Kahn, MD^{1*}, Elizabeth Silver^{2*}, Kathir Balakumaran, MD^{3*} and Agnes S. Kim, MD, PhD^{4*}

¹Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, CT

²University of Connecticut, School of Medicine, Farmington, CT

³Advanced Heart Failure and Transplant Cardiology, University Hospitals Cleveland Medical Center, Cleveland, OH

⁴Calhoun Cardiology Center, University of Connecticut Health Center, Farmington, CT

3433 Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Program: Oral and Poster Abstracts

Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster II

Hematology Disease Topics & Pathways: Diseases, AML, Quality Improvement, Myeloid Malignancies

Sunday, Dec 8, 2019, 6-PM; Hall B, Level 2 (Orange County Convention Center)

Caitlin Siebenaller, PharmD^{1*}, Madeline Waldron, PharmD, BCOP^{2*}, Kelly Gaffney, PharmD^{1*}, Brian P. Hobbs, PhD^{3*}, Ran Zhao^{3*}, Marc Earl, PharmD^{1*}, Marina Feldman, PharmD, BCCCP^{1*}, Hetty E. Carraway, MD, MBA⁴, Anjali S. Advani, MD⁴, Aziz Nazha, MD⁵, Aaron T. Gerds, MD, MS⁶, Bhumi J. Patel, MD⁴, Betty K. Hamilton, MD⁷, Ronald Sobecks, MD⁸, Matt Kalaycio, MD⁹, Mikkael A. Sekeres, MD, MS⁶ and Sudipto Mukherjee, MD, PhD, MPH⁴

¹Department of Pharmacy, Cleveland Clinic, Cleveland, OH

²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁸Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

3448 Impaired Bone Health and Wound Dehiscence in Carriers of Hemophilia a and B

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Non-Malignant Conditions: Poster II

Hematology Disease Topics & Pathways: Diseases, Hemophilia, Bleeding and clotting, Clinically relevant

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Divyaswathi Citla Sridhar, MD¹, Yazan Abou-Ismael, MD², Sindhoosha Malay, MPH, PharmD^{3*} and Sanjay P Ahuja, MD⁴

¹University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

²University Hospitals, Case Western Reserve University, Cleveland, OH

3458 Clinical Outcomes of Cancer-Associated Thrombosis Beyond 6 Months of Anticoagulation

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Non-Malignant Conditions: Poster II

Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, Thrombosis, VTE

Sunday, Dec 8, 2019, 6-8PM; Hall B, Level 2 (Orange County Convention Center)

Shyam K Poudel^{1*}, Chandana A Reddy, MS^{2*}, Deborah Y Park, BS^{3*}, Mailey L Wilks, CNP, MSN, APRN^{4*}, Vicki Pinkava, MSBS, PA-C^{4*}, Meghan O'Brien, MS, ANP-BC^{4*}, Barbara Tripp, CNS^{4*}, Jung-Min Song, RN, CNS^{4*}, Keith R McCrae, MD⁴, Alok A Khorana, MD⁴ and Dana E Angelini, MD⁴

¹Department of Internal Medicine, Western Reserve Health Education, Youngstown, OH

²Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH

³Cleveland Clinic Lerner College of Medicine, Cleveland, OH

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

3465 A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Non-Malignant Conditions: Poster II

Hematology Disease Topics & Pathways: Biological, Therapies, Non-Biological, enzyme inhibitors, Clinically relevant, Quality Improvement

Sunday, Dec 8, 2019, 6-8PM; Hall B, Level 2 (Orange County Convention Center)

Muhammad Zain Farooq, MD, MBBS¹, Prasanth Lingamaneni^{2*}, Saira Farid, MD^{3*}, Muhammad Saad Farooq, MBBS^{4*}, Ishaan Vohra, MD^{1*}, Asim Tameez Ud Din, MD, MBBS^{5*} and Ankit Mangla, MBBS, MD⁶

¹John H. Stroger Hospital of Cook County, Chicago, IL

²John H Stroger Hospital of Cook County, Chicago, IL

³Medstar Washington Hospital Center/ Georgeown University Hospital, Silver Spring, MD

⁴Dow University of Health Sciences, Karachi, Pakistan

⁵Rawalpindi Medical University, Rawalpindi, Pakistan

⁶Division of Hematology and Oncology, Case Western Reserve University, School of Medicine, Cleveland, OH

3483 Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster II

Hematology Disease Topics & Pathways: Diseases, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Clinically relevant, Lymphoid Malignancies

Sunday, Dec 8, 2019, 6-8PM; Hall B, Level 2 (Orange County Convention Center)

Jonathon B. Cohen, MD, MS¹, Jeffrey M. Switchenko, PhD, MS^{2*}, Krithika Shanmugasundaram, MD³, Subir Goyal^{4*}, Oscar Calzada, BS^{1*}, Michael C. Churnetski^{5*}, Bhaskar Kolla, MBBS⁶, Veronika Bachanova, MD, PhD⁶, James N. Gerson, MD⁷, Stefan K. Barta, MD, MRCP, MS⁸, Max J. Gordon, MD⁹, Alexey Danilov, MD, PhD¹⁰, Natalie S Grover, MD¹¹, Stephanie Mathews, MD^{12*}, Madelyn Burkart, MD^{13*}, Reem Karmali, MD¹⁴, Yazeed Sawalha, MD¹⁵, **Brian T. Hill, MD¹⁶, Nilanjan Ghosh, MD, PhD¹⁷, Steven I Park, MD¹⁸, Narendranath Epperla, MD, MS¹⁹, David A. Bond, MD²⁰, Talha Badar, MD²¹, Kristie A. Blum, MD²², Mehdi Hamadani, MD²¹, Timothy S. Fenske, MD²³, Mary-Kate Malecek, MD²⁴, Peter Martin, FRCPC, MD, MS²⁵, Jin Guo, MD²⁶, Christopher R. Flowers, MD, MS²² and Brad S. Kahl, MD²⁷**

¹Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

²Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA

³Emory University School of Medicine, Atlanta, GA

⁴Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA

⁵Winship Cancer Institute, Emory University Medical Center, Atlanta, GA

⁶Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

⁷Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

⁸Lymphoma Department, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁹Oregon Health and Science University, Portland, OR
¹⁰Knight Cancer Institute, Oregon Health & Science University, Portland, OR
¹¹Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
¹²University of North Carolina, Chapel Hill, NC
¹³Northwestern University; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago
¹⁴Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
¹⁵Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
¹⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
¹⁷Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
¹⁸Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC
¹⁹The Ohio State University James Comprehensive Cancer Center, Columbus, OH
²⁰James Cancer Center, The Ohio State University Hospital, Columbus, OH
²¹Medical College of Wisconsin, Milwaukee, WI
²²Winship Cancer Institute, Emory University, Atlanta, GA
²³Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
²⁴Department of Medicine, Washington University School of Medicine, St. Louis, MO
²⁵Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY
²⁶Department of Medicine, Weill Cornell Medicine, New York, NY
²⁷Department of Medicine, Washington University School of Medicine in St. Louis, Saint Louis, MO

3499 Real-World Treatment Patterns and Transfusion Burden Among US Patients with Newly Diagnosed Myelodysplastic Syndromes (MDS)

Program: Oral and Poster Abstracts

Session: 906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster II

Hematology Disease Topics & Pathways:Diseases, MDS, Myeloid Malignancies

Sunday, Dec 8, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Sudipto Mukherjee, MD, PhD, MPH¹, S. Lane Slabaugh^{2*}, Ronda Copher^{3*}, Jonathan Johnson^{4*}, Paul Buzinec^{4*} and Elizabeth S. Mearns^{3*}

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Celgene Corporation, Louisville, KY

³Celgene Corporation, Summit, NJ

⁴Optum Life Sciences, Eden Prairie, MN

3514 A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Program: Oral and Poster Abstracts

Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III

Hematology Disease Topics & Pathways:Anemias, Diseases, PNH

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Austin Kulasekararaj, MBBS MD MRCP FRCPath^{1,2}, Antonio M. Risitano, MD, PhD³, Jaroslaw P.

Maciejewski, MD, PhD⁴, Rosario Notaro, MD^{5,6*}, Peter Browett, BMedSci, MBChB, FRACP, FRCPA⁷, Jong-Wook Lee, MD⁸, Mingjun Huang, PhD^{9*}, Michael Geffner, MD¹⁰ and Robert A. Brodsky, MD¹¹

¹Department of Haematology, King's College Hospital, London, GBR

²King's College London, London, United Kingdom

³Federico II University, Naples, Italy

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁵Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

⁶Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Firenze, Italy

⁷Department of Molecular Medicine and Pathology, University of Auckland School of Medicine, Auckland, NZL

⁸Department of Hematology, Seoul St. Mary's Hospital Catholic University of Korea, Seoul, South Korea

⁹Achillion Pharmaceuticals, Inc, New Haven, CT

¹⁰Achillion Pharmaceuticals Inc, Blue Bell, PA

¹¹Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD

3534 Iron Catalyzed Hydrogen Sulfide and Its Prevalence during Oxidative Events in Sickle Cell Disease

Program: Oral and Poster Abstracts

Session: 102. Regulation of Iron Metabolism: Poster III

Hematology Disease Topics & Pathways: anticoagulant drugs, Biological, sickle cell disease, Diseases, Non-Biological, Therapies, chemical interactions, Biological Processes, Hemoglobinopathies, iron metabolism, pathogenesis, signal transduction

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Jie Yang, PhD¹, Nazmin Bithi, B.Sc^{1*}, Christopher Link, B.Sc^{1*}, Yogenthiran Sauntharajah, MD² and Christopher Hine, PhD^{1*}

¹Lerner Research Institute Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

3607 Small Molecule Screening Identifies Rho-Associate Protein Kinase (ROCK) As a Regulator of NK Cell Cytotoxicity Against Cancer

Program: Oral and Poster Abstracts

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster III

Hematology Disease Topics & Pathways: Biological, therapy sequence, Therapies, Combinations, Biological Processes, NK cells, immune mechanism, pathways

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Grace Lee^{1*}, Sheela Karunanithi^{2*}, Zachary Jackson^{1*} and David Wald, MD, PhD^{2*}

¹Pathology, Case Western Reserve University, Cleveland, OH

²Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

3614 Modulation of Thrombin-Induced Platelet Activation By Defibrotide

Program: Oral and Poster Abstracts

Session: 301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: Poster III

Hematology Disease Topics & Pathways: anticoagulant drugs, Diseases, Non-Biological, Therapies, Bleeding and clotting, Thrombotic Disorders

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Kristin N. Maher, MD, PhD¹, Xu Han, BS, MS², Keith B. Neeves, PhD³, Marvin T. Nieman, PhD² and Jorge Di Paola, MD⁴

¹Department of Pediatrics Section of Hematology, Oncology and Bone Marrow Transplantation, University of Colorado School of Medicine, Denver, CO

²Department of Pharmacology, Case Western Reserve University, Cleveland, OH

³Department of Bioengineering, University of Colorado School of Medicine, Aurora, CO

⁴Department of Pediatrics Section of Hematology, Oncology and Bone Marrow Transplantation, University of Colorado School of Medicine, Aurora, CO

1129 Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Program: Oral and Poster Abstracts

Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster III

Hematology Disease Topics & Pathways: Hemophilia, Diseases, Bleeding Disorders, Bleeding and clotting, Clinically relevant, Quality Improvement

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Jonathan M. Ducore, MD, MPH^{1,2}, Shadan Lalezari, PhD^{3*}, Elena Santagostino, MD, PhD⁴, Sanjay P Ahuja, MD⁵, Monika Maas Enriquez^{6*}, Claudia Tueckmantel, PhD^{6*} and Mark Reding^{7*}

¹Hemostasis and Thrombosis Center, UC Davis, Sacramento, CA

²Hemophilia Treatment Center, UC Davis, Sacramento, CA

³National Hemophilia Center, Tel Hashomer, Israel

⁴A. Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca' Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy

⁵University Hospitals Case Medical Center, Cleveland

⁶Bayer AG, Wuppertal, Germany

⁷Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN

3621 High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice

Program: Oral and Poster Abstracts

Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster III

Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, Thrombotic Disorders

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

*Michael Wayne Henderson, MSc¹, Erica Sparkenbaugh, PhD, BS², Denis Noubouossie, MD, PhD², Reiner Mailer³, Thomas Renne, MD, PhD³, **Keith R McCrae, MD⁴**, Nigel S. Key, MBChB, FRCP² and Rafal Pawlinski, PhD⁵*

¹Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

²Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

³University Medical Center Hamburg, Hamburg, Germany

⁴Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

⁵Department of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC

3643 Identifying miRNA Biomarkers and Predicted Targets Associated with Venous Thromboembolism in Colorectal Cancer Patients

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster III

Hematology Disease Topics & Pathways: Diseases, Adult, Bleeding and clotting, Biological Processes, Thrombosis, Technology and Procedures, Study Population, Thromboembolism, NGS, microenvironment, molecular interactions, RNA sequencing, pathways

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

*Ann S. Kim, BA¹, Matthew F Kalady, MD², Jennifer DeVecchio³, Kahraman Tanriverdi⁴, Jane E. Freedman, MD⁴, John Barnard, PhD⁵, **Tae Hyun Hwang, PhD⁶, Alok A Khorana, MD¹ and Keith R McCrae, MD¹***

¹Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

²Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Digestive Disease and Surgery Institute, Cancer Biology Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

³Cancer Biology Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Medicine, University of Massachusetts Medical School, Worcester, MA

⁵Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland

⁶Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

3648 Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster III

Hematology Disease Topics & Pathways: Diseases, Biological, Bleeding and clotting, Therapies, Adverse Events, Biological Processes, checkpoint inhibitors, immune cells, Cell Lineage, Study Population, Clinically relevant, Thromboembolism, Myeloid Malignancies, immune mechanism

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

*Shadi Swaidani, MD, PhD^{1,2}, Joanna Roopkumar, MBBS, MPH³, Young Jun-Shim, PhD¹, Cathy Charles¹, Slato Paul¹, Suman Kundu, MBA¹, Pauline Funchain, MD³, Patricia Rayman², Paul G. Pavicic², C. Marcela Diaz-Montero, PhD², **Alok A Khorana, MD³ and Keith R McCrae, MD^{1,4}***

¹Cardiovascular & Metabolic Sciences, Cleveland Clinic, Cleveland, OH

²Inflammation and Immunity, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

3651 Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study

Program: Oral and Poster Abstracts

Session: 331. Pathophysiology of Thrombosis: Poster III

Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, Thrombosis, Clinically relevant, VTE

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Lorenzo Gervaso, MD^{1,2*}, Shyam K Poudel, MD^{1,3*}, Joanna Roopkumar, MBBS, MPH^{4*}, Chandana A Reddy, MS^{5*}, Nathan A Pennell, MD, PhD^{1*}, Vamsidhar Velcheti, MD^{6*}, Keith R McCrae, MD¹ and Alok A Khorana, MD¹

¹Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²ICS Maugeri - Translational Oncology, University of Pavia, Pavia, Italy

³Western Reserve Health Education, Youngstown, OH

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH

⁶NYU Langone- Laura and Isaac Perlmutter Cancer Center, New York, NY

3662 Net Clinical Benefit of Low Dose Rivaroxaban in Coronary Heart Disease: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts

Session: 332. Anticoagulation and Antithrombotic Therapy: Poster III

Hematology Disease Topics & Pathways: anticoagulant drugs, Therapies, Non-Biological

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Muhammad Zain Farooq, MD, MBBS¹, Muhammad Saad Farooq, MBBS^{2*}, Saira Farid, MD^{3*}, Talha Aijaz, MD^{4*}, Ishaan Vohra, MD^{1*}, Vatsala Katiyar, MD^{1*} and Ankit Mangla, MBBS, MD⁵

¹John H. Stroger Hospital of Cook County, Chicago, IL

²Dow University of Health Sciences, Karachi, Pakistan

³Medstar Washington Hospital Center/ Georgetown University Hospital, Silver Spring, MD

⁴John Stroger Hospital of Cook County, CHICAGO, IL

⁵Division of Hematology and Oncology, Case Western Reserve University, School of Medicine, Cleveland, OH

3683 Risk of Intracerebral Hemorrhage with and without Anticoagulation in Patients with Brain Metastasis: The Cleveland Clinic Experience

Program: Oral and Poster Abstracts

Session: 332. Anticoagulation and Antithrombotic Therapy: Poster III

Hematology Disease Topics & Pathways: Bleeding Disorders, Diseases, anticoagulant drugs, Therapies, Bleeding and clotting, Non-Biological

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Tariq Zuheir Kewan, MD^{1*}, Shafia Rahman, MBBS², Fahrettin Covut, MD³, Ramsha Ahmed, MD^{1*}, Seba Hasan^{4*}, Yihong Zhou, MD^{2*} and Alok A Khorana, MD⁵

¹Department of Internal Medicine, Cleveland Clinic, Cleveland, OH

²Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH

³Department of Internal Medicine, Case Western Reserve University, Cleveland, OH

⁴Internal medicine, Cleveland Clinic Foundation, Cleveland, OH

⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

3737 Expression of Human SBDS^{R126T} in Sbds Null Background Shows Eif6 Dysregulation: An Adult Zebrafish Model for Shwachman-Diamond Syndrome

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways: Diseases, AML, Bone Marrow Failure, MDS, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Usua Oyarbide Cuervas-Mons, PhD, MSc, BSc¹, Matthew Snyderman, MSc^{1*}, Jacek Topczewski, PhD^{2*} and Seth J. Corey, MD³

¹Department of Cancer Biology, Cleveland Clinic, Cleveland, OH

²Pediatrics, Northwestern University, Chicago, IL

³Departments of Pediatrics, Cancer Biology, THOR, Cleveland Clinic, Cleveland, OH

3743 Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways: Diseases, Bone Marrow Failure, Biological Processes, Clinically relevant, genomics

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Jibran Durrani^{1*}, Hassan Awada^{1*}, Ashwin Kishtagari, MBBS¹, Cassandra M Kerr, MS^{1*}, Vera Adema, PhD^{1*}, Yasunobu Nagata, MD, PhD^{1*}, Teodora Kuzmanovic^{1*}, Sanghee Hong, MD^{2*}, Sunisa Kongkiatkamon^{1*}, Alan Lichtin, MD³, Aziz Nazha, MD⁴, Bhumika J. Patel, MD^{5,6}, Yogenthiran Saunthararajah, MD^{1,7}, Hetty E. Carraway, MD, MBA⁸, Valeria Visconte, PhD¹, Mikkael A. Sekeres, MD, MS⁹ and Jaroslaw P. Maciejewski, MD, PhD^{10,11}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Hematologic Malignancies and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Leukemia Program, Dept. of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁸Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹⁰Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

3750 Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways: Diseases, Bone Marrow Failure

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Hassan Awada^{1*}, Jibran Durrani^{1*}, Ashwin Kishtagari, MBBS¹, Valeria Visconte, PhD² and Reda Z. Mahfouz, MD, PhD^{1*}

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

3752 Effect of the Unfolded Protein Response and Oxidative Stress on Mutagenesis of CSF3R a Model of Evolution of Severe Congenital Neutropenia to Myelodysplastic Syndrome/Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster III

Hematology Disease Topics & Pathways: Diseases, AML, Bone Marrow Failure, Biological Processes, MDS, DNA damage, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Adya Sapra, MS^{1*}, Roman Jaksik, PhD^{2*}, Sara Biesiadny^{3*}, Hrishikesh M Mehta, PhD^{4,5}, Marek Kimmel, PhD, DSc^{6*} and Seth J. Corey, MD⁷

¹Cleveland Clinic, Cleveland, OH

²Silesian University of Technology, Gliwice, Poland

³Rice University, Houston, TX

⁴Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, OH

⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Department of Statistics, Rice University, Houston, TX

⁷Departments of Pediatrics, Cancer Biology, THOR, Cleveland Clinic, Cleveland, OH

3809 Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab

Program: Oral and Poster Abstracts

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III

Hematology Disease Topics & Pathways: CRS, antibodies, Biological, ALL, Leukemia, Diseases, neurotoxicity, Therapies, Adverse Events, Lymphoid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Talha Badar, MD¹, Aniko Szabo, PhD^{2*}, Anjali S. Advani, MD³, Martha Wadleigh, MD^{4*}, Shukaib Arslan, MD^{5*}, Muhammad Khan^{2*}, Ibrahim Aldoss, MD⁶, Caitlin Siebenaller, PharmD^{7*}, Elizabeth Schultz^{4*}, Mehrdad Hefazi, MD⁸, Rory M Shallis, MD⁹, Ilana Yurkiewicz, MD, BS¹⁰, Nikolai A. Podoltsev, MD, PhD¹¹, Anand Ashwin Patel, MD¹², Emily K Curran, MD¹³, Suresh Kumar Balasubramanian, MD¹⁴, Jay Yang, MD¹⁵, Ryan J. Mattison, MD¹⁶, Madelyn Burkart, MD^{17*}, Shira Dinner^{18*}, Michaela Liedtke, MD¹⁹, Mark Litzow, MD²⁰ and Ehab L. Atallah, MD²¹

¹Medical College of Wisconsin, Milwaukee, WI

²Medical College of Wisconsin, Milwaukee

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴Dana Farber Cancer Institute, Boston

⁵Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA

⁶City of Hopes, Duarte

⁷Department of Pharmacy, Cleveland Clinic, Cleveland, OH

⁸Mayo Clinic, Rochester

⁹Department of Internal Medicine, Section of Hematology, Yale School of Medicine, West Haven, CT

¹⁰Stanford University, Palo Alto, CA

¹¹Yale University, Boston

¹²University of Chicago, Chicago, IL

¹³Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

¹⁴Karmanos Cancer Center, Detroit

¹⁵Karmanos Cancer Institute, Detroit, MI

¹⁶University of Wisconsin Carbone Cancer Center, Madison, WI

¹⁷Northwestern University; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago

¹⁸Northwestern University, Chicago

¹⁹Stanford University Cancer Center, Stanford, CA

²⁰Division of Hematology, Mayo Clinic, Rochester, MN

²¹Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, WI

3836 Determinants of “Fitness” for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Adult, AML, Diseases, Study Population, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Abby Statler, PhD, MPH^{1*}, Brian P. Hobbs, PhD^{2*}, Tomas Radivoyevitch, PhD^{3*}, Caitlin Siebenaller, PharmD^{4*}, Sudipto Mukherjee, MD, PhD, MPH⁵, Anjali S. Advani, MD⁵, Aaron T. Gerds, MD, MS⁶, Aziz Nazha, MD⁷, Bhumika J. Patel, MD⁵, Hetty E. Carraway, MD, MBA⁵ and Mikkael A. Sekeres, MD, MS⁶

¹Cancer Biostatistics, Cleveland Clinic, Shaker Heights, OH

²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Departments of Quantitative Health Sciences and Translational Hematology and Oncology Research, Quantitative Health Sciences, Cleveland, OH

⁴Pharmacy Department, Cleveland Clinic, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

3909 The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways: AML, Diseases, HSCs, Adult, Non-Biological, Therapies, biopsy, MDS, Biological Processes, DNA damage, DNA repair, Cell Lineage, Study Population, Clinically relevant, Myeloid Malignancies, pharmacology, mass cytometry, RNA sequencing, WGS

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Namrata S Chandhok, MD¹, Wei Wei, MD, PhD^{2*}, Ranjit Bindra, MD PhD^{3*}, Stephanie Halene, MD⁴, Yu Shyr^{5*}, Jing Li, PhD^{6*}, Michael Berens, PhD^{7*}, Chris Karlovich, PhD^{8*}, S. Percy Ivy, MD^{9*} and Thomas Prebet, MD, PhD¹⁰

¹Hematology, Yale New Haven Hospital, New Haven, CT

²Cleveland Clinic, Cleveland, OH

³Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT

⁴Yale Univ. School of Medicine, New Haven, CT

⁵Center for Quantitative Sciences, Vanderbilt University, Nashville

⁶Department of Oncology, Karmanos Cancer Institute, Detroit, MI

⁷Cancer and Cell Biology Division, The Translational Genomics Research Institute, Phoenix

⁸Molecular Characterization Lab (MoCha) at Frederick National Laboratory for Cancer Research, Frederick, MD

⁹National Cancer Institute Cancer Therapy Evaluation Prog., Rockville, MD

¹⁰Hematology, Yale University, New Haven, CT

3916 Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Amer M. Zeidan, MBBS, MHS¹, Michael W. Schuster, MD², Jürgen Krauter, MD^{3*}, Johan A. Maertens, MD, PhD^{4*}, Emmanuel Gyan, MD, PhD⁵, Magalie Joris, MD^{6*}, Tobias F Menne, MD, PhD, FRCPath^{7*}, Paresh Vyas, MD, PhD⁸, Weidong Wendy Ma^{9*}, Ashleigh O'Connell^{9*}, Mirjana Zeremski, MD^{9*}, Arthur Kudla^{9*}, Geoffrey Chan, MD⁹ and Mikkael A. Sekeres, MD, MS¹⁰

¹Yale School of Medicine and Yale Cancer Center, New Haven, CT

²Stony Brook University Hospital Cancer Center, Stony Brook, NY

³Department of Internal Medicine III, Medizinische Klinikum Braunschweig GmbH, Braunschweig, Germany

⁴UZ Leuven, Leuven, Belgium

⁵CHU de Tours - Hôpital Bretonneau, Tours, France

⁶CHU Amiens-Picardie, Amiens, France

⁷Department of Haematology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom

⁸MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

⁹Pfizer Oncology, New York, NY

¹⁰Leukemia Program, Cleveland Clinic, Cleveland, OH

3920 First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Hematology Disease Topics & Pathways: Adult, Biological, AML, Diseases, Therapies, Biological Processes, Study Population, Myeloid Malignancies, TKI, pathways

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Scott R. Solomon, MD¹, Aziz Nazha, MD², Stephen A. Strickland, MD³, Roland B. Walter, MD, PhD, MS⁴, Ilaria Valimbertis^{5*}, Alessia Tagliavini^{5*}, Paolo Mazzei^{5*}, Caterina Fiesoli^{5*}, Simona Scartonis^{5*}, Daniela Bellarosa^{6*}, Monica Binaschi, PhD^{6*}, Pawel Chrom, MD, PhD^{7*}, Simone Baldini, MD^{5*}, Krzysztof Brzózka, PhD⁷, Angela Capriati^{5*}, Andrea Pellacani, PhD, MD^{5*} and Farhad Ravandi, MD⁸

¹Blood and Marrow Transplant Program, BMT Group of Georgia, Atlanta, GA

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

³Vanderbilt-Ingram Cancer Center, Nashville, TN

⁴Fred Hutchinson Cancer Research Center, Seattle, WA

⁵Menarini Ricerche S.p.A., Firenze, Italy

⁶Menarini Ricerche S.p.A., Pomezia (Rome), Italy

⁷Selvia S.A., Kraków, Poland

⁸Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

3982 Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways: Adult, Follicular Lymphoma, Diseases, Biological, Therapies,
Non-Hodgkin Lymphoma, Study Population, Lymphoid Malignancies, Clinically relevant
Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Allison M. Winter, MD¹, Wei Wei, MS^{1}, Emily C. Ayers, MD², Daniel J. Landsburg, MD², Saba Raya, MD^{3*},
Brad S. Kahl, MD^{3*}, Andrew Rogers, MD, MS⁴, Kami J. Maddocks, MD⁵, Mohammad Khan, DO, MSBS^{1*},
Adam S. Kittai, MD⁶, Alexey Danilov, MD, PhD⁷, Chaitra S. Ujjani, MD⁸, Ryan C. Lynch, MD⁹, Loretta J.
Nastoupil, MD, MSc¹⁰, Melody R. Becnel, MD¹⁰, Luke Zurbriggen, MD¹¹, Vaishalee P. Kenkre, MD¹¹,
Sheenu Sheela, MD¹², Nilanjan Ghosh, MD, PhD¹², Boyu Hu, MD^{13*}, Deborah M. Stephens, DO¹³, Amy
Ayers, MPH^{14*}, Jonathon B. Cohen, MD, MS¹⁴ and **Brian T. Hill, MD¹***

¹Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

³Siteman Cancer Center, Washington University, St Louis, MO

⁴James Cancer Center, The Ohio State University Hospital, Columbus, OH

⁵The James Cancer Hospital at The Ohio State University, Columbus, OH

⁶Knight Cancer Institute, Knight Cancer Institute, Columbus, OH

⁷Knight Cancer Institute, Oregon Health & Science University, Portland, OR

⁸University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

⁹Seattle Cancer Care Alliance, University of Washington, Seattle, WA

¹⁰The University of Texas MD Anderson Cancer Center, Houston, TX

¹¹Carbone Cancer Center, University of Wisconsin, Madison, WI

¹²Levine Cancer Institute, Atrium Health, Charlotte, NC

¹³Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

¹⁴Winship Cancer Institute, Emory University, Atlanta, GA

3997 Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways: Diseases, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma,
Lymphoid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Narendranath Epperla, MD, MS¹, Jeffrey M. Switchenko, PhD, MS^{2}, Krithika Shanmugasundaram, MD³,
Subir Goyal^{4*}, Oscar Calzada, BS^{5*}, Michael C. Churnetski^{6*}, Bhaskar Kolla, MBBS⁷, Veronika Bachanova,
MD, PhD⁷, James N. Gerson, MD⁸, Stefan K. Barta, MD, MRCP, MS⁹, Max J. Gordon, MD¹⁰, Alexey Danilov,
MD, PhD¹⁰, Natalie S Grover, MD¹¹, Stephanie Mathews, MD^{12*}, Madelyn Burkart, MD^{13*}, Reem Karmali,
MD¹⁴, Yazeed Sawalha, MD¹⁵, **Brian T. Hill, MD¹⁶**, Nilanjan Ghosh, MD, PhD¹⁷, Steven I Park, MD¹⁸, David
A. Bond, MD¹⁹, Talha Badar, MD²⁰, Kristie A. Blum, MD²¹, Mehdi Hamadani, MD²⁰, Timothy S. Fenske,
MD²², Mary-Kate Malecek, MD²³, Peter Martin, FRCP, MD, MS²⁴, Jin Guo, MD²⁵, Brad S. Kahl, MD^{26*},
Christopher R. Flowers, MD, MS²¹ and Jonathon B. Cohen, MD, MS²⁷*

¹The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Division of Hematology, Columbus, OH

²Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA

³Emory University School of Medicine, Atlanta, GA

⁴Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA

⁵Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

⁶Winship Cancer Institute, Emory University Medical Center, Atlanta, GA

⁷Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

⁸Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁹Lymphoma Department, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
¹⁰Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
¹¹Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
¹²University of North Carolina, Chapel Hill, NC
¹³Northwestern University; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago
¹⁴Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
¹⁵Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
¹⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
¹⁷Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
¹⁸Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC
¹⁹James Cancer Center, The Ohio State University Hospital, Columbus, OH
²⁰Medical College of Wisconsin, Milwaukee, WI
²¹Winship Cancer Institute, Emory University, Atlanta, GA
²²Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
²³Department of Medicine, Washington University School of Medicine, St. Louis, MO
²⁴Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY
²⁵Department of Medicine, Weill Cornell Medicine, New York, NY
²⁶Siteman Cancer Center, Washington University, St Louis, MO
²⁷Emory University, Atlanta, GA

4004 Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways: Diseases, Therapies, Lymphoma (any), Combinations, Lymphoid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Rachel Hu, MD¹, Wei Wei, MS^{2}, Kristen Gonter-Aubin, DO³, Javier Pinilla Ibarz, MD, PhD⁴, Charlene C. Kabel, PharmD^{5*}, Anthony R. Mato, MD MSCE^{6,7}, Yazan F. Madanat, MD⁸, Sirin Khajavian, MD^{9*}, Mazyar Shadman, MD¹⁰, Ashley Hanlon, MD¹¹, Danielle M. Brander, MD¹¹, Jae H. Park, MD¹², Martin S. Tallman, MD¹³ and Brian T. Hill, MD¹⁴*

¹Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
²Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
³Moffitt Cancer Center/University of South Florida Morsani College of Medicine, Tampa, FL
⁴Department of Immunology, Moffitt Cancer Center, Tampa, FL
⁵Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Center for CLL, Memorial Sloan-Kettering Cancer Center, New York, NY
⁷CLL Program, Leukemia Service, Hematologic Malignancies Division, Memorial Sloan Kettering Cancer Center, New York, NY
⁸UT Southwestern Medical Center, Dallas
⁹Fred Hutchinson Cancer Research Center, Seattle, WA
¹⁰Uw/Fred Hutchinson Cancer Research Center, Seattle, WA
¹¹Duke University Medical Center, Durham, NC
¹²Memorial Sloan-Kettering Cancer Ctr., New York, NY
¹³Memorial Sloan Kettering Cancer Center, New York, NY
¹⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

4027 Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways: antibodies, Biological, Diseases, Non-Biological, Therapies, Elderly, Hodgkin Lymphoma, chemotherapy, Study Population, immunotherapy, Clinically relevant, Lymphoid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Victor M. Orellana-Noia, MD¹, Krista Isaac, DO, MS¹, Nolan A Wages, PhD^{2}, Mary-Kate Malecek, MD³, Nancy L. Bartlett, MD³, Timothy J Voorhees, MD⁴, Natalie S Grover, MD⁴, Steven R. Hwang, MD^{5*}, N. Nora Bennani, MD⁶, Rachel Hu, MD⁷, **Brian T. Hill, MD⁸**, Eric Mou, MD⁹, Ranjana Advani, MD¹⁰, Jordan Carter, MD^{11*}, Kevin A. David, MD¹¹, Hatcher J. Ballard, BS^{12*}, Jakub Svoboda, MD¹², Gabriela Magarelli, APN^{13*},*

Tatyana A. Feldman, MD¹⁴, Michael C. Churnetski^{15*}, Jonathon B. Cohen, MD, MS¹⁶, Andrew M. Evens, DO, MSc¹¹ and Craig A. Portell, MD¹⁷

¹Division of Hematology/Oncology, University of Virginia, Charlottesville, VA

²Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville

³Department of Medicine, Washington University School of Medicine, St. Louis, MO

⁴Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

⁵Mayo Clinic, Rochester, MN

⁶Division of Hematology, Mayo Clinic, Rochester, MN

⁷Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

⁸Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁹Stanford Health Care, Palo Alto, CA

¹⁰Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA

¹¹Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

¹²Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

¹³John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

¹⁴Hackensack University Medical Center, Hackensack, NJ

¹⁵Winship Cancer Institute, Emory University Medical Center, Atlanta, GA

¹⁶Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

¹⁷Division of Hematology and Oncology, University of Virginia, Charlottesville, VA

4074 Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster III

Hematology Disease Topics & Pathways: Biological, Follicular Lymphoma, Diseases, Therapies, Marginal Zone Lymphoma, Lymphoma (any), CAR-Ts, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, Clinically relevant, Lymphoid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Paolo F Caimi, MD¹, Jane Reese^{1*}, Folashade Otegbeye, MBBChir, MPH², Dina Schneider, PhD^{3*}, Kristen Bakalarz, CNP^{1*}, Kirsten M Boughan, DO¹, Brenda Cooper, MD¹, Molly M Gallogly, MD, PhD¹, Erin Galloway, RN BSN^{1*}, Winfried Kruger^{3*}, Andrew Worden^{3*}, Michael Kadan^{3*}, Filipa Blasco Lopes^{4*}, Ashish Sharma^{4*}, Ehsan Malek, MD⁵, Leland Metheny III, MD¹, Seema Patel, PharmD^{6*}, Benjamin K. Tomlinson, MD¹, David Wald, MD, PhD^{4*}, Rafick-Pierre Sekaly^{4*}, Rimas Orentas, PhD^{7*}, Boro Dropulic, PhD^{3*} and Marcos de Lima, MD¹

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Beachwood, OH

³Lentigen Technology Inc., A Miltenyi Biotec Company, Gaithersburg, MD

⁴Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

⁶Adult Hematologic Malignancies & Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH

⁷Lentigen, A Miltenyi Biotec Company, Gaithersburg

4175 Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster III

Hematology Disease Topics & Pathways: Diseases, MPN, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Claire N Harrison, Professor¹, Aaron T. Gerds, MD, MS², Jean-Jacques Kiladjian, MD, PhD³, Konstanze Döhner^{4*}, Sarah A Buckley, MD^{5*}, Jennifer A. Smith, PhD^{5*}, Adam R Craig, MD, PhD⁵, John Mascarenhas, MD⁶ and Srdan Verstovsek, MD, PhD⁷

¹Department of Clinical Haematology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

³Hopital Saint-Louis, Paris, France

⁴Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany

⁵CTI BioPharma, Seattle, WA

⁶Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

⁷University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

4190 Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster III

Hematology Disease Topics & Pathways: Diseases, MPN, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Aaron T. Gerds, MD, MS¹, Roger M. Lyons, MD², Philomena Colucci, DO, MS^{3*}, Patricia Kalafut, PhD^{3*}, Dilan Paranagama, PhD^{3*} and Srdan Verstovsek, MD, PhD⁴

¹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

²Texas Oncology and US Oncology Research, San Antonio, TX

³Incyte Corporation, Wilmington, DE

⁴University of Texas MD Anderson Cancer Center, Houston, TX

4214 Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Program: Oral and Poster Abstracts

Session: 635. Myeloproliferative Syndromes: Basic Science: Poster III

Hematology Disease Topics & Pathways: Diseases, Adult, Therapies, Biological Processes, MPN, Technology and Procedures, Study Population, Clinically relevant, Myeloid Malignancies, hematopoiesis, NGS

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Jennifer O'Sullivan, MD^{1*}, Jason A Taylor, MD, PhD², **Aaron T. Gerds, MD, MS³**, Sarah A Buckley, MD^{2*}, Claire N Harrison, Professor⁴, Stephen T. Oh, MD⁵, Kieran Howard^{6*}, Helene Marie-Pierre Dreau, PhD^{6*}, Angela Hamblin, MD, PhD^{6,7*} and Adam J. Mead, MD, PhD^{8,9}

¹Weatherall Institute of Molecular Medicine, Oxford, United Kingdom

²CTI BioPharma, Seattle, WA

³Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁴Department of Clinical Haematology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom

⁵Washington University School of Medicine, Saint Louis, MO

⁶Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

⁷NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, University of Oxford, Oxford, United Kingdom

⁸Haematopoietic Stem Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

⁹NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom

4216 Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways: Diseases, Biological Processes, MDS, Technology and Procedures, genomics, Myeloid Malignancies, NGS

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Ryunosuke Saiki^{1*}, Yusuke Shiozawa, MD, PhD^{2*}, Tetsuichi Yoshizato, MD, PhD^{3*}, Yasuhito Nannya, MD, PhD¹, June Takeda, MD^{1*}, Kenichi Yoshida, MD, PhD^{1*}, Yuichi Shiraishi, PhD^{4*}, Hiroko Tanaka, BA^{5*}, Kenichi Chiba, PhD^{6*}, Yoshiko Atsuta, MD, PhD^{7,8*}, Makoto Onizuka, MD, PhD⁹, Hidehiro Itonaga, MD, PhD^{10*}, Masashi Sanada, MD¹¹, Yoshinobu Kanda, MD, PhD¹², Bartłomiej Przychodzen^{13*}, **Mikael A. Sekeres, MD, MS^{13,14}**, Kathryn Guinta^{15*}, **Yogenthiran Sauntharajah, MD¹⁶**, Lee-Yung Shih, MD¹⁷, Shuichi Miyawaki, MD, PhD¹⁸, Tsuyoshi Nakamaki, MD, PhD¹⁹, Masataka Taguchi^{20*}, Shigeo Fuji, MD, PhD^{21*}, Nana Sasaki, MD^{22*}, Nobuhiko Uoshima, MD, PhD^{22*}, Yasunori Ueda, MD, PhD²³, Yasushi Miyazaki, MD, PhD¹⁰, Kensuke Usuki, MD, PhD^{24*}, Kazunori Imada, MD, PhD^{25*}, Akifumi Takaori-Kondo,

MD, PhD²⁶, Shigeru Chiba, MD, PhD^{27*}, Senji Kasahara, MD, PhD²⁸, Toru Kiguchi, MD, PhD^{29*}, Hisashi Tsurumi, MD, PhD³⁰, Luca Malcovati, MD^{31,32}, Mario Cazzola, MD³¹, Takayuki Ishikawa, MD, PhD³³, Satoru Miyano, PhD^{5*}, **Jaroslav P. Maciejewski, MD, PhD^{13,34}**, Hideki Makishima, MD, PhD^{35,36} and Seishi Ogawa, MD, PhD¹

¹Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

²Department of Pediatrics, The University of Tokyo, Tokyo, Japan

³Department of Pathology and Tumor Biology, Kyoto University, Graduate school of medicine, Kyoto University, Kyoto, Japan

⁴Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan

⁵Laboratory of DNA Information Analysis, Human Genome Center, The University of Tokyo, Tokyo, Japan

⁶Laboratory of Sequence Analysis, Human Genome Center, The University of Tokyo, Tokyo, Japan

⁷Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

⁸Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

⁹Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan

¹⁰Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

¹¹Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

¹²Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan

¹³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

¹⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹⁶Department of Translational hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

¹⁷Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hosp., Taipei, Taiwan

¹⁸Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, JPN

¹⁹Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

²⁰Atomic Bomb Disease Institute, Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

²¹Department of Hematology, Osaka International Cancer Institute, Osaka, Japan

²²Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan

²³Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan

²⁴Department of Hematology, NTT Medical Center, Tokyo, TKY, JPN

²⁵Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan

²⁶Department of Hematology and Oncology, Kyoto University, Kyoto, Japan

²⁷Department of Hematology, Tsukuba University, Tsukuba, Japan

²⁸Hematology, Gifu Municipal Hospital, Gifu, Japan

²⁹Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan

³⁰Hematology, Gifu University Graduate School of Medicine, Gifu, Japan

³¹Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy

³²Department of Molecular Medicine & Hematology Oncology, University of Pavia Medical School, Piazzale Golgi 2, Pavia, Italy

³³Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan

³⁴Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

³⁵Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan

³⁶Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

4221 Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways: Diseases, Biological Processes, MDS, Clinically relevant, genomics, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Vera Adema, PhD^{1*}, **Laura Palomo^{2*}**, **Cassandra M Kerr, MS^{3*}**, **Wencke Walter, PhD^{4*}**, **Bartłomiej Przychodzen^{1*}**, **Stephan Hutter, PhD^{4*}**, **Thomas Laframboise, PhD^{5*}**, **María Díez-Campelo, MD, PhD^{6*}**, **Mar Mallo, Ph.D.^{7*}**, **Aziz Nazha, MD⁸**, **Blanca Xicoy, MD, MSc^{9*}**, **Manja Meggendorfer, PhD⁴**, **Hetty E. Carraway, MD, MBA¹⁰**, **Claudia Haferlach, MD⁴**, **Mikael A. Sekeres, MD, MS¹¹**, **Valeria Visconte, PhD³**, **Torsten Haferlach, MD¹²**, **Francesc Sole, PhD²** and **Jaroslav P. Maciejewski, MD, PhD^{13,14}**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

²MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁴MLL Munich Leukemia Laboratory, Munich, Germany

⁵Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁶Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain

⁷Institut de Recerca Contra la Leucèmia Josep Carreras, Barcelona, Spain

⁸Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹²MLL Munchner Leukamie Labor GmbH, Munchen, Germany

¹³Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

¹⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

4233 ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia

Program: Oral and Poster Abstracts

Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III

Hematology Disease Topics & Pathways: AML, Diseases, CMML, platelets, MDS, red blood cells, Biological Processes, Myeloid Malignancies, hematopoiesis

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Teodora Kuzmanovic¹*, Bhumika J. Patel, MD², Jibran Durrani¹*, Hassan Awada, MD¹, Cassandra M Kerr, MS¹*, Bartlomiej P. Przychodzen¹*, Samuel Li, BA³*, **Seth J. Corey, MD⁴, Sudipto Mukherjee, MD, PhD, MPH², Anjali S. Advani, MD², Aziz Nazha, MD⁵, Aaron T. Gerds, MD, MS⁶, Hetty E. Carraway, MD, MBA², Thomas Laframboise, PhD³*, Mikkael A. Sekeres, MD, MS⁶ and Jaroslaw P. Maciejewski, MD, PhD^{7,8}**

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁴Departments of Pediatrics, Cancer Biology, THOR, Cleveland Clinic, Cleveland, OH

⁵Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁸Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

4238 Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Adult, Diseases, Bone Marrow Failure, Technology and Procedures, genetic profiling

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Cameron Beau Hilton, BA^{1,2}, Manja Meggendorfer, PhD³, Mikkael A. Sekeres, MD, MS⁴, Jacob Shreve, MD, MS⁵*, Nathan Radakovich⁶*, Yazan Rouphail⁷*, Wencke Walter, PhD⁸*, Stephan Hutter, PhD⁸*, Eric Padron, MD⁹, Michael R. Savona, MD¹⁰, **Aaron T. Gerds, MD, MS⁴, Sudipto Mukherjee, MD, PhD, MPH¹, Brianna N Smith, MD, MS¹¹, Yasunobu Nagata, MD, PhD¹²*, Cassandra M. Hirsch¹³*, Rami S. Komrokji, MD^{14,15,16}, **Babal K. Jha, PhD¹²*, Claudia Haferlach, MD⁸, Jaroslaw P. Maciejewski, MD, PhD¹⁷, Torsten Haferlach, MD¹⁸ and Aziz Nazha, MD¹⁹****

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Heights, OH

³MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁵Department of Internal Medicine, Cleveland Clinic, Cleveland, OH

⁶Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

⁷Ohio State University, Columbus, OH

⁸MLL Munich Leukemia Laboratory, Munich, Germany

⁹Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL

¹⁰Department of Medicine and Program in Cancer Biology, Vanderbilt University Medical Center, Nashville, TN

¹¹Department of Medicine; Department of Pediatrics; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN

¹²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁴Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

¹⁵Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

¹⁶Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

¹⁷Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH

4243 Hematologic Improvement–Neutrophil and –Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Diseases, MDS, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Guillermo Garcia-Manero, MD¹, Ghulam J. Mufti^{2*}, Pierre Fenaux, MD, PhD^{3,4}, Rena Buckstein, MD, FRCPC⁵, Valeria Santini, MD⁶, María Díez-Campelo, MD, PhD^{7*}, Carlo Finelli^{8*}, Mario Cazzola, MD⁹, Osman Ilhan^{10*}, **Mikael A. Sekeres, MD, MS¹¹, Alan F. List, MD¹², Abderrahmane Laadem¹³, Rodrigo Ito^{13*}, Jennie Zhang^{13*}, Anita Rampersad^{13*}, Daniel Sinsimer^{13*}, Peter G. Linde¹⁴, Uwe Platzbecker, MD¹⁵ and Rami Komrokji^{12*}**

¹University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

²Department of Haemato-Oncology, King's College London, London, United Kingdom

³Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

⁴Université Paris 7, Paris, France

⁵Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

⁶MDS Unit, Azienda Ospedaliero Universitaria (AOU) Careggi, University of Florence, Florence, Italy

⁷Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain

⁸Department of Oncology and Hematology, S. Orsola-Malpighi University Hospital, Bologna, Italy

⁹Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

¹⁰Department of Hematology, Ankara University School of Medicine, Ankara, Turkey

¹¹Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹²Moffitt Cancer Center, Tampa, FL

¹³Celgene Corporation, Summit, NJ

¹⁴Acceleron Pharma, Cambridge, MA

¹⁵Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany

4271 Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Diseases, MDS, Cell Lineage, Study Population, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019, 6 PM-8 PM; Hall B, Level 2 (Orange County Convention Center)

Johannes B Goll, MS^{1*}, R. Coleman Lindsley, MD, PhD², William F. Hooper, MS^{1*}, Rafael Bejar, MD, PhD³, Jason Walker^{4*}, Robert Fulton, MS^{5*}, Gregory A. Abel, MD, MPH², Tareq Al Baghdadi, MD^{6*}, H. Joachim Deeg, MD⁷, Amy E. DeZern, MD⁸, Benjamin Ebert, MD⁹, Pearlie Epling-Burnette, PhD, PharmD^{10*}, James M. Foran, MD¹¹, Edward J. Gorak, DO, MBA, MS¹², Steven D. Gore, MD¹³, Rami S. Komrokji, MD^{14,15,16}, Jane Jijun Liu, MD^{17*}, **Jaroslav P. Maciejewski, MD, PhD¹⁸, Eric Padron, MD¹⁹, Wael Saber, MD, MS²⁰, Daniel T. Starczynowski, PhD²¹, Myron Wacławski, PhD^{22*}, Nancy DiFronzo, PhD^{23*}, **Mikael A. Sekeres, MD, MS²⁴**, Ling Zhang, MD^{25*} and **Matthew J. Walter, MD²⁶****

¹The Emmes Company, LLC, Rockville, MD

²Dana-Farber Cancer Institute, Boston, MA

³Moore's Cancer Center, University of California, San Diego, La Jolla, CA

⁴Washington University School of Medicine, St. Louis, MO

⁵McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO

⁶HA Hematology Oncology Consultants, Ypsilanti, MI

⁷Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

⁸Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

⁹Dept. Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

¹⁰Moffitt Cancer Center & Research Institute/Immunology Program, Tampa, FL

¹¹Mayo Clinic Florida, Jacksonville, FL

¹²Baptist MD Anderson Cancer Center, Jacksonville, FL
¹³Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT
¹⁴Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹⁵Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
¹⁶Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹⁷Illinois Cancer Care, P.C., Peoria, IL
¹⁸Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
¹⁹Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL
²⁰CIBMTR, Medical College of Wisconsin, Milwaukee, WI
²¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH
²²National Institutes of Health, National Heart Lung and Blood Institute, Bethesda, MD
²³National Institutes of Health, Division of Blood Diseases & Resources, Bethesda, MD
²⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
²⁵Department of Hematopathology and Lab Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²⁶Department of Medicine, Division of Oncology, Washington University In St. Louis, Saint Louis, MO

4286 The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III

Hematology Disease Topics & Pathways: Leukemia, Diseases, CLL, Clinically relevant, Lymphoid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Max J. Gordon, MD¹, Andy Kaempfer^{2*}, Andrea Sitlinger, MD³, Tareq Salous^{4*}, Hamood Alqahtani, MBBS^{5*}, Michael C. Churnetski^{6*}, Paul Wisniewski^{7*}, Xavier Issac Rivera, BS^{8*}, Krish Patel, MD⁷, Daniel O. Persky, MD⁹, Jonathon B. Cohen, MD, MS¹⁰, Michael Y. Choi, MD¹¹, **Brian T. Hill, MD¹²**, Mazyar Shadman, MD¹³, Deborah M. Stephens, DO¹⁴, Danielle M. Brander, MD¹⁵, Byung Park, PhD^{1*} and Alexey Danilov, MD, PhD¹⁶

¹Oregon Health and Science University, Portland, OR
²Knight Cancer Institute, Biostatistics Shared Resource, Oregon Health & Science University, Portland, OR
³Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC
⁴Cleveland Clinic, Cleveland, OH
⁵Moore's Cancer Center at UC San Diego, San Diego, CA
⁶Winship Cancer Institute, Emory University Medical Center, Atlanta, GA
⁷Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
⁸University of Arizona, Tucson, AZ
⁹Division of Hematology/Oncology, University of Arizona, Tucson, AZ
¹⁰Emory University, Atlanta, GA
¹¹Moore's Cancer Center, University of California San Diego, La Jolla, CA
¹²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
¹³UW/Fred Hutchinson Cancer Research Center, Seattle, WA
¹⁴University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, Salt Lake City, UT
¹⁵Duke University Medical Center, Durham, NC
¹⁶Knight Cancer Institute, Oregon Health & Science University, Portland, OR

4359 Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III

Hematology Disease Topics & Pathways: multiple myeloma, Adult, Diseases, Plasma Cell Disorders, Study Population, Clinically relevant, Lymphoid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Rajshakar Chakraborty, MD¹, Lisa Rybicki, MS^{2*}, Megan Nakashima, MD^{3*}, **Robert M. Dean, MD¹**, Beth M. Faiman, PhD, CNP¹, Christy J. Samaras, DO¹, Nathaniel Rosko, PharmD^{4*}, Jason Valent, MD¹ and Faiz Anwer, MD¹

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
²Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH

4442 Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies

Program: Oral and Poster Abstracts

Session: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Poster III

Hematology Disease Topics & Pathways: ALL, multiple myeloma, Adult, Leukemia, Biological, Diseases, Lymphoma (any), Therapies, CLL, Adverse Events, CAR-Ts, Elderly, Pediatric, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant
Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Tariq Iqtidar Sadiq Syed, MD^{1}, Syed Maaz Abdullah, MBBS^{2*}, Tayyab Rehan, MBBS^{3*}, Muhaddis Ejaz Ahmad, MD^{4*}, Syeda Sabeeka Batool, MBBS, MD⁵, Muhammad Abdullah Yousaf, MBBS, MD^{6*}, Maaz Ahmed Yusufi, MD^{4*}, Saif Ur Rehman, MBBS, MD^{7*}, Sravanthi Kotapati, MBBS^{8*}, Maimoona Khan, MBBS^{9*}, Asma Waheed, MBBS^{9*}, Zainab Ijaz^{10*}, Awais Ijaz, MD^{11*} and Faiz Anwer, MD¹²*

¹Cleveland Clinic, Taussig Center, Cleveland, OH

²King Edward Medical University, Lahore, Pakistan, Lahore, Pakistan

³Nishtar Medical University, Multan, Pakistan

⁴Rawalpindi Medical University, Rawalpindi, Pakistan

⁵UAB-Huntsville Regional Medical Campus, Huntsville, AL

⁶Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan

⁷King Edward Medical University, Lahore, Pakistan

⁸Siddhartha Medical College, Vijayawada, India

⁹Shifa College of Medicine, Islamabad, Pakistan

¹⁰Windsor University School of Medicine, Cayon St. Kitts, Jamaica

¹¹SUNY Upstate Medical University, Syracuse, NY

¹²Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

4452 Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

Program: Oral and Poster Abstracts

Session: 704. Immunotherapies: Poster III

Hematology Disease Topics & Pathways: Biological, Therapies, CAR-Ts

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Agrima Mian, MBBS, MD^{1}, Wei Wei, MS^{2*}, Allison M. Winter, MD¹, Jack Khouri, MD¹, Deepa Jagadeesh, MD, MPH¹, Faiz Anwer, MD¹, Aaron T. Gerds, MD, MS³, Robert M. Dean, MD¹, Ronald Sobecks, MD², Brad Pohlman, MD², Matt Kalaycio, MD⁴, Betty K. Hamilton, MD⁵, Navneet S. Majhail, MD, MS² and Brian T. Hill, MD⁶*

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

³Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

⁴Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁵Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

4516 Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Program: Oral and Poster Abstracts

Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III

Hematology Disease Topics & Pathways: Adult, Diseases, bioengineering, GVHD, Pediatric, Biological Processes, Technology and Procedures, Immune Disorders, Study Population, immune mechanism, inflammation

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

John Koreth, MBBS, DPhil, Saurabh Chhabra, MD², Joseph Pidala, MD^{3}, Thomas C. Shea, MD⁴, Madan Jagasia, MBBS, MS, MMHC⁵, Edmund K. Waller, PhD, MD⁶, Ryotaro Nakamura, MD⁷, Marco Mielcarek, MD^{8,9}, George L. Chen, MD¹⁰, Gabrielle Meyers, MD^{11*}, Daanish Hoda, MD¹², **Betty K. Hamilton, MD¹³**, Cherie Tracy Ng, PhD, MPH^{14*}, Mark Sonnemann^{15*}, Susan Light, MD^{16*}, Nuwan Nanayakkara, PhD^{17*}, David Essayan, MD^{18*}, Joel Rothman, BS^{16*}, Stephen Connelly, PhD, MBA^{14*}, Krishna Polu, MD^{15*}, Leslie Kean, MD, PhD¹⁹, Jerome Ritz, MD¹, Robert J. Soiffer, MD²⁰ and Corey Cutler, MD, MPH, FRCPC²¹*

¹Dana-Farber Cancer Institute, Department of Hematologic Malignancies and Harvard Medical School, Boston, MA

²Medical University of South Carolina, Milwaukee, WI

³Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

⁴Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

⁵Vanderbilt University Medical Center, Nashville, TN

⁶Winship Cancer Institute, Emory University, Atlanta, GA

⁷Department of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, Beckman Research Institute., City of Hope Nat'l Med. Ctr., Duarte, CA

⁸Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

⁹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁰Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

¹¹Knight Cancer Institute, Oregon Health and Science University, Portland, OR

¹²Intermountain Health, LDS Hospital, Salt Lake City, UT

¹³Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

¹⁴Equillium, Inc, La Jolla, CA

¹⁵Equillium Inc, La Jolla, CA

¹⁶Equillium Inc., La Jolla, CA

¹⁷Wuxi, San Diego, CA

¹⁸Oncord Inc., Westlake Village, CA

¹⁹Boston Children's Hospital, Boston, MA

²⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

²¹Dana-Farber Cancer Inst., Boston, MA

4557 Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome

Program: Oral and Poster Abstracts

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III

Hematology Disease Topics & Pathways: Diseases, Biological, Therapies, Adverse Events, Biological Processes, MDS, Technology and Procedures, epigenetics, Myeloid Malignancies, transplantation, NGS
Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

***Wei Wang^{1,2*}**, Paul Auer, PhD^{2*}, Stephen R. Spellman, MS^{1,2*}, Karen-Sue B. Carlson, MD, PhD^{3*}, **Aziz Nazha, MD⁴**, Martin Maiers, MS^{1,2*}, Yung-Tsi Bolon^{1,5,6,7*} and Wael Saber, MD, MS^{1,3,7}*

¹Center for International Blood and Marrow Transplant Research, Milwaukee/Minneapolis

²National Marrow Donor Program/Be The Match, Minneapolis, MN

³Medical College of Wisconsin, Milwaukee, WI

⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁵Bioinformatics and Computational Biology Program, University of Minnesota, Rochester, MN

⁶National Marrow Donor Program/Be the Match (CIBMTR), Minneapolis, MN

⁷Co-Senior Author, Minneapolis/Milwaukee

4567 Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era

Program: Oral and Poster Abstracts

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III

Hematology Disease Topics & Pathways: Adult, AML, ALL, Leukemia, Diseases, MDS, Study Population, Clinically relevant, Lymphoid Malignancies, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Sanghee Hong, MD^{1*}, Lisa Rybicki, MS^{2*}, Donna Corrigan^{3*}, Betty K. Hamilton, MD¹, Ronald Sobecks, MD¹, Matt Kalaycio, MD⁴, Robert M. Dean, MD¹, Brian T. Hill, MD⁵, Brad Pohlman, MD⁶, Deepa Jagadeesh, MD, MPH¹, Faiz Anwer, MD⁷ and Navneet S. Majhail, MD, MS⁸

¹Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁴Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

⁶Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁷Department of Hematology, Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

⁸Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4581 Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster III

Hematology Disease Topics & Pathways: Biological, Diseases, Non-Biological, Therapies, MDS, Myeloid Malignancies, transplantation

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Marie Robin, MD¹, Liesbeth C. de Wreede, PhD^{2*}, Eric Padron, MD³, Junfeng Wang, PhD^{4*}, Sheree Hazelaar^{5*}, Dietrich W. Beelen⁶, Pierre Fenaux, MD, PhD⁷, Martin Bornhäuser, MD^{8*}, Nicolaus Kroeger, MD⁹, Aziz Nazha, MD¹⁰, Aleksandar Radujkovic, MD¹¹, Raajit K. Rampal, MD, PhD¹², Jürgen Finke, MD¹³, Rami S. Komrokji, MD^{14,15,16}, Victoria Potter, MD, PhD^{17*}, Sally Killick, MD^{18*}, Didier Blaise, MD, PhD¹⁹, Eric Solary, MD, PhD²⁰, Angus Broom^{21*}, Guillermo Garcia-Manero, MD²², Vittorio Rizzoli, MD^{23*}, Mrinal M Patnaik, MD, MBBS²⁴, Francesco Onida, MD²⁵, Ibrahim Yakoub-Agha, MD, PhD²⁶ and Raphael Itzykson, MD, PhD²⁷

¹Hôpital Saint-Louis, APHP, Université Paris 7, Paris Cedex 10, France

²Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands

³Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL

⁴EBMT Statistical Unit, Leiden, Netherlands

⁵EBMT data office Leiden, Leiden, Netherlands

⁶Department of Bone Marrow Transplantation, University of Essen, Essen, Germany

⁷Hôpital St Louis/Université Paris 7 / Service d'hématologie séniors, Hôpital Saint-Louis, Paris, France

⁸Universitätsklinikum Dresden, Dresden, Germany

⁹Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

¹⁰Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

¹¹Dept. Medicine V, University Hospital Heidelberg, Heidelberg, Germany

¹²Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

¹³Dept. of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany

¹⁴Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

¹⁵Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

¹⁶Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

¹⁷King's College Hospital NHS Foundation Trust, London, United Kingdom

¹⁸The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United Kingdom

¹⁹Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France

²⁰INSERM U1170, Université Paris-Sud, Gustave Roussy Cancer Center, Villejuif, France

²¹Western General Hospital, Edinburgh, United Kingdom

²²University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

²³U. O. Ematologia CTMO of Hematology, Parma, ITA

²⁴Division of Hematology, Mayo Clinic, Rochester, MN

²⁵BMT Center - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan, Milano, Italy

²⁶CHU de Lille, LIRIC, INSERM U995, Université de Lille, Lille, France

²⁷Hématologie clinique, Hôpital Saint-Louis, Paris, France

4585 Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster III

Hematology Disease Topics & Pathways: Biological, AML, Diseases, bone marrow, Therapies, Myeloid Malignancies, stem cells

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Mary-Elizabeth M. Percival, MD¹, Hai-Lin Wang, MPH^{2*}, Mei-Jie Zhang, PhD^{2,3*}, Elihu H. Estey, MD⁴, Mark Litzow, MD⁵, Partow Kebriaei, MD⁶, Marcos de Lima, MD⁷, Wael Saber, MD, MS⁸, Daniel J. Weisdorf, MD⁹ and Brenda M Sandmaier, MD¹⁰

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

²CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

³Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI

⁴Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

⁵Division of Hematology, Mayo Clinic, Rochester, MN

⁶Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston, TX

⁷University Hospitals Seidman Cancer Center, Cleveland, OH

⁸Medical College of Wisconsin, Milwaukee, WI

⁹Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

¹⁰Division of Medical Oncology, University of Washington and Clinical Research Division,, Fred Hutchinson Cancer Research Center, Seattle, WA

[**4599 Interactions between Donor Activating Killer Immunoglobulin-like Receptors \(KIRs\) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia \(AML\)**](#)

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster III

Hematology Disease Topics & Pathways: Adult, AML, Diseases, Study Population, Clinically relevant, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Sanghee Hong, MD^{1*}, Lisa Rybicki, MS^{2*}, Aiwen Zhang, PhD^{3*}, Dawn Thomas^{3*}, Cassandra M Kerr, MS^{4*}, Donna Corrigan^{5*}, Arden Emrick^{1*}, Hetty E. Carraway, MD, MBA⁶, Aziz Nazha, MD⁷, Sudipto Mukherjee, MD, PhD, MPH⁸, Anjali S. Advani, MD⁸, Matt Kalaycio, MD⁹, Brian J. Bolwell, MD¹⁰, Rabi Hanna, MD¹, Aaron T. Gerds, MD, MS¹¹, Brad Pohlman, MD¹², Betty K. Hamilton, MD¹, Mikkael A. Sekeres, MD, MS¹¹, Navneet S. Majhail, MD, MS¹, Jaroslaw P. Maciejewski, MD, PhD¹³, Medhat Askar, MD, PhD^{14,15*} and Ronald Sobecks, MD¹

¹Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

³Allogen Laboratories, Cleveland Clinic, Cleveland, OH

⁴Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁶Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland

⁷Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Avon Lake, OH

⁸Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁹Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

¹⁰Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

¹¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

¹²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

¹³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland

¹⁴Department of Pathology and Laboratory Medicine, Texas A&M Health Science Center College of Medicine, Houston

¹⁵Transplant Immunology, Baylor University Medical Center, Houston, TX

[**4662 Assessment of Bleeding Phenotype in Hemophilia A By a Novel Point-of-Care Global Assay**](#)

Program: Oral and Poster Abstracts

Session: 803. Emerging Diagnostic Tools and Techniques: Poster III

Hematology Disease Topics & Pathways: Hemophilia, Diseases, bioengineering, Bleeding and clotting, Technology and Procedures, Clinically relevant

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Debnath Maji, M.Tech^{1}, Michael A Suster, PhD^{1*}, Divyaswathi Citla Sridhar, MD², Maria Alejandra Pereda, MD², Janet Martin, BSN, RN-BC^{2*}, **Lalitha V. Nayak, MD^{3,4}**, Pedram Mohseni, PhD^{1*} and **Sanjay P Ahuja, MD⁵***

¹Case Western Reserve University, Cleveland, OH

²University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

³University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH

⁴University Hospitals Cleveland Medical Center, Cleveland, OH

⁵University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

4669 Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways: Diseases, Bleeding and clotting, Thrombosis, Clinically relevant, Thromboembolism

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Ang Li, MD¹, Josh J Carlson, PhD^{2}, Nicole M. Kuderer³, Jordan K Schaefer, MD⁴, Shan Li, PharmD^{5*}, David A. Garcia, MD⁶, **Alok A Khorana, MD⁷**, Marc Carrier, MD⁸ and Gary H. Lyman, MD⁹*

¹University of Washington School of Medicine, Seattle, WA

²University of Washington School of Pharmacy, Seattle, WA

³Advanced Cancer Research Group, Seattle, WA

⁴Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Dexter, MI

⁵Pharmacy Services, University of Washington Medical Center, Seattle, WA

⁶Department of Medicine, Division of Hematology, University of Washington, Seattle, WA

⁷Cleveland Clinic, Cleveland, OH

⁸Department of Medicine, Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada

⁹Fred Hutchinson Cancer Research Center, Seattle, WA

4674 Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways: Therapies, Non-Biological, Clinically relevant, pharmacology

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Kylee L Martens, MD¹, Parisa R Khalighi, BS², Shan Li, PharmD^{3}, Andrew A White, MD^{1*}, Emily Silgard, MS^{4*}, Deborah Frieze, PharmD^{3*}, Elihu H. Estey, MD⁵, David A. Garcia, MD⁵, Sangeeta R Hingorani, MD, MPH^{4,6,7*} and Ang Li, MD^{5*}*

¹Department of Medicine, University of Washington School of Medicine, Seattle, WA

²Case Western Reserve University School of Medicine, Cleveland, OH

³Pharmacy Services, University of Washington Medical Center, Seattle, WA

⁴Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

⁵Division of Hematology, University of Washington School of Medicine, Seattle, WA

⁶Division of Nephrology, Seattle Children's Hospital, Seattle, WA

⁷Department of Pediatrics, University of Washington School of Medicine, Seattle, WA

4713 Clinical Practice Patterns for Hydroxyurea Initiation in Young Children with Sickle Cell Disease

Program: Oral and Poster Abstracts

Session: 901. Health Services Research—Non-Malignant Conditions: Poster III

Hematology Disease Topics & Pathways: sickle cell disease, Diseases, Pediatric, Hemoglobinopathies, Young Adult, Study Population, Clinically relevant, Quality Improvement

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Anna M Hood, PhD^{1}, Yolanda Johnson, MLS^{2*}, Cara Nwankwo, BA^{3*}, Lisa M Shook, MA^{4*}, Aimee K Hildenbrand, PhD^{2*}, Allison A. King, MD, MPH, PhD⁵, Kim Smith-Whitley, MD⁶, Sherif M. Badawy, MD⁷, Alexis A Thompson, MD, MPH^{8*}, Susan E Creary, MD⁹, Connie M. Piccone, MD¹⁰, Lynne D. Neumayr¹¹,*

Jean L. Raphael, MD, MPH¹², Amber M Yates, MD¹³, Sohail Rana, MD^{14}, Steven K Reader, PhD^{15*}, Emily Riehm Meier, MD, MSHS¹⁶, Amy Sobota, MD, MPH¹⁷ and Lori E. Crosby, PhD¹⁸*

¹Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

²Cincinnati Children's Hospital Medical Center, Cincinnati, OH

³Oklahoma State University, Stillwater, OK

⁴Cincinnati Children's Hospital, Cincinnati, OH

⁵Program in Occupational Therapy, Washington University in St. Louis, School of Medicine, Clayton, MO

⁶Children's Hospital of Philadelphia, Philadelphia, PA

⁷Department of Pediatrics, Division of Hematology/Oncology/Stem Cell Transplant, Ann & Robert Lurie Children's Hospital, Chicago, IL

⁸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

⁹Center for Innovation in Pediatric Practice, Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH

¹⁰University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH

¹¹Dept. of Hematology/Oncology, Children's Hospital Oakland, Oakland, CA

¹²Center for Child Health Policy and Advocacy, Baylor College of Medicine, Houston, TX

¹³Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX

¹⁴Howard University, Washington DC, DC

¹⁵Nemours Children's Health System, Wilmington

¹⁶Indiana Hemophilia and Thrombosis Center, Indianapolis, IN

¹⁷Pediatric Hematology and Oncology, Boston Medical Center, Boston, MA

¹⁸Cincinnati Children's Hospital, Cincinnati

4747 Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Registry

Program: Oral and Poster Abstracts

Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

Hematology Disease Topics & Pathways: Diseases, MDS, Technology and Procedures, Myeloid Malignancies, molecular testing

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Tracy I. George, MD¹, Christopher R. Cogle, MD², Guillermo Garcia-Manero, MD³, David L. Grinblatt⁴, Rami Komrokji^{5}, Michael R. Savona, MD⁶, Bart L. Scott, MD⁷, Mikkael A. Sekeres, MD, MS⁸, David P. Steensma, MD⁹, E. Dawn Flick^{10*}, Pavel Kiselev^{11*}, Chrystal U. Louis^{11*}, Melissa Nifenecker^{11*}, Arlene S. Swern^{11*} and Kathryn Foucar¹²*

¹University of Utah and ARUP Laboratories, Salt Lake City, UT

²Medicine, University of Florida, Gainesville, FL

³MD Anderson Cancer Center, Houston, TX

⁴NorthShore University HealthSystem, Evanston, IL

⁵Moffitt Cancer Center, Tampa, FL

⁶Department of Medicine and Program in Cancer Biology, Vanderbilt University Medical Center, Nashville, TN

⁷Fred Hutchinson Cancer Research Center, Seattle, WA

⁸Cleveland Clinic, Cleveland, OH

⁹Dana-Farber Cancer Institute, Boston, MA

¹⁰Celgene Corporation, San Francisco, CA

¹¹Celgene Corporation, Summit, NJ

¹²University of New Mexico Health Sciences Center, Albuquerque, NM

4750 Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis

Program: Oral and Poster Abstracts

Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

Hematology Disease Topics & Pathways: Diseases, cell division, MPN, Myeloid Malignancies

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Tanya Burton^{1}, Kejal Parikh^{2*}, Manish Patel^{2*}, Kevin Sundquist^{3*}, Lincy S. Lal⁴, Ronda Copher^{2*} and Aaron T. Gerds, MD, MS⁵*

¹Optum, Boston, MA

²Celgene Corporation, Summit, NJ

³Optum, Eden Prairie, MN

⁴Optum, Houston, TX

⁵Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

4770 Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster III

Hematology Disease Topics & Pathways: Follicular Lymphoma, Diseases, Adult, Therapies, Lymphoma (any), Adverse Events, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, Study Population, Lymphoid Malignancies, Clinically relevant

Monday, Dec 9, 2019, 6-8 PM; Hall B, Level 2 (Orange County Convention Center)

Shufen Cao^{1*}, Gouri Dharmavaram^{2*}, Kirsten M Boughan, DO³, Brenda Cooper, MD³, Molly M Gallogly, MD, PhD³, Ehsan Malek, MD⁴, Leland Metheny III, MD³, Folashade Otegbeye, MBBChir, MPH⁵, Benjamin K. Tomlinson, MD³, Marcos de Lima, MD³, Pingfu Fu^{1*} and Paolo F Caimi, MD³

¹Case Western Reserve University, Cleveland, OH

²School of Medicine, Case Western Reserve University, Cleveland

³Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Beachwood, OH